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 1 
1 Abstract 
The Chinese hamster ovary (CHO) cell line is currently the most important mammalian cell 
line for the production of therapeutic proteins. CHO cells are proline auxotroph due to 
deficiencies in both pathways to form proline either from glutamate or ornithine. The aim of 
this study was to use the proline auxotrophy of the CHO cell line as a selection system for 
the production of recombinant proteins. 
The gene of the enzyme pyrroline-5-carboxylate synthetase (P5CS), which catalyzes the 
reaction of glutamate to pyrroline-5-carboxylate, was cloned into a dicistronic vector to 
couple the gene of interest (GOI) with the selection marker. Different CHO cell lines were 
analyzed in transfection experiments, growth tests in proline-free media and in Western 
Blots comparing isolated proline-prototroph cell lines to the auxotroph wildtype cells. These 
studies revealed that the CHO-S cell line is suited best for the proline selection system. Using 
the CHO-S cells, selection times and expression levels comparable to those of antibiotic 
selection with neomycin or hygromycin B could be reached. Expressing the green fluorescent 
protein (GFP), three different monoclonal antibodies (anti-CD303, anti-CD14, anti-Biotin) or 
the cytokine hTGF-!1, stable cell lines with producer rates of over 90% were generated in 
less than 20 days. For the expression of antibodies, a two-vector-strategy was chosen 
combining the proline selection system with a zeocin selection. Stable cell lines with titers up 
to 8 mg/L (static, adherent, in minimal medium) and clones expressing up to 140 mg/L 
(limiting dilution, orbital shake reactor, suspension, fed-batch process) were generated for 
the production of anti-CD303. 
To further improve the proline selection system, a tricistronic vector allowing coexpression 
of fluorescent reporter proteins for the use of fluorescence- as well as magnetic-activated cell 
sorting (FACS and MACS) was developed. Using a stable cell line expressing anti-CD303 
and coexpressing two cytosolic fluorescent proteins, clone isolation by FACS improved mean 
titer distribution of the isolated clones 1.9-fold when compared to a traditional limiting 
dilution. Membrane-bound fluorescent proteins allow a very fast and simple enrichment by 
MACS. Enrichment of stable cell lines producing anti-CD303 or hTGF-!1 revealed an initial 
2.5- to 10-fold increase of titer, although these enhanced productivities decreased over the 
following culture time. Therefore, a combination of MACS enrichment of stable producer cell 
lines with clone isolation by FACS was proven to generate clones with similar productivities 
as clones isolated by two FACS subcloning steps, while dramatically improving timelines 
and manual amount of work. Clones producing up to 130 mg/L anti-CD303 antibody 
(orbital shake reactor, suspension, batch process) could be isolated by this combination of 
MACS and FACS. In addition to the demonstrated enrichment successes, proof for the 
correlation of intracellular hTGF-!1 and the cytosolic fluorescent protein levels was 
established by analyzing several FACS-isolated hTGF-!1-expressing clones. 
Abstract  
 2 
 
The developed P5CS expression system enables a selection process without the need for any 
cytotoxic substances. It therefore offers an interesting alternative for the modification of 
parental production cell lines. 
Abstract 
 3 
 
1.1 Zusammenfassung 
 
Die Chinese hamster ovary (CHO) Zelllinie ist momentan die am häufigsten verwendete 
Mammaliazelllinie zur Produktion therapeutischer Proteine. Bereits seit der Isolation dieser 
Zelllinie ist bekannt, dass diese nicht in der Lage ist selbstständig Prolin aus den Vorläufern 
Glutamat oder Ornithin zu synthetisieren. Das Ziel dieser Arbeit war diese 
Prolinauxotrophie als Selektionssystem für die Produktion rekombinanter Proteine in CHO-
Zellen zu nutzen. 
Das Gen des Enzyms Pyrrolin-5-Carboxylat-Synthetase (P5CS), welches die Reaktion von 
Glutamat zu Pyrrolin-5-Carboxylat katalysiert, wurde in einen dizistronischen Expressions-
vektor kloniert, um eine Kopplung des Gens von Interesse und des Selektionsmarkers zu 
erreichen. Verschiedene CHO Zelllinien wurden in erste Transfektionsstudien, 
Wachstumsversuche in prolinfreiem Medium sowie Western Blot-Analysen der 
prolinprototrophen Zelllinien im Vergleich zu den prolin-auxotrophen parentalen Zellen 
verglichen. Diese Studien ergaben, dass sich die CHO-S-Zelllinie am besten für ein 
prolinbasiertes Selektions-system eignet. Mit dieser CHO-S-Zelllinie können sowohl 
Selektionszeiten als auch Expressionslevels vergleichbar zu Antibiotikaselektionssystemen 
mit Neomycin oder Hygromycin B erreicht werden. Stabile Zelllinien, die das grün-
fluoreszierende Protein GFP, drei verschiedene Antikörper (anti-CD303, anti-CD14, anti-
Biotin) oder das Zytokin hTGF-!1 exprimieren, konnten in weniger als 20 Tagen mit 
Produzentenraten von über 90% generiert werden. Für die Expression der Antikörper wurde 
eine Zwei-Vektor-Strategie mit einer Kombination aus P5CS- und Zeocin-Selektion 
verwendet. Für die anti-CD303-Produktion konnten so stabile Zelllinien mit Titern von 8 
mg/L (statisch, adhärent, in Minimalmedium) und Klone mit Titern von bis zu 140 mg/L 
(limiting dilution, Schüttelinkubator, Suspension, fed-batch) isoliert werden.  
Um das neu etablierte Prolinselektionssystem weiter zu optimieren, wurde ein tricistro-
nischer Expressionsvektor entwickelt, der die Koexpression von fluoreszierenden 
Reporterproteinen erlaubt und sowohl für magnetische als auch durchflusszytometrische 
Zellsortierung (MACS und FACS) genutzt werden kann. Im Vergleich zu einer traditionellen 
limiting dilution konnten aus einer anti-CD303-exprimierenden Zelllinie mit Koexpression 
zytoso-lischer Fluoreszenzproteine mittels FACS Klone mit einer 1,9-fach höheren 
durchschnittlichen Produktivität isoliert werden. Membrangebundene Fluoreszenzproteine 
können außerdem für eine schnelle Anreicherung mittels MACS genutzt werden. Sowohl 
eine anti-CD303- als auch eine hTGF-!1-exprimierende Zelllinie konnte um Faktor 2,5 bis 10 
angereichert werden, wobei die Produktivität in der nachfolgenden Zeit in Kultur wieder 
leicht absank. Daher ist eine Kombination aus einer MACS-Anreicherung von stabilen 
Zelllinien mit einer anschließenden Klonisolation mittels FACS optimal, um sowohl Zeit- als 
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auch Arbeitsaufwand zu reduzieren. Desweiteren können mit dieser Kombination ähnlich 
produzierende Klone generiert werden wie mit zwei aufeinanderfolgenden FACS-basierten 
Klonisolationen. Klone mit einer Produktion von 130 mg/L des anti-CD303-Antikörpers 
(Schüttelinkubator, Suspension, batch) konnten mit dieser Kombination aus MACS und 
FACS isoliert werden. Bei der hTGF-!1 Produktion wurde zusätzlich eine Korrelation von 
intrazellulärem hTGF-!1 und dem zytosolischen Fluoreszenzprotein in FACS-isolierten 
hTGF-!1 exprimierenden Klonen nachgewiesen.  
 
Das entwickelte P5CS-Expressionssystem erlaubt eine Selektion völlig ohne zytotoxische 
Substanzen. Daher bietet es eine interessante Alternative für die Modifikation von 
parentalen Produktionszelllinien.  
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2 Introduction 
2.1 Recombinant protein production in CHO cells  
Recombinant proteins play an essential role in research, diagnostics and clinical therapy. 
Due to their ability of correct folding, assembly, glycosylation and secretion (Wurm 2004, 
Khan 2008) about 60-70 % of the clinically approved recombinant proteins are produced in 
mammalian cell lines. Chinese hamster ovary (CHO) cell lines, isolated from a female inbred 
Chinese hamster (Cricetulus griseus) by Tjio and Puck (Tjio and Puck, 1958), are the most 
commonly used mammalian cell lines. Already Puck et al (1958) described the remarkable 
robustness of CHO cells, which together with the ease of transfection and adaptation to 
serum-free media, growth in high cell densities, high production levels and by now good 
characterization makes them the mostly used mammalian cell line (Beatson et al, 2011). 
Recently, Hammond et al (2012) published an online resource making the CHO genome 
publicly available1. In addition, under suitable production conditions, CHO cells are able to 
produce recombinant proteins with major N-linked glycoforms identical to those present in 
human proteins (Jefferis, 2005): Similar to mouse cells, the four major glycoforms G0, G1 (1-
3), G1 (1-6) and G2 (Figure 1) occur in CHO produced N-glycoproteins (Wacker et al, 2011).  
 
 
Figure 1: Structure of major N-linked glycoforms 
Asn= asparagine, GlcNAc= N-acetylglucosamine, Fuc= fucose, Man= mannose, Gal= galactose (Wacker et al, 
2011) 
 
Different from human cells, CHO cells do not express N-acetylglucosaminyltransferase-III 
(GnTIII), an enzyme that mediates the transfer of bisecting N-acetylglucosamine (GlcNAc). 
Additionally, CHO cell derived antibodies contain α2,3-linked sialic acid residues, while 
human IgG mainly contain α2,6-linked sialic acid residues. But since α2,3-linked sialic acid 
residues have been reported in human IgGs, they do not seem to have immunogenic 
capacities. Both, the amount of bisecting N-acetylglucosamine as well as that of sialylated 
oligosaccharides is very small (<5-10% of glycans). In mouse produced antibodies contain 
                                                      
1 http://www.chogenome.org/index.html, 25.10.2012 
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α1,3-linked galactose and N-glycolylneuraminic acid. Both epitopes are known to be 
immunogenic to humans and not to occur in hamster cells (Raju, 2003), making CHO cell 
lines more suitable for therapeutic protein production. In addition to these variations in N-
linked glycosylation, there are several differences in O-glycosylation of human and CHO cell 
derived glycoproteins (Raju, 2003). 
 
Generating production cell lines expressing high levels of recombinant proteins is a time 
consuming, labor-intensive process. Several different aspects, such as selecting a suitable 
CHO cell line, an optimized expression vector, an efficient transfection protocol and selection 
system as well as a fast and potent identification and isolation of high-producing clones, 
have to be considered. Following cell line development, a production process optimized for 
the selected clone has to be established. Depending on the used expression system, the time 
frame needed for identifying a suitable clone alone varies between over 6 month using a 
dihydrofolate reductase (DHFR) expression system and at least 3 months for the glutamine 
synthetase (GS) Gene Expression SystemTM (Butler, 2005), while still requiring clone stability 
and production tests as well as first process optimization. This results in cell line 
development times of 6 months to over a year (Wurm, 2004), as schematically shown in 
Figure 2 for a traditional amplified selection system (Haines, 2009). Therefore there are 
ongoing efforts to improve cell development using new technologies to reduce timelines and 
reach a more robust and faster process (Birch and Racher, 2006).   
 
 
Figure 2: Schematic overview of the cell line development timeline 
Overview of cell line development process using a traditional amplified system with clone isolation by limiting 
dilution (Haines, 2009) 
 
2.1.1 Selection systems for mammalian cells 
Several different selection systems either based on antibiotic selection or on metabolic 
selection are known. Common antibiotic selection systems include resistance to neomycin, 
hygromycin B, puromycin or zeocin (Wurm, 2004). Using these selection systems, the 
resistance gene is integrated into the expression vector and the corresponding antibiotic is 
added into the culture medium. Only positively transfected cells expressing the resistance 
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gene are able to survive the applied selection pressure. In selection systems based on 
metabolic enzymes on the other hand, the gene encoding a metabolic enzyme is integrated 
into the expression vector and positively transfected cells are able to survive selection in a 
medium missing the corresponding nutrient. Currently available and commonly used 
expression systems based on selection with metabolic enzymes are the DHFR expression 
system (Haynes and Weissmann, 1983), which is based on the selection with the enzyme 
dihydrofolate reductase in a medium lacking hypoxanthine and thymidine, and the GS Gene 
Expression System TM (Cockett et al, 1990), which is based on the selection with the enzyme 
glutamine synthetase (GS) in a glutamine-free medium. For the DHFR selection system, 
special cell lines with a deficiency in DHFR activity, such as the CHO DG44 or CHO DXB11, 
are required. The DHFR enzyme catalyzes the reduction reaction from dihydrofolate acid to 
tetrahydrofolic acid (coenzyme F), which is an essential methyl donor for the amino acid and 
especially the nucleic acid (thymine and purine) metabolism. The DHFR inhibitor 
methotrexate (MTX), which acts as a folic acid antagonist, can be used for amplification by 
stepwise increase of inhibitor concentration and selection of resistant cells. This time-
consuming MTX amplification facilitates high copy numbers and therefore increases 
recombinant protein production, but implicates a high cytotoxicity (Kaufman et al, 1985) and 
genetic instability of the production cell lines (Kim et al, 1998 A). In addition, MTX 
transporter mutations are known to lead to resistant phenotypes (Assaraf and Schimke, 
1987). For the GS selection no special cell lines are required, although CHO cells 
endogenously express the glutamine synthetase. Using the toxic drug methionine 
sulphoximine (MSX), a glutamine synthetase inhibitor, facilitates selection and may be used 
for amplification. Recently GS-knock out cell lines generated by zinc-finger-nucleases have 
been described (Liu et al, 2010) to increase the selection stringency and to lead to an elevated 
recombinant protein production (Fan et al, 2012).  
 
2.1.2 Different CHO cell lines 
Several different CHO cell lines have been derived from the originally isolated CHO cell line. 
Early subclones were mainly generated to study the genetics and metabolism of mammalian 
cells. More recently, since CHO cells have evolved into the major mammalian cell line for 
recombinant protein production, a number of special production strains have been isolated. 
The CHO-K1 cell line is a subclone derived directly from the first isolated CHO line (Kao 
and Puck, 1969). It only possesses 20 chromosomes compared to 22 in the normal Chinese 
hamster (Taylor and Hanna, 1982). The CHO-S cell line, a separate subclone of the parental 
CHO cell, is characterized as less anchor-dependent compared to the CHO-K1 cell line 
(Kurano et al, 1990). In addition, the CHO-S cells are aneuploid (D´Anna et al, 1996) 
containing 21 chromosomes (Taylor and Hanna, 1982). Invitrogen recloned this CHO-S cell 
line by limiting dilution to obtain a cell line (FreeStyleTM CHO-S) further optimized for 
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growth in serum-free conditions and with improved transfection efficiencies 2 . Several 
different subclones with mutated phenotypes with regard to metabolic markers have been 
isolated from these parental cell lines; of importance for recombinant protein expression are 
the DHFR deficient cell lines CHO DXB11 and CHO DG44. Urlaub and Chasin (1980) 
isolated the CHO-K1 subclone CHO DXB11 (DUXB11) by chemical and radioactive 
mutagenesis. This subclone has a deletion in one of the DHFR alleles and a missense 
mutation in the other. Therefore reversion to a DHFR prototroph phenotype can be 
observed; reversion rates range between 0.001% described by Urlaub and Chasin (1980) and 
0.31% in serum-free suspension media described by Sinacore et al (1996). Three years later, 
the MTX-resistant mutant CHO MtxRIII, isolated from the proline-dependent CHO-pro3 
strain, was mutagenized by ionizing radiation to yield the CHO DG44, a cell line with 
deletion of both DHFR alleles (Urlaub et al, 1983). 
 
2.1.3 Vector design 
The gene of interest (GOI) encoding for the recombinant protein and the selection marker 
gene are inserted into the host cell by expression vectors. These expression vectors are 
mainly plasmids consisting of circular double-stranded DNA. In addition to the GOI and the 
selection marker gene, vectors encode for a bacterial replication site and a bacterial selection 
marker to facilitate plasmid amplification and isolation from bacteria. For expression in 
mammalian cells, the expression vector contains a suitable promoter for transcription 
initiation of the following gene. To archive high expression of the GOI, a strong promoter 
such as the cytomegalovirus 5 (CMV5) promoter is needed. The CMV5 promoter is an 
improved CMV promoter consisting of the human CMV immediate early promoter and 
enhancer. Additionally this promoter contains the tripartite leader (Ad-tpl) and a splice site 
from the human adenovirus 5 major late promoter. Compared to the non-optimized CMV 
promoter, the CMV5 promoter enables expression of about 5-12 –fold higher recombinant 
protein levels in HEK 293 cells (Massie et al, 1998). In a traditional expression vector, each 
gene is transcribed individually and is therefore controlled by its own promoter (Figure 3). 
For the expression of the selection marker gene, a less efficient promoter than the CMV5 
promoter, such as the simian virus 40 (SV40) early promoter, is used. The disadvantage of this 
vector design is the independent expression of GOI and selection marker gene allowing cells, 
which only express the selection marker gene, to survive in the selection medium. This 
expression of selection marker but no GOI might be either due to integration of only the 
selection marker expression cassette or subsequent loss or down-regulation of the integrated 
GOI (Pu et al, 1998). These non-producers might even have a growth advantage due to a 
reduced expression burden compared to producing cells and may overgrow the latter in a 
mixed population.  
                                                      
2 http://de-de.invitrogen.com/site/de/de/home.html, 25.10.2012 
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Figure 3: Comparison of different vector designs 
Two different vector designs used for the expression of recombinant proteins. In a multiple cassette, the gene of 
interest and the selection marker are encoded by a promoter and polyA signal for each gene. In a dicistronic 
cassette, the gene of interest and the selection marker are controlled by a single promoter and polyA signal due to 
a coupling element such as an IRES element (Chen et al, 1998). 
 
This effect can be avoided by coupling of GOI and selection marker gene in a dicistronic 
expression cassette (Figure 3). This might be realized by integrating an internal ribosomal 
entry site (IRES) between GOI and selection marker gene. IRES elements were first identified 
in the polio virus (Human enterovirus C) and Encephalomyocarditis virus (EMCV) but have also 
been identified in several other viruses and eukaryotic organisms ranging from yeast to 
mammals. The 80 to 500 nucleotide long element allows a cap-independent translation of the 
mRNA. The gene cloned downstream of the IRES element is translated less efficiently (10-
50%) compared to the upstream cap-dependent translation (Szymczak and Vignali, 2005). 
For expression of recombinant proteins, the coupling of GOI and selection maker gene has 
some major advantages: First, since GOI and selection marker gene are encoded on one 
common mRNA, cells are not able to exclusively express the selection marker gene. Thereby, 
the frequency of non-producers is massively reduced. Second, the reduced IRES-dependent 
expression of the selection marker compared to the cap-dependent expression of GOI 
ensures higher levels of GOI expression in order to reach selection marker amounts sufficient 
to survive the applied selection (Pu et al, 1998).  
Another element suitable to couple different genes is a 2A peptide sequence. These about 18-
22 amino acid long sequences can be found in picornaviruses like foot-and-mouth disease 
virus (FMDV) and EMCV, insect viruses and Type C rotaviruses (Rotavirus C). The 2A 
peptide sequence contains a highly conserved consensus motif at the C-terminus (D-V/I-E-
X-S-N-P-G*P), which mediates the “cleavage” between the C-terminal glycine and the N-
terminal proline. This “cleavage” does not require any additional factors like proteases and 
was first thought to be an autoproteolytic event, but recently the “cleavage” has been 
proposed to be a ribosomal-skip mechanism (Figure 4) and 2A peptides are referred to as 
CHYSELs (cis-acting hydrolase elements) (Szymczak and Vignali, 2005).  
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Figure 4: Ribosomal-skip mechanism at 2A peptide 
Ribosome skipping at the 2A peptide sequence: The 2A peptide disrupts translation and impairs normal peptide 
bond formation resulting in translation of two separate proteins from one open reading frame (ORF) 3.  
 
The primary translated pre-mRNA is processed into a mature mRNA and transported into 
the cytoplasm for translation. For these processes, several elements are necessary on an 
expression vector to initiate processing and transport. Shortly after transcription, a modified 
guanine nucleotide is added to the 5´ end of the mRNA resulting in the cap-structure, which 
is necessary for cap-dependent translation. This process does not require any additional 
sequences. To protect the mRNA from degradation, the expression vector contains a 
polyadenylation signal (PolyA), which leads to addition of a tail of multiple adenosine 
monophosphates at the 3´ end. Azzoni et al (2007) compared the bovine growth hormone 
(BGH), the SV40 and a synthetic PolyA signal in CHO. Using the BGH PolyA signal led to 
the highest numbers of transfected cells and highest GOI expression levels making it a 
suitable PolyA signal for an expression vector for high level recombinant protein expression. 
Eukaryotic protein-coding genes often contain introns, which are non-coding sequences 
between the protein-coding sequences (exons). These introns are removed from the pre-
mRNA by splicing according to donor and acceptor splice sites surrounding the intron 
sequence. The mRNA splicing and its export into the cytoplasm are closely connected. The 
exon junction complex (EJC) formed by different proteins at the junction of two exons is a 
platform for the binding of several export factors. This splicing memory ensures that only 
mature mRNAs consisting of exons are exported (Knippers, 2006). In expression vectors for 
recombinant protein expression, genes are mainly encoded as cDNA. Different from 
genomic DNA they do not contain introns. Since mRNA splicing and export are closely 
connected, the lack of introns might lead to reduced mRNA export (Huang and Gorman, 
1990; Buchmann and Berg, 1988). Therefore, most expression vectors contain at least one 
                                                      
3 http://viralzone.expasy.org/all_by_protein/914.html, 25.10.2012 
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intron (Walls et al, 1993). Positive, but sequence-dependent and cell line-dependent 
influences of these added introns on expressed recombinant protein levels have been 
observed (Huang and Gorman, 1990; Mariati et al, 2010).  
 
2.1.4 Clone isolation 
For high-level recombinant protein production not only an optimized vector and selection 
system is necessary, but also the process of clone isolation is critical. After transfection, only 
about 0.1% of the cells stably integrate the foreign DNA into their genome (Gray, 1997). 
Although the applied selection pressure enriches the number of producing cells, the 
remaining stable producer cell line is still a mixture of cells with different integration sites, 
expression levels and growth properties. Identifying clones with extraordinarily high 
production capacities and stability as well as growth characteristics suitable for the 
production process is a labor- and time-consuming process. The most simple method for 
clone isolation is limiting dilution to concentrations that will likely dispense one or less than 
one cell per culture well. Each up-growing clone has to be screened for its production and 
growth capacities. While automation of this process can enhance the number of screened 
clones, the number remains a limiting factor (Chartrain and Chu, 2008). Therefore, different 
methods have been developed allowing a faster identification and isolation of clones 
according to their production capacities.  
For isolation of high-producing clones, two sorting methods come into consideration. The 
fluorescence activated cell sorting (FACS) is of special importance for the isolation of the 
identified high-producing clones as it allows isolation of cells according to their fluorescence 
as single cells or in a bulk. To obtain high purities, lower flow rates of about 1,000 to 3,000 
cells per second are suitable allowing the screening of up to 1x107 cells per hour. Another 
potent method for cell enrichment is the magnetic activated cell sorting (MACS), although it 
has only been described for isolation of high-producing stable cell lines in few publications. 
For example Hoch (2010) developed an “antibody CHO capture system” and Carroll and Al-
Rubeai (2005) describe a MACS-based high-producer enrichment protocol using affinity 
capture surface display (ACSD). The MACSelectTM system (Miltenyi Biotec) allows isolation 
of transiently transfected cells by MACS using different cell surface markers, but does not 
include a selection system. For magnetic separation, cells expressing a surface marker are 
labeled directly or indirectly with antibodies conjugated to superparamagnetic particles. 
Ferromagnetic columns are placed in a magnetic field amplifying the magnetic field 10,000-
fold. Labeled cells are applied onto the column and non-magnetically cells flow through the 
column. Magnetically labeled cells are retained and can be eluted in the following step 
(Miltenyi et al, 1990) (Figure 5). Isolation of positive cells from a starting population of up to 
2x1010 cells is possible in one isolation step in less than 2 hours (Philipps, 2004).  
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Figure 5: Schematic overview of a positive enrichment with MACS 
Target cells expressing a certain surface marker are labeled with a magnetic bead-coupled antibody and applied 
to a column placed in a magnetic field. The unlabeled cells pass through while the magnetically labeled cells are 
retained within the column. After a washing step, the column is removed from the separator, and the 
magnetically labeled cells can be eluted from the column 4. 
 
To isolate high-producing cells one first needs to identify these cells. Several methods to 
identify high-producing cells are based on the detection of the secreted recombinant protein: 
Holmes and Al-Rubeai (1999) used an immobilized affinity surface display matrix that 
specifically bound the secreted target protein, which was then detected by a fluorescently 
labeled antibody and the brightest fluorescent cells were finally isolated by FACS. With this 
method it is possible to screen up to 5x106 cell in about 4 hours. This method of capturing the 
secreted recombinant antibody in an antibody-capture matrix can also be used in 
combination with MACS instead of FACS described by Carroll and Al-Rubeai (2005) and 
Hoch (2010). A similar approach was used by Caron et al (2009), where cells were seeded in a 
semi-solid medium ensuring clonal colonies and trapping secreted protein in the 
surroundings of the colonies. A FITC-labeled secondary antibody specific for the secreted 
recombinant protein was used for staining. Large and bright colonies indicating good 
growth and productivity were isolated by automated or manual clone picking. Secreted 
recombinant proteins can also be detected without a capture matrix using a “cold capture 
assay”. According to Brezinsky et al (2003), secreted recombinant antibodies stay transiently 
attached to the cell membrane at low temperatures and can be stained using a labeled 
antibody. 
The second possibility to identify high-producing clones is via a modified vector 
coexpressing reporter proteins, such as fluorescent proteins or surface proteins. These 
surface proteins are usable for antibody staining, followed by clone isolation by FACS or 
fluorescence plate readers. Different vector configurations, reporter proteins and isolation 
strategies have been described: Meng et al (2000) reported the coexpression of GFP in a 
separate transcription unit. In contrast Mancia et al (2004) prefered the GFP coupled to the 
GOI via an IRES to improve correlation of GOI and GFP expression. Sleiman et al (2008) used 
two IRES-coupled reporter proteins for each heavy and light chain of a recombinant 
antibody. Like Meng et al (2000) and Mancia et al (2004) Sleiman et al (2008) used FACS to 
                                                      
4 http://www.miltenyibiotec.com/en/NN_1146_Basic_principle.aspx, 25.10.2012 
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isolate the brightest cells. An IRES-coupled GFP can also be used for identification of high-
producers by fluorescence plate reader (Freimark et al, 2010). Instead of fluorescent proteins, 
IRES-linked reporter genes encoding surface markers such as CD2 or CD4 might be used in a 
FACS approach (DeMaria et al, 2007; Liu et al, 2000). A different vector design allowing 
coupled expression of GOI and reporter protein was described by Cairns et al (2011). In 
detail, non-AUG start codons to initiate reporter protein (CD52) expression with reduced 
efficiency upstream of the GOI were used in combination with FACS. A very interesting 
vector design was described in a patent application by Jostock et al (US 2001/0281751 A1) 
using a “leaky” stop, which terminates the recombinant protein followed by a membrane 
anchor in frame. A certain amount of ribosomes reads over the first “leaky” stop and thereby 
the recombinant protein is expressed as a membrane-bound form and can easily be used for 
detection. Another possible vector design includes the fusion of reporter and selection 
marker protein, as described by Bennett et al (1998) for a GFP-zeocin selection marker fusion 
and by Bailey et al (2002) for a GFP-metallothionein fusion, which confers heavy metal 
resistance.  
In addition to capturing secreted recombinant proteins or coexpression of fluorescent 
proteins by novel vector designs, Kober et al (2012) described a modified CHO cell line 
allowing identification of high-producers. Overexpression of recombinant proteins triggers 
endoplasmatic reticulum (ER) stress response. A generated CHO DG44 cell line with stable 
integration of GFP controlled by the ER stress sensitive glucose-regulated protein 78 kDa 
(GRP78) promoter allows FACS isolation of clones. These clones show a relation between 
GFP ER stress signal and recombinant antibody expression.  
 
2.1.5 Recombinant proteins 
Complex glycosylated proteins require mammalian expression systems to facilitate correct 
folding, assembly, glycosylation and secretion of the proteins (Wurm, 2004; Khan and 
Schroder, 2008). The first recombinant protein produced in CHO cells that gained FDA-
approval for therapeutic use in humans was the human tissue plasminogen activator (tPA) 
in 1987 (Kozlowski, 2007). By 2010 recombinant proteins such as hormones, growth factors 
or antibodies comprised most of the over 200 approved biopharmaceuticals (Walsh, 2010) 
with CHO cell lines as the predominantly used host cell line (Costa et al, 2009). But 
recombinant proteins produced by mammalian cells are not only used for therapeutic 
applications in humans. The applications range from veterinary pharmaceuticals to research 
and diagnostic applications.   
 
2.1.5.1 Monoclonal antibodies 
Antibodies, also called immunoglobulins, are heterodimeric proteins composed of two heavy 
chains of about 50-70 kDa and two light chains of about 25 kDa. Non-covalent and covalent 
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bonds connect the chains. The two heavy chains are connected to each other and to the light 
chains by disulfide bonds. There are five different types of heavy chains (µ, δ, γ, α and ε), 
resulting in the different immunoglobulin subclasses (IgM, IgD, IgG, IgA and IgE) 
(Holländer, 2006). Most therapeutically used antibodies belong to the IgG subclass 
(Chartrain and Chu, 2008) (Figure 6). The constant region of IgG molecules contains one 
conserved glycosylation site in the Fc region resulting in a N-linked biantennary structure at 
Asn 297 (Wright and Morrison 1997). The glycosylation pattern plays a critical role for the 
effector function and immune clearance (Wright and Morrison, 1997). Deglycosylated IgGs 
have been reported to inefficiently mediate Fc receptor binding therefore being unable to 
trigger antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent 
cytotoxicity (CDC) (Abés and Teillaud 2010). Similar hypogalactosylation and 
monosialylation of IgG lead to poor activity in ADCC, while blockage of the processing of 
the oligomannose intermediate generates IgG1 unable of complement-dependent 
cytotoxicity (CDC). In addition, the presence of oligomannose (Abès and Teillaud, 2010) or 
terminal (α1!3) galactose expressed by murine cells (Wright and Morrison, 1997) leads to a 
rapid clearance of the antibody.  
For the light chain, two different types are known: κ- and λ-chains. But no functional 
difference has been observed. Heavy (H) and light (L) chain are both formed by a constant 
(C) and a variable (V) region: The variable regions VL and VH mediate the ability of 
recognition of specific antigens; the constant regions CL and three to four CH regions, 
depending on the heavy chain subtype, mediate effector functions (Holländer, 2006) (Figure 
6). 
 
Figure 6: Schematic structure of IgG antibodies 
IgG molecules consist of two heavy and two light chains connected by disulfide bonds. They form a variable and 
constant domain connected by the hinge region. Each heavy chain contains a conserved glycosylation site at Asn 
297 (Chartrain and Chu, 2008). 
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short overview of the biochemistry of IgG antibodies high-
lights the fact that synthesis of biologically active mAbs is a 
highly complex and well orchestrated biochemical process 
that encompasses folding, trafficking, post-translational 
modifications, and effective secretion. The choices of a pro-
ducing platform (host cell) and of the physico-chemical con-
ditions that will support mAb synthesis have been shown to 
greatly affect the abundance and quality of the N-linked gly-
cans, molecule folding, and the yield of the mAb of interest.  
 Since the advent of mAb production in the late 1970s, 
production platforms have relied on mammalian cells. As 
discussed above, monoclonal antibodies are highly complex 
molecules that require post translational modifications such 
as inter and intra-chain disulfide bond formations, and the 
addition of N-linked glycans at specific sites. Until recent 
metabolic engineering advances, only mammalian cells 
which possess the intrinsic required machinery could pro-
duce mAbs with the desired folding and post-translational 
modifications, and were therefore the de facto production 
platforms for mAbs. Although considerable progress has 
recently been (and continues to be) made in the use of other 
biological production platforms [31-33], to our knowledge, 
as of today only mammalian cells are used for the production 
of commercial and late stage clinical mAb supplies. Judging 
by the pace and the significance of the discoveries made in 
the use of yeasts, it is however very likely that during the 
next decade, these non-mammalian expression systems will 
be in use for the production of clinical or commercial mAbs.  
2. GENERATION AND MOLECULAR BIOLOGY 
BASED MANIPULATIONS OF MABS. 
2.1. General Principles 
 Traditionally, the generation of most therapeutic antibod-
ies relies on the immunization of mice or other mammals 
with the desired antigen target. Upon repeated injections, the 
animals develop a strong response to the antigen and will 
present a large number of cells secreting antibodies against 
the injected antigen. It is important to understand that multi-
ple antibodies directed at different epitopes of the antigen are 
secreted by a mixed population of B cells with each cell only 
secreting one specific antibody [34]. Therefore if one secret-
ing B cell was to be isolated and expanded (cloned), only 
one type of antibody molecule (monoclonal or mAb) would 
be secreted. Unfortunately, secreting B cells can only repli-
cate a limited number of times, therefore rendering produc-
tion of mAbs by their cultivation all but impossible. In vitro 
production of mAbs was only a concept until the ground-
breaking hybridoma technology was developed in the 1970s 
by Kohler and Milstein [35-37]. Antibody secreting cells 
originating from the spleen of an animal immunized with the 
antigen target of choice are fused with immortalized (i.e. 
cells that will divide forever when cultivated in permissive 
conditions) non-antibody secreting cells. To facilitate the 
isolation of the desired fused clones, the immortalized non-
secreting cells are engineered to be deficient in a key meta-
bolic pathway. For example, deficiencies in the hypoxan- 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Schematic representation of an IgG mAb. 
The mol cule is symmetric and can engage through its binding regions with two antigens at once. The presence of the hinge region allows 
for flexibility and facilitates this process.  
The insert provides details of the glycan structure. Symbols key is as follow : 
Fucose (FUC ), N acetyl glucose amine (NAGA ) galactose (GAL ), mannose (MAN ), N-acetylneuramic acid or sialic acid 
(NANA ). 
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Monoclonal antibodies have become increasingly important for research and diagnostics as 
well as therapeutic applications. Their ability to specifically bind a target molecule is used in 
several research and diagnostic methods including Enzyme-Linked Immunosorbent Assay 
(ELISA) (Engvall and Perlmann, 1971), Enzyme Linked Immunospot (ELISPOT) (Czerkinsky 
et al, 1983), Immunoblot (Renart et al, 1979), Immunoprecipitation (IP) (Bonifacino et al, 
2001), Immunohistochemistry (IHC)/Immunocytochemistry (ICC) (Coons et al, 1942) and 
flow cytometry (Herzenberg and Sweet, 1976). Antibodies are also used for cell enrichment 
strategies such as FACS (Herzenberg and Sweet, 1976) and MACS (Miltenyi et al, 1990).  
In addition, recombinant antibodies are used for therapeutic applications. They constitute 
more than 30% of the total biopharmaceutical production and are the major part of proteins 
currently tested in clinical trials (Rodriges et al, 2010). The two major application fields of 
therapeutic monoclonal antibodies are cancer and autoimmune diseases. The “big five” 
therapeutic antibodies representing about 78% of the total antibody sales in the US reflect 
this focus: Infliximab (Remicade®) and adalimumab (Humira®) targeting the tumor necrosis 
factor alpha (TNF-α) are used to treat the autoimmune diseases rheumatic arthritis, Crohn's 
disease and plaque psoriasis. Trastuzumab (Herceptin®) targets the human epidermal 
growth factor receptor 2 (HER2) and is used as well as bevacizumab (Avastin®) targeting the 
vascular endothelial growth factor A (VEGFA) to treat several types of cancer including 
colorectal, lung, breast, glioblastoma, kidney and ovarian. The fifth best selling antibody 
rituximab (Rituxan®/Mabthera®) targets CD20 and is used against both rheumatoid arthritis 
and non-Hodgkin's lymphoma (Leavy, 2010). 
 
2.1.5.2 Cytokines 
Cytokines are cell-signaling molecules, which are released by various cells in the body as 
answer to an activating stimulus (Holländer, 2006). They are small (about 25 kDa), 
glycosylated proteins, which require an expression system with suitable glycosylation 
patterns (Ramani and Kondaiah, 1998). Cytokines can be divided into several families such 
as interferons (IFN), interleukins (IL), tumor necrosis factors (TNF), colony-stimulating 
factors (CSF) and transforming growth factors (TGF) (Holländer, 2006). 
The TGF family consists of homodimeric proteins with a broad range of biological activities. 
For TGF-β, three isoforms are known in mammals: β1, β2 and β3 (Bourdrel et al, 1993). First 
isolated from human platelets, TGF-β1 is best characterized of this group (Gentry et al, 1987) 
and is expressed by nearly all cell types in low amounts. Interestingly, TGF-β1 is a highly 
conserved protein with amino acid homologies of 100% between porcine, canine and bovine 
and 99% homology between the mouse, rat and equine orthologs (Beatson et al, 2011). The 
human and the murine forms only differ in one amino acid (Gentry et al, 1987). Human TGF-
β1 is expressed as a 390 amino acid precursor molecule containing a 29 amino acid leader 
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sequence. Immature TGF-β1 is activated by proteolysis to the mature TGF-β1. When 
matured, TGF-β1 contains only the 112 C-terminal amino acids of the precursor and forms a 
homodimer (25 kDa) of two mature TGF-β1 molecules bound by non-covalent interactions. 
The mature homodimer still remains in a latent form due to the binding of the latency 
associated peptide (LAP) forming the small latency complex. Alternatively, the homodimer 
bound to LAP can additionally bind the latent TGF-β-binding protein 1-4 (LTBP1-4) forming 
the large latency complex. This latent form can be activated by several mechanisms: In vitro 
by acid or heat, in vivo also by acid (pH stress), thrombospondin interaction, protease 
cleavage or mild mechanical stress. Active TGF-β1 inhibits growth of cells expressing the 
TGF-βRII receptor on their surface by up-regulation of p15 and p21 leading to cell cycle 
arrest. It therefore plays an important role in development, differentiation, wound healing, 
metastasis and angiogenesis (Beatson et al, 2011). TGF-β1-knockout mice show a severe 
inflammation response (Ramani and Kondaiah, 1998) demonstrating the importance of TGF-
β1 for immunosuppression and immunotolerance. TGF-β1 is responsible for the induction of 
regulatory T-cells (Tregs), the class switch in B-cells from IgG to IgA production, the 
induction of tolerogenic antigen presenting cells and the inhibition of Th1 and Th2 T-cell 
development (Beatson et al, 2011). Recombinantly produced TGF-β1 is of interest for both 
research and clinical applications. The potent immunosuppressive effects of TGF-β1 make it 
an interesting candidate for treatment of autoimmune diseases such as multiple sclerosis 
(Mirshafiey and Mohsenzadegan, 2009). In research, TGF-β1 has several applications. For 
example, it can be utilized for the in vitro differentiation of naive CD4+ T cells towards TH17 
cells (Ayyoub et al, 2012), the in vitro generation of FoxP3+ inducible regulatory T cells 
(iTregs) (Horwitz et al, 2008) and stem cell differentiation models, since TGF-β1 regulates the 
stemness as well as various differentiation pathways (Puceat, 2007). 
 
2.2 Proline metabolism 
Proline is one of 22 natural genetically encoded proteinogenic amino acids. It is traditionally 
classified as nonessential in mammals, since there are two metabolic pathways available to 
synthesize proline either from glutamate or ornithine (Hu et al, 2008 B) as shown in Figure 7. 
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Figure 7: Metabolic pathways involved in proline synthesis  
In mammals there are two proline-forming pathways, both joining at γ-glutamic semi-aldehyde (GSA). GSA can 
either be formed from glutamic acid linking proline synthesis to the citric acid cycle catalyzed by the enzyme Δ1-
pyrroline-5-carboxylate synthetase (P5CS) or from ornithine by the enzyme ornithine aminotransferase (OAT) 
linking proline synthesis to the urea cycle (modified after Kao and Puck, 1967). 
 
 The bifunctional ATP- and NAD(P)H-dependent enzyme Δ1-pyrroline-5-carboxylate 
synthetase (P5CS) catalyzes the conversion of glutamate to γ-glutamic semi-aldehyde (GSA), 
which is in tautomeric equilibrium with Δ1-pyrroline-5-carboxylate (P5C) (Figure 8). P5CS 
contains two enzymatic domains: The γ-glutamyl kinase (γ-GK) converts glutamate to γ-
glutamyl phosphorylate (γ-GP), a labile and reactive intermediate. The γ-glutamyl 
phosphorylate reductase (γ-GPR) then enables the reaction to γ-glutamic semi-aldehyde (γ-
GSA) (Hu et al, 2008 A). Two different P5CS isoforms generated by alternative splicing are 
known in multicellular eukaryotes. They differ only by a two amino acid insert at the N-
terminus of the γ-GP site: P5CS.short is non-competitively inhibited by ornithine whereas 
P5CS.long is insensitive to ornithine. P5CS is a unidirectional enzyme. The reverse reaction 
from pyrroline-5-carboxylate to glutamate is catalyzed by pyrroline-5-carboxylate 
dehydrogenase (P5CDH). The key enzyme of the second proline-forming pathway is the 
ornithine-aminotransferase (OAT) catalyzing the reversible reaction from ornithine to GSA. 
Different from the enzyme P5CS, both reactions are catalyzed by the bidirectional OAT. Both 
P5CS and OAT are nuclear-encoded, but are localized in the mitochondria: P5CS in the inner 
membrane and OAT in the matrix (Hu et al, 2008 A). From pyrroline-5-carboxylate, which 
forms an equilibrium with γ-glutamic semi-aldehyde, synthesis to proline is catalyzed by the 
cytosolic enzyme pyrroline-5-carboxylate reductase (P5CR) (Figure 8). The opposite reaction 
from proline back to P5C is enabled by the inner-membrane mitochondrial enzyme proline 
oxidase (POX) (Hu et al, 2008 B). 
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Figure 8: Proline forming pathways from glutamate and ornithine in detail 
The bifunctional enzyme P5CS with kinase and dehydrogenase activity facilitates the conversion of glutamate to 
glutamic semialdehyde via the intermediate glutamate-5-phosphate. In addition, glutamic semialdehyde can be 
synthesized from ornithine catalyzed by the enzyme OAT. The common intermediate is in an equilibrium with 
the spontaneously formed Δ1-pyrroline-5-carboxylate, which can then react to proline catalyzed by the enzyme 
P5CR. 
 
The CHO cell line is known to be proline auxotroph. Kao and Puck (1967) analyzed the 
required proline concentration in media for growth and survival of the proline auxotroph 
parental CHO cell line and described the formation of proline prototroph cell lines from 
proline-free media. This proline auxotrophy is caused by a deficiency in both available 
proline catabolic pathways: Baich (1977) describes a deficiency of CHO-K1 cell in the OAT 
function and Smith et al (1980) were able to demonstrate the inability of CHO-K1 to form 
P5C from glutamate indicating a deficiency in the P5CS enzyme. Hu et al (1999) were able to 
demonstrate that both murine P5CS isoforms complement the proline auxotroph phenotype 
in CHO cells. After transfection of murine P5CS cDNA into a subclone of CHO-K1 cells 
known for deficiency in P5CS activity, they selected stable transfectants in a medium lacking 
proline and assayed P5CS activity on individual clones.  
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2.3 Aim of thesis 
CHO cell lines are the major host cell lines for recombinant protein production for 
therapeutic as well as research applications due to their ability of post-translational 
modifications. Cell line development is currently one of the critical steps. Therefore, there are 
ongoing efforts to further improve not only the timeline of cell line development but also the 
development of novel robust selection and enrichment strategies.  
  
The aim of this project is to establish an improved CHO expression system for the 
production of recombinant proteins. One aspect is the development and characterization of a 
novel selection system based on the proline metabolism. Furthermore, the project comprises 
the development of an improved process for the isolation of high-producers.  
CHO cells are known to be proline auxotroph (Kao and Puck, 1967). But no selection system 
based on the proline metabolism has been described so far. In the first step, the proline 
metabolism of different CHO cell lines will be characterized by isolation of proline 
prototroph cell lines from proline-free medium and analysis of these different cell lines 
regarding P5CS and OAT sequence, protein expression and mRNA levels. Based on these 
results, a novel selection system using the enzyme P5CS as a selection marker should be 
established. This includes the construction of a suitable dicistronic expression vector as well 
as the optimization of transfection and selection protocols for a fluorescent protein. Once the 
novel expression system will be established, general applicability should be demonstrated by 
the expression of different recombinant proteins of interest for production processes 
including monoclonal antibodies and cytokines. To further analyze production capacities of 
the novel expression system based on P5CS, clones will be isolated and analyzed in batch 
and fed-batch shake flaks cultures.  
In addition to a suitable selection system, the isolation of clones with extraordinarily high 
production capacities and growth characteristics suitable for the production process is a 
critical step during cell line development. In the second part of this project a tricistronic 
expression vector allowing coupled expression of GOI, selection marker and an additional 
reporter protein will be constructed and optimized making use of the novel P5CS selection 
system. GOI and reporter protein expression should correlate due to the coupled expression 
and will be revised. Finally, high-producer isolation by both FACS and MACS will be 
established and compared to traditional clone isolation by limiting dilution. 
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3 Results 
3.1 Development of a novel selection system 
3.1.1 Characterization of proline metabolism in CHO cells 
3.1.1.1 Isolation of proline-prototroph CHO cell lines 
To characterize their ability to grow in proline-free medium, CHO-K1 cells were seeded in a 
24-well plate at 2x104 cells per well in mimimum essential medium (MEM), supplemented 
with 10% dialyzed FBS (dFBS), glutamine without and with 40 mg/L proline. Cells of two 
wells were detached from the plate using trypsin and counted in a Neubauer chamber on a 
daily base. As shown in Figure 9 A, CHO-K1 cells cultivated in a medium containing proline 
grew to a maximal cell number of 5x105 cell per 24-well within 5 days. In contrast, cells 
cultivated in proline-free medium had a period of over 10 days with no visible growth. 
Eventually, single colonies recovering to a proline-prototroph (Pro+) cell line started to grow 
up. This Pro+ cell line showed similar growth properties in proline-free medium as wildtype 
proline-auxotroph CHO-K1 cells in medium containing proline, as shown in Figure 9 B. 
From the number of seeded cells and the number of visibly formed colonies in proline-free 
medium, a reversion rate of 0.01 to 0.015% from a proline-auxotroph (Pro-) to a proline-
prototroph (Pro+) phenotype for CHO-K1 cells could be calculated. 
 
       
Figure 9: Isolation of proline-prototroph CHO-K1 cell lines  
(A) 5x105 CHO-K1 proline-auxotroph (Pro-) cells per 24-well were cultivated in MEM supplemented with 10% 
dialyzed FBS with proline (Pro- in MEM+P) and without proline (Pro- in MEM-P). (B) 5x104 CHO-K1 Pro+ cells 
were in proline-free medium and wildtype CHO-K1 Pro- cells in proline-supplemented medium.  
 
3.1.1.2 Expression of P5CS and OAT in different CHO cell lines 
As described for the CHO-K1 cell line, Pro+ cell lines able to survive and grow in proline-
free medium (MEM supplemented with glutamine and 10% dialyzed FBS) were isolated 
from CHO-S and CHO DG44 cells in the same manner. Western Blot analysis (Figure 10) of 
P5CS protein levels revealed no detectable P5CS expression in all Pro- parental cell lines. In 
(A)        (B)  
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the Pro+ cell lines, however, P5CS expression could be detected although P5CS levels 
differed between the different Pro+ cell lines. The CHO-S Pro+ cell line did not express 
detectable amounts of P5CS; the CHO DG44 Pro+ expressed P5CS at barely detectable levels, 
whereas the CHO-K1 Pro+ cell line expressed high amounts of P5CS. To ensure similar total 
protein levels between the different cell lines, GAPDH expression was analyzed. As shown 
in Figure 10, total protein levels showed only slight variations between the different CHO 
cell lines. In addition, OAT expression levels were analyzed. As a positive control, HEK cells 
giving a strong OAT and P5CS signal at lower total protein levels were used. None of the 
analyzed CHO cell lines, neither parental proline-auxotroph (Pro-), nor proline-prototroph 
(Pro+) cell lines, showed a detectable OAT expression.  
 
 
Figure 10: Western Blot analysis of P5CS and OAT in different Pro- and Pro+ CHO cell lines 
107 Pro- or Pro+ CHO-K1, CHO-S or CHO DG44 and HEK cells were lysed in 1 mL RIPA buffer and after three 10 
sec 30% sonification pulses, 70 µg protein (only 20 µg for HEK cells) per lane were separated by SDS-PAGE (4-
20% Tris-Glycine gel). Proteins were transferred onto a nitrocellulose membrane and stained with anti-P5CS or 
anti-OAT primary antibodies and anti-rabbit HRP coupled secondary antibody or directly with an anti-GAPDH 
HRP-coupled antibody. The membranes were developed using an HRP substrate.  
 
3.1.1.3 Genetic background of the Pro+ phenotype 
To analyze the genetic background of the reversion from the Pro- to the Pro+ phenotype, the 
cDNA sequence and mRNA levels of P5CS and OAT were analyzed. Since the hamster 
genome sequence was not available at that point in time the P5CS and OAT ORF of ten 
different species (Table 1) were aligned (Appendix 1, Appendix 2). These alignments were 
used to design several normal and degenerated primers. RNA was prepared from Pro+ and 
Pro- CHO-K1 cell lines and translated into cDNA. The cDNAs were amplified using the 
designed P5CS- and OAT-specific primers in a PCR and were then sequenced directly as a 
PCR product or after cloning into pGEM-T Easy vectors to facilitate better sequencing 
efficiencies. Sequence analysis of Pro+ compared to the Pro- P5CS ORF from CHO-K1 cells 
revealed no difference in the nucleotide sequence (Appendix 3).  
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Table 1: Organisms used for sequence alignment to generate P5CS and OAT specific primer  
Dipodomys ordii Kangaroo rat 
Oryctolagus cuniculus Rabbit 
Mus musculus Mouse 
Rattus norvegicus Rat 
Canis familiaris Dog  
Bos taurus Cattle 
Equus caballus Horse 
Spermophilus tridecemlineatus Thirteen-lined ground squirrel 
Cavia porcellus Guinea pig 
Homo sapiens Human 
 
In addition, the mRNA levels of P5CS and OAT in CHO-S and CHO-K1 Pro+ cells were 
compared with respect to Pro- cells using real-time PCR. The target genes (OAT and P5CS) 
of CHO-K1 Pro- and the reference gene (GAPDH) were amplified via PCR from cDNA and 
cloned into the pGEM-T Easy vector as described above. Real-time PCR using dilutions of 
these control vectors indicated that all three genes had similar efficiencies allowing a ΔΔ-CT 
analysis. The mRNA of CHO-K1 and CHO-S Pro- and Pro+ was isolated, transcribed into 
cDNA and analyzed comparing P5CS or OAT expression against the reference gene 
GAPDH. As shown in Figure 11, P5CS mRNA levels were increased in both Pro+ CHO cell 
lines when compared to the Pro- cell lines. However, the up-regulation did not directly 
correlate with protein levels. In the CHO-S Pro+ cell line, the P5CS mRNA level was about 
21.9-fold increased and about 4.5-fold in the CHO-K1 Pro+ cell line. In contrast, no 
significant increase of OAT mRNA levels could be observed in the Pro+ cell lines. The fold 
change of Pro+ compared to Pro- ranged from 1.7 to 1.9. 
 
 
Figure 11: ΔΔ-CT analysis of real-time PCR data detecting P5CS and OAT in Pro+ compared to Pro- CHO-S 
and CHO-K1 cells 
P5CS and OAT cDNA levels were detected in a semi-quantitative real-time PCR and were normalized by 
GAPDH expression levels. For ΔΔ-CT analysis the fold change of CHO-S and CHO-K1 Pro+ cell lines compared 
to Pro- parental cell lines was calculated (n= 3-4).  
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It can be concluded that the proline prototroph phenotype was caused by an increased 
expression of P5CS and that this up-regulation was dependent on the used CHO cell line.  
 
3.1.2 Generation of the dicistronic pMACS-CHO expression vector  
The pMACS 4-IRES.II vector (Figure 12 A) was used as a backbone to generate the pMACS-
CHO expression vector (Figure 12 B) with coupled expression of GOI and selection marker. 
This backbone comprised a bacterial amplification site, consisting of an ampicillin resistance 
gene and an origin of replication, a CMV5 promoter (human CMV immediate early promoter 
and enhancer fused with the tripartite leader and splicing site from the human adenovirus 5 
major late promoter) and an EMCV IRES. The multiple cloning site (MCS) and the 
intervening sequence (IVS) between promoter and IRES were replaced by a small synthetic 
intron (donor site from first intron of human beta-globin gene and branch/acceptor site from 
intron of an immunoglobulin gene) and a new MCS featuring different restriction enzyme 
sites. The CD4 cDNA and PolyA behind the IRES were replaced by a second MCS and a 
BGH PolyA sequence.  
 
                   
Figure 12: Vector maps of the pMACS 4-IRES.II used for MACS-isolation of transiently transfected cells and 
the new designed and generated pMACS-CHO expression vector 
The bacterial amplification site, promoter and IRES were used from the original pMACS 4-IRES.II vector (A). 
Integration of new multiple cloning sites, a synthetic intron, a BGH PolyA signal and different GOIs and selection 
markers generated the pMACS-CHO expression vector (B). 
 
The GOIs were integrated into this novel pMACS-CHO expression vector in the first MCS in 
front of the IRES. The latter were cDNA sequences of different model proteins: GFP, heavy 
and light chain of a humanized anti-CD303 antibody (humanized variable regions, human 
IgG1 and kappa constant regions), heavy and light chain of chimeric anti-Biotin and anti-
CD14 antibodies (murine variable regions, human IgG1 and kappa constant regions) and 
human TGF-β1 with a signal sequence of α-Fibrinogen (FGA). Selection markers, again 
(A)             (B)  
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integrated as cDNA sequences into the second multiple cloning site behind the IRES, 
included: mouse P5CS (Aldh18a1) transcription variant 1, neomycin, hygromycin B and 
zeocin resistance genes and CHO-K1 GS. All sequences were either synthetically produced 
(DNA2.0) and codon optimized for expression in mammalian cells or cloned from different 
commercial vectors. All gene sequences comprised the Kozak sequence “GCC GCC ACC” in 
front of the start codon for optimized initiation of translation. 
 
3.1.2.1 Characterization of pMACS-CHO in transient transfections 
To determine the characteristics of the pMACS-CHO expression vector, several different 
constructs (pAS-5, pAS-8, pAS-16, pAS-17, pAS-18) were transiently transfected into CHO-
K1 cells and GFP expression was monitored by flow cytometry 48 hours after transfection. 
To determine whether the second gene behind the IRES does influence the first gene in front 
of the IRES in transient transfections, the vectors contained GFP as a GOI and either no gene 
or different selection marker genes behind the IRES. As shown in Table 2, the expression 
intensity measured as GFP mean fluorescence intensity (MFI) was reduced from 9% to 31% 
due to the second gene in five independent transfections at similar transfection efficiencies.  
 
Table 2: Influence of the second gene on the expression of the first gene in the pMACS-CHO vector in 
transient transfections  
CHO-K1 cells were transfected with the vectors pAS-5, pAS-8, pAS-16, pAS-17 or pAS-18 and the GFP 
fluorescence was analyzed by flow cytometry 48 hours after transfection (n=5). 
Vector Vector description Size of gene behind 
IRES 
% GFP GFP MFI 
   Mean Standard 
deviation 
Mean Standard 
deviation 
pAS-5 GFP-IRES 0 bp 46.7 6.7 567.4 68.5 
pAS-8 GFP-IRES-neoR 1041 bp 40.8 4.7 511.6 73.3 
pAS-16 GFP-IRES-P5CS 2439 bp 38.7 8.4 408.5 63.9 
pAS-17 GFP-IRES-GS 1176 bp 44.3 3.6 478.0 47.7 
pAS-18 GFP-IRES-hygroR 1062 bp 37.2 5.6 391.1 60.2 
 
In parallel, the vectors pAS-5, pAS-9, pAS-31, pAS-32 were transiently transfected and the 
GFP fluorescence was monitored by flow cytometry after 48 hours. This set of experiments 
was dedicated to find out how strong the expression of the second gene is compared to the 
first gene and whether the integration of a first gene influences the IRES-dependent 
translation. As shown in Table 3, the expression intensity of GFP at the second position 
behind the IRES was only 3% of the CAP-translated intensity at the first position. Integration 
of two different sequences in front of the IRES did not further reduce the expression of the 
IRES-dependent GFP. In fact, an even higher GFP MFI could be observed with one of the 
sequences (pAS-32).  
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Table 3: Influence of the second gene on the expression of the first gene in the pMACS-CHO vector in 
transient transfections 
CHO-K1 cells were transfected with the vectors pAS-5, pAS-9, pAS-31 or pAS-32 and the GFP fluorescence was 
analyzed by flow cytometry 48 hours after transfection (n=5). 
Vector Vector description Size of gene 
before IRES 
% GFP GFP MFI 
   Mean Standard 
deviation 
Mean Standard 
deviation 
pAS-5 GFP-IRES - 46.7 6.7 567.4 68.5 
pAS-9 IRES-GFP 0 bp 18.1 6.2 18.4 2.0 
pAS-31 HC anti-CD-303-IRES-GFP 1098 bp 7.4 1.8 16.0 1.2 
pAS-32 LC anti-CD303-IRES-GFP 723 bp 18.7 4.0 34.6 3.7 
 
3.1.2.2 Comparison of different vector designs 
The newly generated pMACS-CHO expression vector (Figure 12 B) features a coupled 
expression of GOI and selection marker, due to an IRES site. It was compared to a pSV2-
hCMV (pSV2) vector with a two-promoter strategy. Both vectors comprise the same hCMV 
promoter, GFP as GOI and neomycin resistance gene as selection marker. In the pSV2-hCMV 
vector, the expression of the selection marker is under control of a SV40 early promoter. Both 
vectors (pSV2neo-hCMV-GFP and pAS-8) were transfected (T4.3 and T4.4) into CHO-K1 
cells in two separate transfections. Stable cell lines were generated by neomycin selection 
and GFP expression was monitored at every passage using flow cytometry. For or all used 
antibiotic selection markers, optimal antibiotic concentrations were determined by titration 
in killing curves with parental cells and by testing of different concentrations during the 
selection process (data not shown). As shown in Figure 13 A, stable cell lines generated with 
the pMACS-CHO vector (pAS-8) showed high GFP producer rates of 78% to 90% on day 20 
after transfection, while still increasing over culture time and reaching up to 99% GFP 
producers around day 40 after transfection. Stable cell lines generated using the pSV2 vector 
(pSV2neo-hCMV-GFP) only reached maximum GFP producer rates of 32% declining over 
culture time. In addition, differences can also be seen in the MFI of the GFP signal. The MFI 
of cell lines generated by transfection of the pMACS-CHO vector ranged from 70 to 150. Cell 
lines generated by transfection of the pSV2 vector had a much lower MFI, ranging from 20 to 
40 (Figure 13 B).  
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Figure 13: Stable cell lines expressing GFP generated by different vector designs 
Expression vectors with separate expression cassettes of GFP and neomycin selection marker (pSV2) or IRES 
coupled expression (pMACS-CHO) were compared in a stable cell line generation process (T4.3/4.3 pSV2-hCMV-
GFP or pAS-8): (A) number of GFP positive cells, (B) GFP MFI. 
 
Thus, although integration of an IRES-dependent gene into the pMACS-CHO vector did 
reduce the expression levels of the CAP-dependent gene in transient transfection, the 
coupling of GOI and selection marker led to stable cell lines with high producer rates and 
expression levels. 
 
3.1.3 P5CS as a novel selection marker 
For first studies of the suitability of P5CS as a selection marker in CHO cells, the enhanced 
GFP was chosen as GOI, due to its ease of detection in flow cytometry and microscopy. 
CHO-K1 cells were transfected (T4.4) with the vector pAS-16 (pMACS-CHO, GOI: GFP, 
selection marker: P5CS) and stable cell lines were generated in a proline-free selection 
medium containing 10% dialyzed FBS (MEM supplemented with glutamine and 10% dFBS). 
At each passage the stable cell lines were analyzed for their GFP fluorescence by flow 
cytometry. Using P5CS as selection marker, it was possible to generate stable cell lines (T4.4 
pAS-16 I and II) with up to 98% GFP-expressing cells and stable GFP MFI (Figure 14). As one 
drawback the long selection time must be mentioned. Up to 100 days were required to reach 
producer rates of over 90%. In about 50% of all generated cell lines, it was possible to 
generate high producer cell lines with over 90% GFP-positive cells (e.g. T4.4 pAS-16 II). In 
other cases the producer rate stagnated or even decreased again (e.g. T4.4 pAS-16 I). 
 
 
 
 (A)            (B)  
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Figure 14: Stable GFP-expressing CHO-K1 cell lines selected by P5CS in proline-free medium  
CHO-K1 cells were transfected (T4.4) with the vector pAS-16 and selected in MEM supplemented with 10% 
dialyzed FBS. GFP expression was monitored at every passage using flow cytometry: (A) Percentage of GFP 
positive cell, (B) GFP MFI. 
 
Since Western Blot analysis of P5CS protein levels of Pro+ cells and parental Pro- cell lines 
revealed differences between CHO cell lines (Figure 10), it was suspected that the different 
CHO cells might also differ in their sensitivity to P5CS selection. Therefore, the stable cell 
line generation process was tested with the different CHO cell lines CHO-K1, CHO-S and 
CHO DG44 (T4.4/4.11 pAS-16) and the rate of GFP-positive cells was again monitored. As 
shown in Figure 15, the selection times of different CHO cell lines showed large variations. 
On day 50 after transfection, a stable CHO-S cell line (CHO-S T4.11 pAS-16) had a GFP-
producer rate of 79% compared to a CHO-K1 cell line (CHO-K1 T4.4 pAS-16) with 60% and a 
CHO DG44 cell line (CHO DG44 T4.11 pAS-16) with only 27% GFP-producers. Similarly, the 
GFP MFI was highest in the CHO-S cell line, followed by CHO-K1 and CHO DG44 cell lines. 
 
          
 
Figure 15: Test of feasibility of different CHO cell lines in a P5CS selection system 
CHO-K1, CHO-S and CHO DG44 cells were transfected (T4.4/4.11) with the vector pAS-16 and selected in MEM 
supplemented with 10% dialyzed FBS. GFP expression was monitored at every passage using flow cytometry: (A) 
Percentage of GFP positive cell, (B) GFP MFI. 
 
(A)        (B)  
(A)           (B)  
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To further improve selection times, MEM supplemented with glutamine, ITS+3 and a 
reduced dialyzed FBS concentration of 5% was tested in the cell line generation process. The 
reduction of dialyzed FBS led to a reduction of proline traces in the medium. Amino acid 
analysis of the used FBS lot revealed a proline concentration of 0.39 mM proline (Appendix 
4). Using 10% FBS supplement in the medium, this resulted in a concentration of 0.039 mM 
proline, while using 5% FBS resulted in 0.0195 mM. Reduction of proline concentration 
dramatically improved the selection time in all tested CHO cell lines. In CHO-K1 cells it was 
possible to reach over 90% GFP-positive cells within 16 days (Figure 16, T4.44 pAS-16 I) 
instead of over 100 days (Figure 16, T4.17 pAS-16), previously.  
 
 
Figure 16: Influence of FBS concentrations in selection medium on P5CS selection system 
CHO-K1 cells were transfected (T4.17) with the vector pAS-16 and selected in MEM supplemented with ITS+3 
and with 5% or 10% dialyzed FBS. Number of GFP positive cells was monitored at every passage using flow 
cytometry. 
 
    
 
Figure 17: Reproducible and fast P5CS selection in CHO-S cells 
CHO-S cells were transfected (T4.18) with the vector pAS-16 and selected in CHO-MEM supplemented with 5% 
dialyzed FBS. GFP expression was monitored at every passage using flow cytometry: (A) Percentage of GFP 
positive cell, (B) GFP MFI. 
(A)           (B)  
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Transfecting the CHO-S cell line in triplicates and generating stable cell line (T4.18 pAS-16 I, 
II and II) in the serum-reduced selection medium with 5% dialyzed FBS showed that 
reproducible producer rates of over 90% in 20 days with constant GFP MFIs could be 
reached with the novel P5CS selection (Figure 17 A and B).  
 
From these experiments it was concluded that the CHO-S cell line might be the most suitable 
one for the P5CS selection system. Using CHO-S cells allowed fast and reproducible stable 
cell line generation for the expression of a fluorescent protein.  
 
3.1.3.1 P5CS as a selection marker for the expression of monoclonal antibodies 
To test the performance of the P5CS selection system for the expression of monoclonal 
antibodies, a two-vector strategy was chosen. In a first transfection (T4.14 pAS-21+23) the 
anti-CD303 antibody was expressed in CHO-S cells and stable cells were selected by a 
combination of P5CS selection for the heavy chain and neomycin selection for the light chain 
in a selection medium containing 10% dialyzed FBS. The isolated stable cell line produced 
about 100 ng/mL antibody. Clones were isolated by manual clone picking from a semi-solid 
medium containing a FITC-labeled antibody to stain secreted antibody. The isolated clones 
produced between 95 and 364 ng/mL (Figure 18).  
 
 
Figure 18: Stable cell line expressing anti-CD303 and isolated clones thereof  
CHO-S cells were cotransfected with pMACS-CHO vectors (T4.14 pAS-21 and pAS-23) encoding for heavy and 
light chain of the anti-CD303 antibody. Stable cells were selected by P5CS and neomycin selection. Clones were 
isolated from the stable cell line by a manual clone picking process from semi-solid medium with identification of 
producing clones by labeling of secreted antibody via a FITC-conjugated detection antibody. 
 
Similar to the expression of GFP as a model protein, the reduction of dialyzed FBS from 10% 
to 5% greatly enhanced the productivity of isolated cell lines. Furthermore, different 
selection protocols such as different splitting rates 24 hours after transfection and different 
points in time of addition of the selection medium (24 hours, 48 hours or 72 hours after 
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transfection) were tested (data not shown). Experiments indicated that a harsh split (1:20) 
together with the addition of selection medium (both removal of proline and addition of 
antibiotics) 24 hours after transfection resulted in the highest titers. As a low serum proline-
free medium the CHO-MEM medium was developed containing 5% dialyzed FBS and 
various supplements to enhance growth and productivity (data not shown). As mentioned 
above, similar results were obtained expressing GFP in a one-vector strategy using the P5CS 
selection system only. To further improve the selection system, expression vectors containing 
heavy or light chain genes were combined with different selection markers. Stable cell lines 
expressing anti-CD303 were generated using the low serum (5%) protocol and productivity 
was measured as maximum antibody concentrations in the supernatant of overgrown 
cultures (T4.20/25 pAS-21+23, pAS-19+25, pAS-21+55, pAS-25+54, pAS-21+47, pAS-25+46). 
Of all tested selection marker combinations the expression of the heavy chain using P5CS 
selection and expression of the light chain using zeocin selection resulted in the highest 
antibody titers with a mean of 3.7 µg/mL (Figure 19).  
 
 
Figure 19: Comparison of different selection marker combinations for generation of anti-CD303-expressing 
cell lines 
CHO-S cells were cotransfected (T4.20/25) with pMACS-CHO vectors encoding for heavy and light chain of the 
anti-CD303 antibody containing different selection markers (pAS-21+23, pAS-19+25, pAS-21+55, pAS-25+54, 
pAS-21+47, pAS-25+46). Cells were selected in CHO-MEM supplemented with 5% dialyzed FBS missing 
corresponding amino acids (P5CS: proline, GS: glutamine) or containing antibiotics needed for selection. An 
IgG/kappa-specific ELISA was used to monitor the antibody titers in supernatants of overgrown cultures on day 
55 after transfection (n=1-2). 
 
In further experiments, the combination of HC-P5CS and LC-zeocin selection was compared 
to a selection using antibiotics only. A neomycin resistance gene for the heavy chain selection 
replaced the P5CS, while the zeocin resistance gene remained on the vector for the light 
chain selection. The generated cell lines (T4.25 pAS-21+55 I and II or pAS-19+55 I and II) 
produced about 1-2 mg/L monoclonal antibody on day 45 after transfection using a 
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combination of P5CS and zeocin selection or a combination of neomycin and zeocin selection 
(Figure 20). At around day 60, the stable producer cell lines showed an additional increase in 
titers. Using P5CS combined with zeocin selection antibody titers of up to 8 mg/L were 
reached in minimal medium (CHO-MEM) and up to 4 mg/L using neomycin and zeocin 
selection. 
 
 
Figure 20: Comparison of P5CS/zeocin selection to neomycin/zeocin selection for generation of anti-CD303-
expressing cell lines 
CHO-S cells were cotransfected (T4.25) with pMACS-CHO vectors (pAS-19+55 or pAS-21+55) encoding for heavy 
and light chain of the anti-CD303 antibody containing different selection markers. Cells were selected by proline-
free zeocin-containing CHO-MEM or by a proline-supplemented zeocin- and neomycin-containing CHO-MEM 
supplemented with 5% dialyzed FBS. The antibody titers in supernatants of overgrown cultures were monitored 
by an IgG/kappa-specific ELISA. 
 
Intracellular staining of the cell lines T4.25 pAS-19+55 II (= HC-neomycin+LC-zeocin) and 
pAS-21+55 II (= HC-P5CS+LC-zeocin) on day 72 after transfection using an APC-labeled 
anti-human IgG antibody and a FITC-labeled anti-human kappa antibody analyzed by flow 
cytometry (Figure 21) revealed double producer rates of heavy and light chain of 85% for the 
P5CS/zeocin selection (Figure 20: T4.25 pAS-21+55 II) and 77% for the neomycin/zeocin 
selection (Figure 20: T4.25 pAS-19+55 II). 
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Figure 21: Intracellular staining of IgG (HC) and kappa (LC) in stable anti-CD303-expressing CHO-S cell lines 
CHO-S cells expressing anti-CD303 selected by (A) P5CS/zeocin (T4.25 pAS-21+55 II) or (B) neomycin/zeocin 
(T4.25 pAS-19+55 II) selection were fixed and permeabilized. Intracellular IgG chains were stained with a specific 
antibody coupled to APC and intracellular kappa chains were stained with a specific antibody coupled to FITC. 
APC and FITC signals were monitored by flow cytometry. 
 
On day 57 after transfection, a limiting dilution of the highest producing cell lines (Figure 20: 
T4.25 pAS-21+55 II and pAS-19+55 II) for each selection marker combination was performed. 
After about 20 days, the supernatants of 75 to 81 wells containing single clones were 
screened in an ELISA. The determined antibody concentrations are shown in Figure 22. The 
titer distribution of clones isolated by limiting dilution confirmed the high producer rates 
determined by previous intracellular staining of the starting producer cell lines, as hardly 
any of the screened clones secreted no antibody.  
 
      
Figure 22: Clone distribution of clones isolated by limiting dilution from the stable cell lines T4.25 pAS-21+55 
II or pAS-19+55 II 
Stable CHO-S cell lines expressing anti-CD303 selected by (A) P5CS/zeocin (T4.25 pAS-21+55 II) or (B) 
neomycin/zeocin (T4.25 pAS-19+55 II) were subjected to a limiting dilution. Supernatants of 96-wells containing 
a clone were screened in IgG/kappa-specific ELISA. 
 
 (A)             (B)  
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All clones expressing more than 0.5 mg/L in the first screen were expanded. For further 
analysis 2x105 cells were seeded per 12-well. After 52 hours, cells were counted to determine 
the clones´ growth properties. Also, the antibody concentration of the supernatants was 
determined at that point in time (Figure 23). For both selection marker combinations 
proliferation during the 52 hours ranged from no expansion to doubling times of 26 hours 
(data not shown). However, the range of observed proliferation rates is comparable between 
the different selection marker combinations. The amount of antibody produced by 1x105 cells 
during the culture period ranged from 0.4 to 1.71 µg/mL.  
 
         
Figure 23: Clone analysis of clones isolated by limiting dilution from the stable cell lines T4.25 pAS-21+55 II 
or pAS-19+55 II 
CHO-S clones expressing anti-CD303 were isolated by limiting dilution from (A) T4.25 pAS-21+55 II or (B) T4.25 
pAS-19+55 II. Best producing clones of the 96-well screen were expanded. For analysis 2x105 cells of these clones 
were seeded per 12-well and antibody titer as well as viable cell number were determined after 52 hours. The 
produced antibody amount during this time frame was calculated per 1x105 cells. 
 
 
        
Figure 24: Clone analysis of clones isolated by limiting dilution from the stable cell lines T4.25 pAS-21+55 II 
or pAS-19+55 II 
CHO-S clones expressing anti-CD303 were selected by (A) P5CS/zeocin (T4.25 pAS-21+55 II) or (B) 
neomycin/zeocin (T4.25 pAS-19+55 II). Best producing clones of the 96-well screen were expanded. For analysis 
2x105 cells of these clones were seeded per 12-well and the antibody titer of overgrown cultures was determined 
by an IgG/kappa-specific ELISA. 
 
 (A)                                (B)  
  (A)                                     (B)  
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As an additional parameter for clone selection, a second 12-well with 2x105 seeded cells was 
used to determine the maximum titer (Figure 24). For the analyzed clones selected by P5CS 
and zeocin, the mean titer amounted to 6.9 µg/mL, with individual clones ranging from 1.7 
to 13.4 µg/mL. In comparison, the mean of all analyzed clones isolated with neomycin and 
zeocin selection was only 5.4 µg/mL, with individual clones ranging from 1.2 to 15.1 µg/mL. 
The mean titer of clones selected by P5CS and zeocin was 1.3-fold higher than that of clones 
selected by neomycin and zeocin. 
 
To verify the usability of the P5CS selection system for the expression of other monoclonal 
antibodies, the cell line generation process and the clone isolation by limiting dilution were 
repeated for two additional antibodies, anti-Biotin (T4.32 pAS-97+100 II or pAS-98+100 I and 
II) and anti-CD14 (T4.33 pAS-102+105 I and II or T4.32 pAS-103+105 I and II). Both 
antibodies are encoded by mouse variable regions and human constant regions (IgG1 and 
kappa). For both test constructs, it was possible to generate stable producer cell lines with 
titers of about 0.2-1.5 µg/mL, as shown in Figure 25.  
 
          
Figure 25: Comparison of P5CS/zeocin selection to neomycin/zeocin selection for generation of anti-Biotin- 
and anti-CD14-expressing cell lines 
CHO-S cells were cotransfected (T4.32/4.33) with pMACS-CHO vectors for heavy and light chain of the (A) anti-
Biotin (pAS-97+100 or pAS-98+100) or (B) anti-CD14 (pAS-102+105 or pAS-103+105) antibody containing 
different selection markers. Cells were selected in a proline-free, zeocin-containing or a proline-supplemented, 
zeocin- and neomycin-containing CHO-MEM supplemented with 5% dialyzed FBS. The antibody titers in 
supernatants of overgrown cultures were monitored by an IgG/kappa-specific ELISA over time. 
 
Analysis of the titer distribution of clones isolated by limiting dilution from the stable 
producer cell lines (T4.32 pAS-97+100 II, T4.32 pAS-98+100 II, T4.33 pAS-102+105 I or T4.32 
pAS-103+105 I) on day 23 to 37 after transfection again revealed high producer rates of 93% 
(A)                                     (B)  
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to 98% (Table 4). Maximum titers of clones isolated by limiting dilution ranged from 3.9 
µg/mL for anti-Biotin to 3.2 µg/mL for anti-CD14. Mean titers ranged from 1.0 µg/mL for 
anti-Biotin to 0.8 µg/mL for anti-CD14. In contrast to the model antibody anti-CD303, for 
both anti-CD14 and anti-Biotin the titers of clones isolated by P5CS/zeocin selection were 1.4 
to 2.0-fold lower compared to neomycin/zeocin selection. 
 
Table 4: Comparison of P5CS/zeocin and neomycin/zeocin selection for the expression of three monoclonal 
antibodies in CHO-S stable cell lines or clones isolated by limiting dilution. 
Stable cell lines expressing anti-CD303 (T4.25 pAS-21+55 II or pAS-19+55 II), anti-Biotin (T4.32 pAS-97+100 II or 
pAS-98+100 II) or anti-CD14 (T4.33 pAS-102+105 I or T4.32 pAS-103+105 I) were used to isolate clones by limiting 
dilution. Upgrowing clones were screened in the 96-well plate for antibody titers. The producer rates were 
calculated from the number of clones expressing antibody and the total amount of screened clones.  
 
Starting cell 
line titer  
(µg/mL) 
Number of 
screened clones 
Maximal 
titer clones 
(µg/mL) 
Mean titer 
clones 
(µg/mL) 
Producer 
rate 
 
anti-CD303 
 
P5CS 
+zeocin 5.73 81 >6.50 1.68 91% 
neomycin 
+zeocin 2.83 75 3.75 0.76 97% 
 
anti-Biotin 
 
P5CS 
+zeocin 0.36 53 1.76 0.55 98% 
neomycin 
+zeocin 1.07 83 3.90 1.04 94% 
 
anti-CD14 
 
P5CS 
+zeocin 0.83 124 2.14 0.58 98% 
neomycin 
+zeocin 1.17 67 3.17 0.81 91% 
 
Based on the results obtained by expressing different recombinant antibodies, it was 
concluded that the developed P5CS system might lead to similar expression levels as 
antibiotic selections. 
 
3.1.3.1.1 Batch production in suspension shake cultures 
The ten highest producing clones (of the stable cell line T4.25 pAS-21+55 II) expressing the 
anti-CD303 antibody isolated by P5CS/zeocin selection and limiting dilution (Figure 20 and 
Figure 24) were adapted to the serum-free and zeocin-containing production medium CHO 
MACS CD custom-made without proline. The cells were incubated in Erlenmeyer flasks in 
an orbital shake reactor. After a period of about four weeks to allow adaptation to serum-free 
conditions and the shake incubator, viability recovered to over 90% and clones were 
subjected to a determination of specific productivities. Therefore, clones were seeded at 2x105 
cells/mL and each day an aliquot was taken to measure antibody titer and cell number 
(Figure 26 and Table 5). For all analyzed clones, an increase in maximum titers of 2- to 6-fold 
compared to static, adherent culture condition could be observed. The highest antibody 
concentration was produceded by clone 4A2 and amounted to 63 mg/L. Viable cell densities 
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of up to 7.5x106 cells/mL could be reached by day 6 in this batch process (clone 4A5). The 
highest specific productivity, defined as pg amount of recombinant antibody produced by 
one cell in 24 hours, obtained in this batch process was 10 pg/(cell*day) (pcd) (clone 3C3) 
(Figure 26 and Table 5).  
 
 
Figure 26: Batch process with anti-CD303-expressing clones isolated by P5CS and zeocin selection  
CHO-S clones (of the stable cell line T4.25 pAS-21+55 II) expressing anti-CD303 were selected by P5CS and zeocin 
and isolated by limiting dilution. Clones were seeded at 2x105 cells/mL in 30 mL proline-free CHO MACS CD 
containing 100 µg/mL zeocin in 125 mL Erlenmeyer flask and were cultivated in an orbital shake incubator. 
Daily, samples were taken to determine antibody titers and cell numbers to calculate specific productivities.  
 
Table 5: Overview of batch process with limiting dilution clones of stable cell line T4.25 pAS-21+55 II  
Batch process with CHO-S clones (of stable cell line T4.25 pAS-21+55 II) expressing anti-CD303 isolated by 
limiting dilution.  
Clone Max. titer  
(mg/L) 
Max. viable cell density  
(mL-1) 
Specific 
productivity (pcd) 
Days of culture before 
vitality dropped under 80% 
2B4 25.30 4.08 x106 2 7 
4A5 28.40 8.90 x106 1 7 
3B3 32.13 7.45 x106 1 7 
4C5 36.79 2.70 x106 3 5 
4A4 37.35 5.38 x106 3 6 
2C3 43.53 6.12 x106 2 7 
3D5 45.26 2.85 x106 5 6 
3A5 46.59 5.01 x106 1 8 
3C3 56.06 1.79 x106 10 5 
4A2 63.00 5.10 x106 3 7 
 
To further improve the batch process, different production media containing proline – 
namely ExCell CD CHO, HyClone SFM4CHO, Gibco FreeStyle CHO, CD FortiCHO and 
CHO MACS CD – were tested with the two best producing clones T4.25 pAS-21+55 II 3C3 
and 4A2. Clones were adapted to the different proline-containing media supplemented with 
100 µg/mL zeocin for 4 weeks. The clone 3C3, which showed slow growth and had 
previously difficulties adapting to the shake incubator, did only survive adaptation to ExCell 
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CD CHO and HyClone SFM4CHO. For the batch process, zeocin was removed and cells 
were seeded at 2x105 cells/mL with daily monitoring of antibody concentration in the 
supernatant and cell counting. As shown in Figure 27 and Table 6, maximum titers of only 
18.7 mg/L could be reached. When comparing the growth and production properties of 
clone 4A2 in the different media, HyClone SFM4CHO led to highest titers, closely followed 
by CHO MACS CD (8.5% lower). However, the highest viable cell density being 3-fold 
higher compared to the density in HyClone SFM4CHO could be observed in CHO MACS 
CD. Cultivation of the clone in the other tested media led to lower titers.  
 
 
Figure 27: Batch process to test different production media 
Two best CHO-S clones (T4.25 pAS-21+55 II 3C3 and 4A2) expressing anti-CD303 selected by P5CS and zeocin 
were adapted to five different serum-free commercially available production media with proline. Cells were 
seeded at 2x105 cells/mL in 30 mL of in 125 mL Erlenmeyer flasks and were cultivated in an orbital shake 
incubator. Daily, samples were taken to determine antibody titers and cell numbers to calculate specific 
productivities.  
 
Table 6: Overview of batch process with different production media 
Batch process with the CHO-S clones 3C3 and 4A2 (of stable cell line T4.25 pAS-21+55 II) expressing anti-CD303 
and isolated by limiting dilution in different media.  
Clone! Medium Max. titer 
(mg/L)!
Max. viable 
cell density 
(mL-1)!
Specific 
productivity 
(pcd)!
Days of culture 
before vitality 
dropped under 80% 
3C3 ExCell 10.43 7.72 x10
6 5 4 
HyClone 18.69 1.34 x106 9 5 
 
4A2 
ExCell 11.03 1.34 x106 5 4 
HyClone 16.49 3.33 x106 4 6 
CHO MACS 15.09 9.44 x106 1 6 
FreeStyle 6.51 6.72 x106 1 4 
FortiCHO 12.77 4.04 x106 2 4 
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3.1.3.1.2 Fed-batch production in suspension shake cultures 
The two best producing clones (T4.25 pAS-21+55 II 3C3 and 4A2) of the batch process 
(Figure 26) were cultivated in a fed-batch process. Cultures for inoculation were maintained 
in CHO MACS CD medium without proline, containing 100 µg/mL zeocin. For the fed-
batch, 2x105 cells/mL were seeded in proline-free CHO MACS CD medium containing 0, 50 
or 100 µg/mL zeocin to get first indications about the stability of clones with respect to 
zeocin. Starting on day 3, cells were fed with CHO MACS Feed Supplement, which containes 
proline. Thus, the selection pressure of the P5CS selection was removed in all cultures at this 
point in time. For two to three days, a feed of 3.1% of culture volume was given. Once viable 
cell densities of over 5x106 cells/mL were reached, the feed was increased to 7.5% for another 
two days and finally raised to 8% for the remaining culture time. Using a fed-batch process 
with an antibiotic concentration of 100 µg/mL zeocin, for both clones a final antibody 
concentration of over 140 mg/L could be reached (Figure 28 and Table 7). At a concentration 
of 100 µg/mL zeocin, clone 4A2 showed superior growth with a maximum living cell 
density of 2x107 cells/mL compared to clone 3C3. Clone 3C3 showed lower viable cell 
densities of maximal 7x106 cells/mL, but a higher specific productivity of 5 pcd (Figure 28 
and Table 7). With decreasing zeocin concentrations, the maximum antibody concentrations 
declined. With 0 µg/mL zeocin, clone 4A2 only produced 75% of the titer at 100 µg/mL and 
clone 3C3 only 44%. In contrast, the growth and maximum viable cell density was positively 
influenced by the removal of zeocin being up to 1.6-fold higher (clone 4A2) at 0 µg/mL 
zeocin concentrations compared to concentrations of 100 µg/mL zeocin. 
 
 
Figure 28: Fed-batch process with anti-CD303-expressing clones isolated by P5CS and zeocin selection  
The two best producing clones (T4.25 pAS-21+55 II 3C3 and 4A2) identified in the batch process were cultivated 
in a fed-batch process: 2x105 cells/mL were seeded in 25 mL CHO MACS CD without proline containing 0, 50 or 
100 µg/mL zeocin in 125 mL Erlenmeyer flasks and were cultivated in an orbital shake incubator. Starting on day 
3, cultures were fed with CHO MACS Feed Supplement (3% to 8% of culture volume, increased over time). Daily, 
samples were taken to determine antibody titers and cell numbers to calculate specific productivities.  
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Table 7: Overview of a fed-batch process of T4.25 pAS-21+55 II limiting dilution clones 3C3 and 4A2 
Fed-batch process with the CHO-S clones 3C3 and 4A2 (of stable cell line T4.25 pAS-21+55 II) expressing anti-
CD303 isolated by limiting dilution in CHO MACS CD with different zeocin concentrations. Cells were fed with 
CHO MACS Feed Supplement daily.  
Clone Zeocin 
concentration 
(µg/mL) 
Max. 
titer 
(mg/L) 
Max. viable 
cell density  
(mL-1) 
Specific 
productivity 
(pcd) 
Days of culture 
before vitality 
dropped under 80% 
3C3 
0 61.52 9.10 x106 2 8 
50 133.18 1.08 x107 3 8 
100 140.28 6.75 x106 5 7 
4A2 
0 106.92 3.17 x107 2 11 
50 125.20 2.37 x107 2 11 
100 142.40 2.01 x107 2 12 
 
These results demonstrate that the isolated P5CS/zeocin-selected clones were suitable for 
protein expression under production conditions in batch and fed-batch processes.  
 
3.1.3.2 Comparison of different selection markers for the expression of cytokines 
To validate the P5CS selection system for the expression of recombinant proteins such as 
cytokines, the human transforming growth factor beta 1 (hTGF-β1) was chosen as a model 
protein. To compare the P5CS selection to antibiotic selections, vectors with P5CS as well as 
resistance genes for neomycin, hygromycin B and zeocin were generated (pJN-1, pJN-2, pJN-
3, pJN-4). CHO-S cells were transfected (T6.1/6.2) with these vectors and stable cell lines 
were generated in selection medium with a reduced dialyzed FBS content of 5%. The hTGF-
β1 expression was monitored as a maximum titer, which was determined by seeding the 
cells in a separate plate in addition to the normal culture and letting these cells overgrow to 
reach the maximum titer. The hTGF-β1 concentration in the cell culture supernatant was 
determined by a hTGF-β1-specific ELISA after acid activation. Figure 29 shows the 
production of hTGF-β1-expressing cell lines generated by the different selection markers. 
Stable cell lines generated by P5CS selection (T6.1 pJN-1 I and II) and neomycin (T6.2 pJN-2 I 
and II) or hygromycin B (T6.2 pJN-3 I and II) selection have similar hTGF-β1 production 
levels of about 17 to 34 ng/mL. In contrast, stable cell lines generated by zeocin selection 
(T6.1 pJN-4 I and II) produce 78 to 95 ng/mL hTGF-β1, which represents an approximate 
increase of about 3 to 4-fold. 
 
Results 
 40 
 
Figure 29: Comparison of different selection markers for the generation of hTGF-β1-expressing cell lines 
CHO-S cells were transfected (T6.1/6.2) with pMACS-CHO vectors (pJN-1, pJN-2, pJN-3, pJN-4) containing the 
cDNA of hTGF-β1 as GOI and P5CS or the resistance gene against neomycin, hygromycin B or zeocin as selection 
markers. Cells were selected in proline-free CHO-MEM supplemented with 5% dialyzed FBS for P5CS selection 
or in CHO-MEM supplemented with 5% dialyzed FBS and proline containing selection antibiotics. The hTGF-β1 
expression was monitored in supernatants of overgrown cultures by a TGF-β1 specific ELISA. 
 
These results demonstrate that another recombinant protein beside antibodies could be 
expressed using the P5CS selection system with comparable expression levels to neomycin 
and hygromycin B selection.  
 
3.2 Development of a novel cell enrichment system 
3.2.1 Generation and validation of the tricistronic pMACS-CHO II expression vector  
To generate the tricistronic pMACS-CHO-2A expression vector (Figure 30) with coupled 
expression of GOI and selection marker and an additional reporter protein, a 2A peptide was 
used. The 2A sequence from the foot and mouth disease virus (FMDV) (=F2A) flanked by 
two multiple cloning sites was integrated into the second multiple cloning site behind the 
IRES element of the pMACS-CHO vector. Selection marker genes were PCR-amplified with 
new restriction enzyme sites and without a stop codon and integrated in frame into the new 
second multiple cloning site between the IRES element and the 2A peptide sequence. As 
reporter proteins the fluorescent proteins RFP, GFP or membrane-bound GFP were used. 
Reporter proteins without the Kozak sequence and the start codon were integrated in frame 
behind the 2A sequence. This resulted in a fusion ORF of selection marker gene and reporter 
protein gene coupled by the 2A peptide sequence, which should lead to a cotranslational 
separation of the two proteins. As a model GOI, cDNAs of the heavy and light chains of the 
anti-CD303 antibody were integrated into the first multiple cloning sites. 
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Figure 30: Vector map of the tricistronic pMACS-CHO-2A expression vector 
Replacing the second multiple cloning site of the pMACS-CHO vector by a fusion ORF consisting of the selection 
marker gene, a 2A peptide sequence and a reporter protein generated the tricistronic pMACS-CHO-2A. 
 
Using this tricistronic pMACS-CHO-2A (pAS-83, pAS-84, pAS-85, pAS-86, pAS-107) 
expression vector for the generation of stable cell lines (T4.28/4.29/4.32/4.33) according to 
the standard selection protocol revealed several difficulties: 1. The cells did not survive the 
applied selection pressure, even with reduced antibiotic concentrations (25-50% of usual 
concentration). 2. Successfully isolated cell lines (T4.32 pAS-84+85, T4.33 pAS-85+108 and 
T4.33 pAS-86+107), which were identified as double positive in the transient transfection, 
lost expression of reporter proteins although an antibody titer comparable to cell lines 
generated with the dicistronic pMACS-CHO vector (T4.20 pAS-21+23 or T4.25 pAS-21+55 I 
or II) was determined (Figure 31). 
 
 
Figure 31: Loss of reporter protein expression in stable cell lines generated with pMACS-CHO-2A vectors 
Flow cytometry analysis of a stable CHO-S cell line (T4.33 pAS-86+107 I) cotransfected with the vectors pAS-86 
and pAS-107 expressing the anti-CD303 antibody and coexpressing the reporter proteins RFP and a membrane-
bound GFP (A) on day 2 (titer 3.0 µg/mL), (B) on day 23 (titer 1.7 µg/mL) and (C) on day 44 (titer 2.5 µg/mL) 
after transfection.  
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3. Staining CHO-S cells expressing the membrane-bound GFP, which should localize in the 
plasma membrane on the cell surface, using a GFP-specific polyclonal antibody and an 
AlexaFluor647-labeled secondary antibody did not stain any cells transiently transfected 
with a pMACS-CHO-2A expression vector (pAS-107) (Figure 32). An AlexaFluor647/GFP-
double positive population could be detected analyzing CHO-S cells transiently transfected 
with a positive control vector, the pDisplay-GFP with higher expression levels of the 
membrane-bound GFP. 
 
 
Figure 32: Staining of the membrane-bound GFP of transiently transfected cells 
Flow cytometry analysis of a CHO-S cell line transiently transfected with the vectors (A) pDisplay-GFP or (B) 
pAS-107. The cells were stained with a polyclonal rabbit anti-GFP antibody and a secondary anti-rabbit-
AlexaFluor 647 antibody. 
 
In summary, it was concluded that an inefficient cleavage of selection marker and 
fluorescent protein might be causing the observed problems. 
 
To solve these problems of the pMACS-CHO-2A vector such as inability to stain surface 
reporter proteins and diminishment of reporter protein expression, the tricistronic cassette 
was swapped. The F2A sequence was exchanged by the T2A sequence from the Thosea asigna 
virus containing a serine-glycine linker to facilitate improved cleavage. Selection marker 
genes were PCR-amplified with new restriction enzyme sites without a start codon and 
Kozak sequence but containing a stop codon and were integrated in frame into the third 
multiple cloning site. In addition, reporter proteins were PCR-amplified with new restriction 
enzyme sites without a stop codon but containing a start codon and Kozak sequence and 
were integrated in frame into the second multiple cloning site resulting in a fusion ORF of 
reporter protein, 2A peptide sequence and selection marker. Again as a model GOI the 
heavy and light chain of the anti-CD303 antibody or the hTGF-β1 sequences were integrated 
into the first multiple cloning site of this pMACS-CHO II vector (Figure 33) 
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Figure 33: Vector map of tricistronic pMACS-CHO II expression vector 
Changing the order of selection marker gene and reporter protein gene of the pMACS-CHO-2A and replacing the 
F2A peptide sequence by a T2A peptide sequence with serine-glycine linker resulted in the pMACS-CHO II 
vector. 
 
Using this tricistronic pMACS-CHO II expression vector, stable cell lines could be generated 
according to the standard selection process. Difficulties surviving the selection process, as 
seen using the pMACS-CHO-2A vector, could not be observed. As observed for the 
generation of stable cell lines with the dicistronic pMACS-CHO vector, cells recovered from 
selection and started expanding again during the first 7 to 10 days after transfection. 
Expressing anti-CD303 as a model antibody with a combination of P5CS selection for the 
heavy chain and zeocin selection for the light chain and GFP and RFP as reporter proteins 
(T4.44 pAS-125+133 II), producer rates of over 90% in less than 18 days can be reached 
monitored by the GFP/RFP-double positive rate by flow cytometry (Figure 34). 
 
 
Figure 34: Monitoring of stable CHO-S cell line generated with pMACS-CHO II vectors 
Flow cytometry analysis over time of stable CHO-S cell lines (T4.44 125+133 II and pAS-130+131 I) cotransfected 
with the vectors pAS-125 and pAS-133 (LC-GFP-zeocin + HC-RFP-P5CS) or pAS-130 and pAS-131 (LC-RFP-
zeocin + HC-GFP-P5CS). 
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To ensure that the additional reporter protein in the tricistronic construct has no negative 
effect on the GOI expression, the di- and tricistronic constructs were compared expressing 
hTGF-β1 as a model cytokine. As shown in Figure 35, hTGF-β1 produced by stable cell lines 
generated with the dicistronic vector (T6.1 pJN-1 I and II) or the tricistronic vectors 
coexpressing GFP (T6.2 pJN-5 I and II) or the membrane-bound (T6.1 pJN-6 I and II) were 
monitored over time. As usual for the selection process, variations even between cell lines 
generated with the same vector can be seen. But within these normal variability, the 
integration of a third gene into the original pMACS-CHO vector does not reduce the hTGF-
β1 expression levels. 
 
 
Figure 35: Influence of an additional reporter protein on expression level of the GOI 
Expression levels of hTGF-β1 in stable CHO-S cell lines selected by P5CS generated with a dicistronic pMACS-
CHO vector (T6.1 pJN-1 I and II) or with tricistronic pMACS-CHO II vectors coexpressing GFP (T6.2 pJN-5 I and 
II) or a membrane-bound GFP (T6.1 pJN-6 I and II). 
 
Using the improved pMACS-CHO II vector the additional problems with the cell surface 
staining of the membrane-bound GFP were solved. As shown in Figure 36, staining the 
membrane-bound GFP with a GFP-specific polyclonal antibody and an AlexaFluor647-
labeled secondary antibody led to a correlation between AlexaFluor647 and GFP signal in 
both pMACS-CHO II vectors, pAS-126 (anti-CD303 LC- mGFP - zeocin) and pAS-132 (anti-
CD303 HC- mGFP - P5CS). As a positive control, the pDisplay-GFP vector was used again.  
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Figure 36: Staining of the membrane-bound GFP of transiently transfected cells 
Flow cytometry analysis of a CHO-S cell line transiently transfected with the vectors (A) pDisplay-GFP or (B)  
pAS-126 (LC-mGFP-zeocin) and (C) pAS-132 (HC-mGFP-P5CS). The cells were stained with a polyclonal rabbit 
anti-GFP antibody and a secondary anti-rabbit-AlexaFluor 647. 
 
Based on these results, it was concluded that using the improved pMACS-CHO II vector, a 
correct cleavage of selection marker and fluorescent protein occured and that this tricistronic 
vector setting did not negatively influence the GOI expression levels. 
 
3.2.2 Clone isolation by FACS sorting 
3.2.2.1 Clone isolation by FACS sorting compared to limiting dilution 
To validate clone isolation by FACS sorting using the coexpression of the fluorescent 
reporter proteins, it was compared to a traditional clone isolation method, the limiting 
dilution. A stable cell line (T4.44 pAS-130+131 I) expressing 1.5 µg/mL anti-CD303 as a 
model antibody selected by P5CS and zeocin coexpressing GFP and RFP on day 25 after 
transfection with a producer rate of 93% monitored by GFP/RFP-double positive cells in 
flow cytometry (Figure 37 A) was used. For FACS sorting, the brightest 0.8% double positive 
cells  (Figure 37 B) were sorted as single cells into five 96-well plates in CHO-MEM 
containing no proline and no zeocin and an increased dialyzed FBS concentration of 10%. 
After 5 days of cultivation, medium was added to reach zeocin and FBS concentrations of the 
usual selection medium (CHO-MEM with glutamine, 10% dialyzed FBS and 100µg/mL 
zeocin). 
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Figure 37: Flow cytometry analysis of an antibody-expressing CHO-S cell line coexpressing RFP and GFP 
 (A) Flow cytometry analysis of a stable CHO-S cell line (T4.44 pAS-130+131 I) cotransfected with the vectors 
pAS-130 and pAS-131 expressing the anti-CD303 antibody and coexpressing the reporter proteins RFP and GFP 
selected by P5CS and zeocin on day 25 after transfection. (B) FACS sorting gate of the same cell line. The brightest 
0.8% RFP/GFP-double positive cells were isolated as single cells in 96-well plates. 
 
In parallel, a limiting dilution of the same stable cell line was performed. 0.5 cell was seeded 
per well of a 96-well plate in the usual selection medium. After 11 days, all 96-well plates 
were screened for formation of colonies either by microscope for the limiting dilution plates 
or fluorescence bottom reader for the FACS-sorted plates. The antibody concentrations of the 
supernatants of wells with a fluorescence signal above the background level or visually 
containing cells were determined in an ELISA. A maximum antibody concentration of 6.0 
µg/mL was detected for clones isolated by limiting dilution and of 40.8 µg/mL for clones 
isolated by FACS, being 6.8-fold higher (Figure 38).   
 
     
Figure 38: Clone isolation by FACS sorting compared to limiting dilution  
CHO-S clones (from T4.44 pAS-130+131 I) expressing anti-CD303 selected by P5CS and zeocin coexpressing the 
reporter proteins GFP and RFP were either isolated by (A) FACS sorting or (B) limiting dilution. The supernatants 
of the 96-wells containing a clone were screened by an IgG/kappa-specific ELISA. 
 
(A)                         (B)
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The best 24 to 29 of the screened 140 to 170 clones isolated by FACS or limiting dilution were 
expanded into T75 flasks. Clones were analyzed for cell growth, antibody production in 52h 
and additionally maximal antibody production by seeding 2x105 cells/well in 12-well plates. 
In Figure 39, the maximal titer results are shown. The highest producing clone isolated from 
the stable cell line T4.44 pAS-130+131 I by limiting dilution produced 8.6 µg/mL, which 
equates to a 5.7-fold increase compared to the starting cell line (Figure 39 B). In comparison, 
the highest producing clone from the FACS sorting produced an antibody concentration of 
15 µg/mL, which equates to a 10-fold increase (Figure 39 A). The average antibody 
concentration of all expanded clones was 4.3 µg/mL for the limiting dilution clones and 8.1 
µg/mL for the FACS-sorted clones (Table 8).  
 
 
 
Figure 39: Clone isolation by FACS sorting compared to limiting dilution  
CHO-S clones (from stable cell line T4.44 pAS-130+131 I) expressing anti-CD303 selected by P5CS and zeocin 
coexpressing the reporter proteins GFP and RFP were isolated by (A) FACS sorting or (B) limiting dilution. Best 
clones of the 96-well screen were expanded. For analysis, 2x105 cells per well of a 12-well plate were seeded and 
antibody titers of overgrown cultures were determined by ELISA. 
 
Table 8: Clone isolation by FACS sorting compared to limiting dilution 
Clones were isolated from the stable cell line T4.44 pAS-130+131 I by limiting dilution or FACS.  
 FACS Limiting dilution 
Starting mAb concentration (T4.33 pAS-130+131 I) 
(in static adherent culture) 1.5 µg/mL 1.5 µg/mL 
Cloning recovery 35% 9% 
max. mAb concentration of best clone after expansion of 24 
to 27 best clones (in static adherent culture) 15 µg/mL 8.6 µg/mL 
Increase of mAb concentration 10-fold 5.7-fold 
(A)
(B)
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In summary, FACS-sorted clones had a 1.7-fold (highest producing clone) to 1.9-fold (mean 
clone distribution) higher productivity compared to clones isolated by limiting dilution.  
 
3.2.2.2 Multiple FACS subcloning step to isolate high-producers 
One of the best clones (5C8) isolated by the first FACS sort (Figure 39) from the cell line T4.33 
pAS-130+131 I was subjected to a second subcloning step. The 0.5 % brightest double 
positive cells were FACS sorted into single cells, the 96-well plates screened and the best 20 
clones were expanded as described for the first sorting step. The highest producing clone 
(1A4) of this second FACS sorting step produced an antibody concentration of 26µg/mL as 
mamixum titer (Figure 40), which equates to a 3.9-fold increase in the second cloning step; 
the total titer increase from both cloning steps is 17.3-fold (Table 9). The mean antibody 
concentration of all 20 expanded clones of the second FACS sorting step was 14 µg/mL. 
 
 
Figure 40: Subcloning by FACS of a FACS-isolated clone 
The FACS-isolated clone 5C8 (from the stable cell line T4.44 pAS-130+131 I) expressing anti-CD303 selected by 
P5CS and zeocin coexpressing the reporter proteins GFP and RFP was subcloned by FACS. The best clones of the 
96-well screen were expanded. For analysis 2x105 cells per well of a 12-well plate were seeded and antibody titers 
of overgrown cultures were determined by ELISA. 
 
Table 9: Overview of multiple subcloning steps by FACS for high-producer clone isolation 
Clones were isolated from the stable cell line T4.44 pAS-130+131 I by two sequential FACS sorting steps.  
 1. FACS sort 2. FACS sort 
Starting mAb concentration 
(in static adherent culture) 
1.5 µg/mL 
Pool (T4.33 pAS-
130+131 I) 
6.6 µg/mL 
Clone 5C8 
Cloning recovery 35% 10% 
max. mAb concentration after expansion  
(in static adherent culture) 
11.6 µg/mL 
Clone 5C8 (third 
highest) 
26 µg/mL 
Clone 5C8-1A4 (highest 
producing) 
Increase of mAb concentration 7.7-fold 3.9-fold 
Inrease of mAb concentration 1.+2. 
FACS sort 
17.3-fold 
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Comparing these results, it was concluded that using the described FACS sorting strategy it 
was possible to improve the clone isolation process.  
 
3.2.2.3 Clone isolation by FACS of cytokine-expressing cell line 
To verify the universal applicability of the tricistronic vector for clone enrichment using 
FACS sorting, the clone isolation process was additionally performed with a stable CHO-S 
cell line (T6.1 pJN-5 I) selected by the P5CS system expressing the cytokine hTGF-β1 as a 
second model protein and GFP as a reporter protein. As described above for the antibody-
producing cell lines, the FACS sort, the 96-well plate screen and the expansion of the best 
clones were repeated for this hTGF-β1-producing cell line. In the 96-well screen, the highest 
hTGF-β1 concentration detected was 45.6 ng/mL (data not shown). In the 12-well screen, the 
highest producing clone of this FACS sort produced a hTGF-β1 concentration of 163 ng/mL 
(Figure 41), which equates to a 8.8-fold increase in this cloning step from the starting cell line 
with a maximal cytokine production of 18.5 ng/mL (Figure 35, GFP-P5CS I and Figure 41 
Pool). The mean hTGF-β1 concentration produced of all expanded clones was 79 ng/mL 
(Figure 41).  
 
 
Figure 41: Clone isolation by FACS of a cytokine-expressing cell line 
CHO-S clones isolated from the stable cell line T6.1 pJN-5 I expressing hTGF-β1 selected by P5CS coexpressing 
the reporter protein GFP were isolated by FACS sorting. Best clones of the 96-well screen were expanded. For 
analysis, 2x105 cells per well of a 12-well plate were seeded and antibody titers of the overgrown cultures were 
determined by ELISA. 
 
To explore a possible connection of expression levels of the GOI and the fluorescent reporter 
protein, 16 of the hTGF-β1-expressing clones isolated by FACS from the stable cell line T6.1 
pJN-5 I as described above (Figure 41) were analyzed for secreted cytokine concentration, 
intracellular levels of the cytokine and the MFI of the fluorescent protein. For the 
intracellular staining of the cytokine, cells were fixed, permeabilized and stained with anti-
LAP APC-coupled antibody. LAP binds inactive hTGF-β1. By staining LAP, intracellular 
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hTGF-β1 levels can be determined. APC fluorescence of fixed and stained cells and GFP 
fluorescence of non-fixed cells was analyzed by flow cytometry. A TGF-β1-specific ELISA 
was used to determine secreted hTGF-β1 concentrations in the cell culture supernatants. As 
shown in Figure 42 A, the intracellular LAP levels, measured as APC fluorescence in the 
intracellular staining, and GFP fluorescence of the reporter protein showed a strong 
correlation (Figure 42 A, R2= 0.8341). In contrast, the hTGF-β1 concentrations and the GFP 
MFI of the clones did not correlate (Figure 42 B, R2= 0.0697). This was mainly due to the 
missing correlation (R2= 0.0922) of secreted and intracellular cytokine levels as demonstrated 
in Figure 42 C.  
 
          
 
 
Figure 42: Correlation of cytokine productivity and reporter protein levels 
16 CHO-S clones were previously isolated from the stable cell line T6.1 pJN-5 I by FACS sorting expressing hTGF-
β1 selected by P5CS coexpressing the reporter proteins GFP. These clones were analyzed regarding intracellular 
levels of the LAP protein bound to hTGF-β1 as well as GFP reporter protein expression by flow cytometry and 
the secreted hTGF-β1 in the supernatant by ELISA. (A) Correlation between intracellular LAP and reporter 
protein, (B) missing correlation between secreted hTGF-β1 in the supernatants and reporter protein, (C) missing 
correlation between intracellular LAP levels and secreted hTGF-β1. 
 
The ten highest producing clones expressing the hTGF-β1 isolated from the stable cell line 
T6.1 pJN-5 I by FACS  (Figure 41) were adapted to the serum-free production medium CHO 
MACS CD custom-made without proline. The two best producing clones (4E5 and 2A10) of 
the 12-well screen could not be adapted to serum-free growth conditions. Already in 
adherent culture, they showed a more attached phenotype and slow growth. Following the 
(A)          (B)
(C)       
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serum-free adaptation, the remaining 8 clones were incubated in an orbital shake reactor in 
Erlenmeyer flasks. Some clones showed faster recovery of viability if adapted 
simultaneously to serum-free conditions and the shake incubator. Once clones recovered to a 
viability of over 90%, they were subjected to a determination of specific productivities. 
Therefore, clones were seeded at 2x105 cells/mL in 30 mL medium in 125 mL Erlenmeyer 
flaks, and an 0.5 mL aliquot was taken daily to measure antibody titers and cell numbers.  
 
 
Figure 43: Batch process with hTGF-β1-expressing clones isolated by FACS  
CHO-S clones isolated from the stable cell line T6.1 pJN-5 I by FACS sorting expressing hTGF-β1 selected by 
P5CS and coexpressing GFP were seeded at 2x105 cells/mL in 30 mL CHO MACS CD without proline in 125 mL 
Erlenmeyer flasks and were cultivated in an orbital shake incubator. Daily, samples were taken to determine 
antibody titers and cell numbers to calculate specific productivities.  
 
For all analyzed clones, an increase in maximum titer of 1.7-fold to 3.5-fold compared to 
static, adherent culture condition could be observed. The highest hTGF-β1 concentration 
reached by clone 1C7 was 257 µg/L. This clone had also the highest specific productivity of 
0.03 pcd. Viable cell densities of up to 9.8x106 cells/mL could be reached in this batch process 
by clone 2G9 (Figure 43 and Table 10). Interestingly, viabilities dropped faster in this batch 
with hTGF-β1-producing clones compared to anti-CD303-producing clones (from stable cell 
line T4.25 pAS-21+55 II, compare 3.1.3.1.1). The viability of all hTGF-β1-producing clones 
was reduced below 80% at the seventh day of batch culture (Table 10). The viability of 
antibody-producing clones stayed over 80% for up to nine days with most clones having 
viabilities lower than 80% on day eight of culture (Table 5).  
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Table 10: Overview of batch process with hTGF-β1-expressing clones isolated by FACS 
Batch process with CHO-S clones isolated by FACS from the stable cell line T6.1 pJN-5 I expressing hTGF-β1. 
 Clone Max. titer  
(µg/L) 
Max. viable cell density  
(mL-1) 
Specific 
productivity (pcd) 
Days of culture before 
vitality dropped under 80% 
3E2 160.7 8.96 x106 0.01 6 
5F7 161.0 7.96 x106 0.01 6 
1D8 163.4 7.56 x106 0.01 6 
2E1 168.4 4.20 x106 0.02 5 
3B4 169.7 7.68 x106 0.01 6 
5H2 177.0 7.60 x106 0.01 6 
2G9 186.8 9.80 x106 0.02 6 
1C7 256.8 8.72 x106 0.03 6 
 
The nine highest hTGF-β1-producing clones isolated from the stable cell line T6.1 pJN-5 I by 
FACS sorting (Figure 41) also used for the batch production were tested regarding their 
stability in proline-containing medium. Clones were cultivated in parallel in CHO-MEM 
supplemented with 5 % dialyzed FBS with or without proline and hTGF-β1 titers of 
supernatants of overgrown cultures were analyzed by an hTGF-β1-specific ELISA. 
Comparing the titers in the medium with and without proline after 17 days revealed that 
titers in proline-containing medium were 13 % lower to 16 % higher compared to the ones 
from proline-free media (Figure 44 A). After 40 days, all clones showed a reduced 
productivity in proline-containing medium. Titer decreases ranged from 1% to 42% (Figure 
44 B). 
                  
     
Figure 44: Stability of P5CS-selected  hTGF-β1-expressing clones  
Nine CHO-S clones isolated from the stable cell line T6.1 pJN-5 I by FACS sorting expressing hTGF-β1 selected by 
P5CS and coexpressing GFP were cultivated both in CHO-MEM with proline or without proline. After (A) 17 
days and (B) 40 days hTGF-β1 concentrations in the supernatants of overgrown cultures were determined.  
 
From these data it was concluded that FACS-isolated clones showed a correlation between 
intracellular recombinant protein levels and reporter protein fluorescence, which might 
  (A)                (B)
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explain the enrichment during FACS sorting. These FACS-isolated clones were stable in 
medium without selection pressure for a certain time frame.  
 
3.2.3 High-producer enrichment by MACS  
The coexpression of reporter proteins can additionally be used for enrichment by the MACS 
technology. For this, at least one reporter protein needs to be membrane-bound. To validate 
high-producer enrichment using MACS technology, a stable cell line (T4.44 pAS-126+133 II) 
expressing the anti-CD303 model antibody selected by P5CS and zeocin coexpressing RFP 
and membrane-bound GFP was generated. The starting producer cell line expressed about 
0.7 to 2.0 µg/mL antibody (data not shown). For the MACS enrichment, the membrane-
bound GFP was stained indirectly with a polyclonal rabbit anti-GFP antibody followed by a 
monoclonal anti-rabbit microbead-coupled antibody. Cells were MACS enriched using a MS 
column. The enriched cells were cultivated in the usual selection medium and expanded for 
the next MACS enrichment. For the first and second MACS enrichment, cells were separated 
using only one column. For the third and forth enrichment, the more stringent protocol using 
two sequential columns was used. The enrichment rate was monitored as GFP fluorescence 
by flow cytometry and additionally the maximum antibody concentration in the supernatant 
was monitored. As an example, the percentage of GFP-expressing cells could be increased 
from 50% (Figure 45 A) to 95% (Figure 45 B) in the first enrichment step of the described 
stable cell line. Due to the low expression of GFP in cell lines due to the tricistronic pMACS-
CHO II vector setting, only cells expressing high levels of GFP are enriched, which is 
demonstrated by an increase of MFI from 2.5 to 5.2 (Figure 45 A and Figure 45 B).  
 
 
Figure 45: MACS enrichment of an antibody-producing cell line 
A Stable CHO-S cell line (T4.44 pAS-126+133 II) expressing the anti-CD303 antibody selected by P5CS and zeocin 
and coexpressing RFP and a membrane-bound GFP was stained with a polyclonal rabbit anti-GFP antibody and a 
secondary anti-rabbit antibody conjugated to microbeads and enriched by MACS technology using a MS column. 
GFP fluorescence was monitored by flow cytometry (A) before and (B) after enrichment. 
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Since both, the starting cell line as well as the MACS-enriched cell line, showed the usual 
titer variations over culture time, the titer increase could only be estimated. Due to the 
coupled expression of GOI and mGFP, it was possible to increase the produced antibody 
concentration about 2-fold looking at the more constant titer levels after the initial higher 
increase (Figure 46 B: stable cell line T4.44 pAS-126+133 II to MACS 1). Also in the following 
enrichment steps, the number of GFP-positive cells (Figure 46 A) and the antibody titer 
(Figure 46 B) could further be improved. The final four times enriched production cell line 
(Figure 46, MACS 4) produced an antibody concentration of 8 µg/mL, which decreased to 5 
µg/mL during the following 40 days of culture. This resulted in an initial increase of 8-fold 
reducing to an about 4.5-fold enrichment compared to the starting cell line.  
 
       
 
Figure 46: Repeated MACS enrichment of an antibody-producing cell line 
A stable CHO-S cell line (T4.44 pAS-126+133 II) expressing the anti-CD303 antibody selected by P5CS and zeocin 
and coexpressing RFP and a membrane-bound GFP was repeatedly enriched four times by MACS technology. 
The enriched cell lines were monitored for (A) GFP fluorescence by flow cytometry and (B) antibody 
concentration in the supernatants by ELISA. 
 
To verify the universal applicability of the MACS enrichment, the process was repeated with 
a stable CHO-S cell line (T6.2 pJN-6 I) expressing the human cytokine hTGF-β1. The cell line 
coexpressed the membrane-bound GFP as a reporter protein and was selected by the P5CS 
system (Figure 35, mGFP-P5CS I). Due to a lower expression level of the membrane-bound 
GFP in combination with P5CS as a selection marker compared to zeocin (Figure 36), two 
different enrichment strategies were compared using either a monoclonal direct labeling or a 
polyclonal indirect labeling. As shown in Figure 47 A, the starting producer cell line 
contained about 45% GFP-positive cells. Enrichment with the polyclonal indirect strategy led 
to an increase to 66% GFP-positive cells (Figure 47 B) and an increase of GFP MFI from 0.77 
to 2.18, but with a very low cell recovery rate of less than 0.1% for the GFP-positive cells 
 (A)            (B)
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(data not shown). The expanded cells did not show any improved productivity compared to 
the starting cell line (Figure 48) and were discarded after a few passages.  
 
 
Figure 47: MACS enrichment of a cytokine-producing cell line 
A stable CHO-S cell line (T6.1 pJN-6 I) expressing hTGF-β1 selected by P5CS and coexpressing a membrane-
bound GFP was labeled with microbeads using a polyclonal indirect anti-GFP labeling or a monoclonal direct 
labeling. GFP fluorescence was monitored by flow cytometry (A) before and after enriched by MACS technology 
using a MS column with (B) polyclonal indirect or (C) monoclonal direct staining. For the polyclonal indirect as 
well as the monoclonal direct staining the same volumes of enriched cell fractions were measured. 
 
 
Figure 48: MACS enrichment of a cytokine-producing cell line 
A stable CHO-S cell line (T6.1 pJN-6 I) expressing hTGF-β1 selected by P5CS and coexpressing a membrane-
bound GFP was labeled with microbeads using a polyclonal indirect anti-GFP staining or a monoclonal direct 
staining. The secreted hTGF-β1 levels were measured by ELISA. 
 
Using the monoclonal direct strategy, it was possible to enrich GFP-positive cells from 45% 
to 92% (Figure 47 C) and increase the GFP MFI from 0.77 to 1.55 with a recovery rate of GFP-
positive cells of over 2% (data not shown). The monitored hTGF-β1 concentrations improved 
from about 30 ng/mL before to over 200 ng/mL after the monoclonal MACS enrichment 
(Figure 48). These levels are comparable to FACS-enriched clones (Figure 41). During the 
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following passages, the hTGF-β1 production dropped to about 120 ng/mL but remained 
stable at this level for the following 25 days of culture. This still corresponds to a titer 
increase of about 4-fold compared to the starting cell line. 
 
To characterize the difference between the monoclonal direct and polyclonal indirect 
staining, cells were additionally stained with the labeling check reagent-APC, which 
specifically binds to microbeads. As shown in Figure 49, both staining strategies specifically 
stain the membrane-bound GFP-positive cells and lead to similar GFP/APC-double positive 
rates of 86%. A correlation between APC and GFP MFI is visible. High GFP-positive cells are 
also high APC-positive with the exception of one APC-dim population. The important 
difference between both staining strategies is the mean APC fluorescence. The monoclonal 
direct staining (APC MFI 77.4) leads to an APC MFI about 3 times higher compared to the 
polyclonal indirect staining (APC MFI 26.6). 
 
 
Figure 49: Labeling check of direct and indirect stained cells 
A stable CHO-S cell line (T6.1 pJN-6 I) expressing hTGF-β1 selected by P5CS and coexpressing a membrane-
bound GFP was labeled with microbeads using a (A) polyclonal indirect anti-GFP staining or a (B) monoclonal 
direct staining. Staining was controlled using the labeling check reagent-APC. GFP and APC fluorescence were 
monitored by flow cytometry. 
 
From these results it was concluded that MACS enrichment might be a potent and fast 
method to improve stable cell lines. 
 
3.2.3.1 Clone isolation by FACS of a MACS pre-enriched cell line  
To test a combination of a MACS pre-enrichment and a FACS clone isolation process, the 
four times enriched stable cell line T4.44 pAS-126+133 II M4 cell lines described in Figure 46 
(MACS 4) was FACS sorted as described in 3.2.2.1. The 0.5% best GFP/RFP-double positive 
cells were sorted as single cells into 5x 96-well plates. Fluorescence bottom reader and 
microscope were used to identify the 122 wells containing clones. The supernatants of these 
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wells were analyzed by ELISA. Already 8 days after FACS sorting, the highest titer detected 
in the 96-well plate screen was 2.0 µg/mL. The 19 highest expressing clones were expanded 
and analyzed by seeding 2x105 cells/well of a 12-well plate. Analysis of cell growth and 
antibody production in 52h and additionally maximally produced antibody concentrations 
were performed. The mean maximal antibody concentration of these clones was 16 µg/mL. 
The highest maximal antibody concentration amounted to 23 µg/mL, which equates to a 4.6-
fold increase in the FACS cloning step (Figure 50). The total increase of antibody production 
from MACS enrichment and FACS sort is 20.9 (Table 11), which is similar to the results 
obtained from the two repeated FACS sorting steps described in 3.2.2.2.  
 
 
Figure 50: Clone isolation by FACS of a MACS pre-enriched cell line 
A MACS pre-enriched cell line (T4.44 pAS-126+133 II M4) expressing anti-CD303 selected by P5CS and zeocin 
coexpressing the reporter proteins mGFP and RFP was subcloned by FACS. Best 19 clones of the 96-well screen 
were expanded. For analysis, 2x105 cells per well were seeded in 12-well plates and antibody titers of 
supernatants of overgrown cultures were determined by ELISA. 
 
Table 11: Overview of clone isolation by FACS of a MACS pre-enriched cell line 
The stable cell line T4.44 pAS-126+133 II was MACS-enriched and clones were isolated by FACS. 
 MACS enrichment FACS sort 
Starting mAb concentration 
(in static adherent culture) 
1.1 µg/mL 
T4.44 pAS-126+133 II 
5 µg/mL 
T4.44 pAS-126+133 II M4 
Cloning recovery - 25% 
mAb concentration after expansion of 
20 best clones  
(in static adherent culture) 
5 µg/mL 
T4.44 pAS-126+133 II 
M4 
23 µg/mL 
T4.44 pAS-126+133 II M4 
Clone 5G12 
Increase of mAb concentration 4.5-fold 4.6-fold 
Increase of mAb concentration: MACS 
enrichment + FACS sort 
20.9-fold 
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To test productivity in a batch process, the starting stable cell line (Pool= T4.44 pAS-126+133 
II), the four times MACS-enriched stable cell line (M4 = T4.44 pAS-126+133 II M4) and the 
eight highest producing clones isolated by FACS were used. Cells were adapted to serum-
free conditions and cultivation in an orbital shake incubator. The batch process was 
performed as described in 3.1.3.1.1: 2x105 cells/mL were seeded in 30 mL proline-free CHO 
MACS CD with 100 µg/mL zeocin. Each day an aliquot was taken to measure antibody titers 
and cell numbers.  
 
 
Figure 51: Batch process with clones isolated by MACS and FACS  
CHO-S clones isolated from a MACS-enriched stable cell line (T4.44 pAS-126+133 II M4) expressing anti-CD303 
selected by P5CS and zeocin coexpressing RFP and the membrane-bound GFP. The starting cell line (Pool= T4.44 
pAS-126+133 II), a four time MACS pre-enriched cell line (M4= T4.44 pAS-126+133 II M4) and eight clones 
isolated by FACS from the MACS pre-enriched stable cell line were seeded at 2x105 cells/mL in 30 mL CHO 
MACS CD without proline containing 100 µg/mL zeocin in 125 mL Erlenmeyer flasks and were cultivated in an 
orbital shake incubator. Daily, samples were taken to determine antibody titers and cell numbers to calculate 
specific productivities.  
 
Table 12: Overview of batch process with clones isolated by MACS and FACS 
Batch process with the stable cell line T4.44 pAS-126+133 II, the MACS pre-enriched cell lines T4.44 pAS-126+133 
II M4 and FACS-isolated clones from this enriched cell line.  
 Cell line or clone! Max. 
titer  
(µg/L)!
Max. viable 
cell density  
(mL-1)!
Specific 
productivity 
(pcd)!
Days of culture before 
vitality dropped under 80% 
T4.44 pAS-126+133 II M4 38.58 8.57 x106  2 8 
T4.44 pAS-126+133 II 38.82 11.3 x106 2 7 
3B4 41.71 6.20 x106 3 7 
3H5 52.38 5.76 x106 3 7 
4D7 58.69 5.80 x106 4 7 
3G10 70.01 5.72 x106 4 7 
1H1 72.03 6.88 x106 4 7 
5F9 84.56 6.00 x106 6 6 
5G12 92.37 6.40 x106 5 7 
4F7 130.42 9.40 x106 4 9 
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For all analyzed clones, an increase in maximum titers of 2.6-fold to 7.5-fold compared to 
static, adherent culture condition could be observed (Figure 50). The highest antibody 
concentration could be reached by clone 4F7 with 130 mg/L and the highest specific 
productivity was reached by clone 5F9 with 6 pcd (Figure 51 and Table 12). Viable cell 
densities of up to 1.1x107 cells/mL could be reached by the starting stable cell line (Figure 51 
Pool). 
 
Based on the obtained results, it was concluded that a combination of MACS enrichment and 
FACS clone isolation might be very potent method to isolate high producing clones, which 
are suitable for production in a batch process.  
 
3.2.3.2 Correlation of fluorescent protein and recombinant antibody expression 
Futher experiments were dedicated to analyze whether a correlation between expression of 
one of the fluorescent reporter proteins and the recombinant antibody secretion exists. 
Therefore, different clones expressing the anti-CD303 antibody generated by a two-vector 
strategy were analyzed. As shown in Figure 52 A, there exists no correlation between 
cytoplasmic GFP and antibody expression in 14 clones isolated from the T4.44 pAS-130+131 I 
cell line by two FACS cloning steps as described in 3.2.2.2. Analyzing 14 clones from the 
MACS pre-enriched T4.44 pAS-130+131 I M4 cell lines isolated by FACS cloning as described 
in 3.2.3.1 reveals a correlation between membrane-bound GFP and antibody expression (R2= 
0.50) as shown in Figure 52 B. 
 
          
Figure 52: Analysis of correlation between fluorescent protein and recombinant antibody expression 
Analysis of fluorescent protein by flow cytometry and recombinant antibody expression by ELISA of (A) highest 
producing clones isolated by two FACS cloning steps from the T4.44 pAS-130+131 I cell line coexpressing RFP 
and GFP and (B) clones isolated from the T4.44 pAS-126+133 II M4 four times MACS pre-enriched cell line 
followed by FACS cloning coexpressing RFP and membrane-bound GFP. 
 
These results indicate that using a membrane-bound fluorescent protein in combination with 
MACS might increases a correlation of GOI and reporter protein expression. 
(A)                      (B)
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3.2.4 Combination with an amplifiable selection system 
To test a combination of P5CS and zeocin selection with an additional amplification step, the 
DHFR gene with a separate SV40 promoter was integrated into the tricistronic vector pAS-
130 encoding the anti-CD303 light chain, the zeocin resistance gene and RFP to obtain the 
vector pAS-158 (Figure 53).  
 
Figure 53: pMACS-CHO II vector with additional DHRF gene 
The DHFR gene controlled by a separated SV40 promoter was added into the pAS-130 vector. 
 
The vectors pAS-131 and pAS-158 were cotransfected into CHO-S (T4.50) and first selected 
with the usual selection medium for P5CS and zeocin selection (CHO-MEM without proline, 
with 100 ng/mL zeocin and 5% dialyzed FBS). Once stable cell lines (T4.50 pAS-131+158 I 
and II) were established, 100 or 200 nM MTX were added. These MTX concentrations were 
more challenging than a usual selection process. Many cell lines did not recover. The ones 
that did recover had selection periods of over 3 months and showed reduced growth 
properties after recovery. Antibody titers on day 105 after transfection show that the MTX 
treatment did not increase the productivity. Stable cell lines treated with 100 or 200 nM MTX 
produced about 30-fold less antibody than the starting cell line T4.50 pAS-131+158 I as 
shown in Figure 54. 
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Figure 54: Productivity of stable cell line after MTX selection 
The stable CHO-S cell line T4.50 pAS-131+158 I was treated with 100 or 200 nM MTX after the initial P5CS/zeocin 
selection. Secreted antibody was measured by an IgG/kappa-specific ELISA on day 105 after transfection. 
 
The fluorescent protein expression of the coexpressed RFP and GFP was changed by the 
MTX treatment, as shown in Figure 55. The untreated stable cell line T4.50 pAS-131+158 I 
had the lowest RFP expression intensity, but the highest number of double positive cells. 
Treatment with MTX shifts the cells to a higher expression of RFP, which is encoded on the 
same vector as the light chain and DHFR. In addition, the MTX treatment reduced the 
number of GFP-expressing cells in this vector setting, which encodes GFP on the same vector 
as the heavy chain. 
 
 
Figure 55: Flow cytometry analysis of MTX treated stable cell lines 
The stable CHO-S cell line (A) T4.50 pAS-131+158 I was treated after the initial P5CS/zeocin selection with (B) 
100 nM or (C) 200 nM MTX. Coexpressed RFP and GFP were monitored by flow cytometry on day 98 after 
transfection. 
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Among the cells transfected with the vectors pAS-131 and pAS-158 (T4.50 and T5.52) and 
directly selected with MTX only few stable cell lines recovered although different 
concentrations of MTX and zeocin were tested: All selection media were proline-free and 
contained different zeocin concentrations (0, 50, 100 ng/mL) combined with different MTX 
concentrations (50, 100, 200 nM). The cell line generation for each medium was repeated at 
least in duplicates. The few stable cell lines that did grow up after 3 to 4 month showed 
massively reduced growth rates making expansion impossible. 
 
These results demonstrate that a combination of P5CS and zeocin selection with a DHFR 
amplification has to be further optimized.  
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4 Discussion 
Mammalian expression systems are necessary for the production of complex proteins due to 
their ability of post-translational modifications. These post-translational modifications, such 
as glycosylation, are often crucial for the biological activity and stability (Hung et al, 2010). 
Chinese hamster ovary cell lines are the most commonly used hosts for recombinant protein 
production in mammalian cells, both, for laboratory and biopharmaceutical production. 
They combine several properties essential for a production cell line including high-level 
productivity, stability over time, growth in high cell densities, ease of adaptation to serum-
free media and suspension, scalability to large-scale production and glycosylation with high 
similarity to human glycan patterns (Costa et al, 2009). Recombinant proteins produced by 
CHO cells have been proven to be safe for the use in humans. Several therapeutic proteins 
have been FDA-approved (Carroll and Al-Rubeai, 2004).  
Currently, selection systems used either depend on antibiotic or metabolic selection. 
Commonly used metabolic selection systems include the DHFR and the GS selection system. 
Antibiotics have highly toxic effects on cells lacking the corresponding resistance gene 
(Schiedner et al, 2008). Protein synthesis is inhibited by the aminoglycoside antibiotics 
hygromycin B and Geneticin (G418, neomycin) due to the induction of misreading of 
aminoacetyl-tRNA by distorting the ribosomal A site and the translocation process (Cabanas 
et al, 1978; Vicens and Westhof, 2003). The aminonucleoside antibiotics puromycin and 
Blasticidin S (Tunkel and Studzinski, 1981; Kuwano et al, 1979) also inhibit protein synthesis 
but based on the integration into the ribosomal RNA and blockage of further elongation of 
the rRNA chain (Tunkel and Studzinski, 1981). Regarding the glycopeptide antibiotic zeocin, 
which belongs to the bleomycins, the exact mode of action is not known. But zeocin is 
believed to intercalate into DNA and thereby cleave DNA (Ranft et al, 2009; Drocourt et al, 
1990). The use of toxic antibiotics has several negative effects: First, these cytotoxic 
substances do not only inhibit growth of untransfected cells, they also influence cells 
carrying a resistance gene. As seen in this study addition of zeocin reduced the maximal 
viable cell density in a fed-batch process. Rodolosse et al (1998) describe that hygromycin B-
selected stable cell lines exhibit dramatically changed metabolic properties with strongly 
increased glucose consumption and lactic acid production. In addition, the frequency of 
sister chromosome exchange, which is correlated with mutagenic and carcinogenic events, is 
increased by both aminoglycoside antibiotics, hygromycin B and G418, in a dose-dependent 
manner in different cell lines transfected with the corresponding resistance genes (McDaniel 
and Schultz, 1993).  
Toxic substances are also used in metabolic selection systems. The DHFR selection system is 
based on the use of DHFR deficient CHO DG44 cells, therefore not requiring the use of an 
inhibitor during the initial selection. To archive high-producing cell lines, the DHFR 
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inhibitor MTX, which acts as a folic acid antagonist, can be used for amplification (Wurm, 
2004), but implicates a high cytotoxicity, mutagenicity and teratogenicity (Kaufman et al, 
1985; Khera, 1976). The high cytotoxicity can also be observed in humans. Alarcón et al 
(1989) report major life-threatening, and minor toxic events after MTX treatment in 54% of all 
patients. In addition, amplified CHO cell lines show heterogenicity in the chromosomal 
location and the copy number of the amplified sequence. Rearrangements, highly extended 
regions, joined chromosomes at amplified regions and even circular chromosomes mainly 
consisting of amplified regions lead to a high genetic instability of the production cell lines 
(Schiedner et al, 2008; Kim et al, 1998 A).  
CHO-K1 cells used for the GS selection are not deficient for the enzyme glutamine 
synthetase. Since a glutamine-free medium only provides a weak selection pressure, this 
system requires the permanent use of the cytotoxic GS inhibitor MSX to ensure sufficient 
selection pressure and prevent deletion or silencing of the foreign DNA (Shaw et al, 1999; 
Chartrain and Chu, 2008). Recently GS-knockout cell lines generated by zinc-finger-
nucleases have been described (Liu et al, 2010). The lack of endogenous GS increased 
selection stringency and lead to an increased recombinant protein production. But also for 
the GS-deficient CHO cell line cytotoxic MSX is used in the selection process (Fan et al, 2012). 
Antibiotics as well as other inhibitory substances need to be removed from the culture 
medium for the production process of therapeutic proteins to minimize cellular stress and to 
eliminate the risk of contamination with cytotoxic substances (Kaufman et al, 2008).  
 
One aim of this project was the development of a novel selection system based on the proline 
metabolism. The goal was to develop a selection system without the need of an inhibitory, 
toxic substance facilitating fast, reliable and stable generation of producer cell lines 
expressing suitable amounts of recombinant proteins.  
 
4.1 Characterization of proline metabolism in CHO cells 
The CHO cell line is known to be proline auxotroph (Kao and Puck, 1967) due to a deficiency 
in both available proline catabolic pathways (Baich, 1977; Smith et al, 1980). The ability of 
spontaneous reversion from a proline auxotroph to a prototroph phenotype has been 
observed (Kao and Puck, 1967).  
The first set of experiments in this study was dedicated to the characterization of the proline 
metabolism of CHO cells. Hence, parental CHO cell lines (Pro-) were seeded in proline-free 
medium and after about 10 days single proline prototroph colonies (Pro+) started growing 
up. Isolated CHO-K1 and CHO DG44 Pro+ cell lines showed similar growth properties in 
proline-free medium as parental Pro- CHO cell lines in proline-supplemented medium. All 
media were supplemented with 10% dialyzed FBS containing traces of proline. In contrast, 
CHO-S Pro+ cell lines showed significantly reduced growth in proline-free medium (data 
not shown) indicating that the grade of deficiency in proline metabolism differs between 
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different CHO cell lines. Similar to the results of Kao and Puck (1967), it was found in this 
study that there are also slight variations between individual Pro+ cell lines isolated from the 
same parental cell line under identical conditions regarding growth rates. The reversion rate 
of CHO-K1 from a proline auxotroph to a prototroph phenotype was calculated to be 0.01% 
to 0.015%. This reversion rate is higher than the one described by Kao and Puck (1967). The 
used CHO cell line in their studies showed lower reversion rates of 1x10-6 with reduced 
plating efficiencies and growth rates of the proline prototroph cell lines in the absence of 
proline when compared to naturally proline prototroph Chinese hamster lung (CHL) cells. 
This reduced growth rate is comparable to the CHO-S Pro+ cell lines isolated in this study, 
but could not be observed in CHO-K1 and CHO DG44 Pro+ cells, indicating that certain 
CHO cell lines might be more suitable for a proline-based selection system. Reversions to a 
selection independent phenotype are known for other metabolic selection systems as well. 
For example, reversion rates from a DHFR-sensitive to a DHFR-insensitive phenotype for the 
CHO DXB11 have been described between 0.001% (Urlaub and Chasin, 1980) and 0.3% in 
serum-free suspension media (Sinacore et al, 1996). For CHO DG44, a cell line with deletion 
of both DHFR alleles, MTX-resistance due to a mutated MTX transport system has been 
described (Assaraf and Schimke, 1987).  
To further characterize the isolated CHO Pro+ cell lines, P5CS and OAT protein levels were 
analyzed by Western Blot experiments. It was found that OAT expression could not be 
observed in any parental or Pro+ cell line. P5CS expression could not be detected in parental 
CHO cells, but was detected in CHO-K1 and CHO DG44 Pro+ cell lines, explaining their 
ability to grow normally in proline-free medium. This indicates that P5CS and not OAT is 
the more important pathway for proline synthesis in CHO cells, which correlates with data 
from plants (Verbruggen and Hermans, 2008) and humans (Krishnan et al, 2008). Comparing 
the different CHO cell lines, no P5CS expression could be observed in the isolated CHO-S 
Pro+ cell line, making the CHO-S cell line a promising candidate for a production cell line, 
which can be selected by P5CS. Further this explains the reduced growth rates of CHO-S 
Pro+ cell lines in proline-free medium compared to CHO-K1 and CHO DG44 Pro+ cell lines. 
Sequence analysis of P5CS from Pro- and Pro+ CHO-K1 cell lines revealed no differences in 
cDNA sequences indicating that the P5CS deficiency of the parental cell line is not due to a 
mutation in the P5CS DNA sequence as supposed by Kao and Puck (1967) but indicating an 
up-regulation of P5CS expression during the reversion from a proline auxotroph to a 
prototroph phenotype, which could be due to an increased transcription rate or increased 
mRNA stability. This theory is supported by real-time PCR analysis data, confirming 
different levels of P5CS mRNA in the Pro- and Pro+ CHO-K1 and CHO-S cell lines. The rate 
of mRNA up-regulation in Pro+ cells shows no direct correlation with the observed P5CS 
protein levels. These differences between proteomic and genomic analysis have been 
reported by various groups (Jansen et al, 2002; Pradet-Balade et al, 2001). They are caused by 
the fact that mRNA levels and resulting protein levels are not only determined by 
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transcription and translation rates but also by additional control factors. These factors 
include mRNA stability, export and protein degradation (Pradet-Balade et al, 2001).  
 
4.2 P5CS as novel selection marker for the expression of recombinant proteins 
There are two available catabolic pathways for proline synthesis in CHO cells. Both enzymes 
have been previously used to functionally complement proline auxotroph CHO cells (Brody 
et al, 1992; Hu et al, 1999). However, no selection system based on the proline metabolism 
has been described. Several factors were taken into account when deciding which of the key 
metabolic enzymes to use as a selection marker: First, several publications indicate that the 
metabolic pathway from glutamate is the more important one under stress conditions. 
Proline is known to protect plant as well as mammalian cells from stress for example it can 
act as reactive oxygen species (ROS) scavenger. ROS might be produced by salt and drought 
stress in plants (Verbruggen and Hermans, 2008) or UVA and osmotic stress in mammalians 
(Wondrak et al, 2005; Krishnan et al, 2008). It has also been proposed that proline functions 
as a chaperone, buffers cytosolic pH and balances the cell´s redox status (Verbruggen and 
Hermans, 2008). In plants, proline is mainly made from ornithine under normal conditions. 
Under osmotic or drought stress, the glutamate pathway becomes dominant (Kishor et al, 
1995; Verbruggen and Hermans, 2008) with the enzyme P5CS as the rate-limiting step of the 
proline synthesis (Verbruggen and Hermans, 2008). Similarly, Krishnan et al (2008) found 
that OAT expression is down-regulated during oxygen stress in HEK293, HeLa and HepG2 
cells. Since OAT is a bidirectional enzyme, it catalyzes the reaction from ornithine to P5C and 
back. Under stress conditions, OAT might be down-regulated to avoid any formation of 
ornithine and instead ensure maximal formation of proline by up-regulation of the P5CS 
pathway (Krishnan et al, 2008). These findings indicate that under production conditions, 
which do lead to oxygen stress (Selvarasu et al, 2012; Han et al, 2011) resulting in growth 
limitations and apoptosis, P5CS might be the more interesting candidate as a selection 
marker. Second, although Smith and Phang (1979) described CHO cell lines isolated from 
proline-free medium that only expressed OAT and no P5CS, it was only possible to generate 
Pro+ CHO cell lines that expressed P5CS and no detectable OAT in this study. This might 
indicate that the metabolism from glutamate is be predominant in the here used cells and 
under the given culture conditions. Third, OAT is a bidirectional enzyme catalyzing the 
proline synthesis as well as the degradation towards ornithine and arginine, resulting in 
more complex regulation mechanisms (Brody et al, 1992). Therefore, it was decided to test 
murine P5CS in the P5CS.long splice form, which is not inhibited by ornithine (Hu et al, 
1999), as a selection marker. 
For expression studies, the enhanced GFP was used as GOI due to its ease of detection via 
microscopy and flow cytometry. To validate the newly constructed dicistronic expression 
vector pMACS-CHO, stable cell lines were generated using a standard neomycin antibiotic 
selection and were then compared to cell lines generated with a two-promoter expression 
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vector. Consistent with the results of Lucas et al (1996), Pu et al (1998) and Ho et al (2012) 
coupling of GOI and selection marker by an IRES element resulted in higher producer rates 
and higher GOI expression levels.  
In the next step, it was tried to use the enzyme P5CS as selection marker. Again, GFP was 
used as a model protein. Already in first experiment it was possible to generate stable CHO-
K1 cell lines selected by P5CS in proline-free medium with GFP producer rates of up to 99% 
However, the respective selection times of over 100 days were too time consuming. 
Furthermore, these high producer rates could only be obtained in about 50% of all 
transfected and P5CS-selected cell lines indicating that untransfected cells spontaneously 
reversed to a Pro+ phenotype and were able to overgrow transfected cells.  
Three changes strongly improved the P5CS selection system: First, switching to CHO-S cells 
as a host cell line; second, optimizing the selection protocol with a harsh split 24 hours after 
selection and third, using a serum-reduced proline-free medium containing only 5% 
dialyzed FBS. By these changes, it was possible to generate a fast and reproducible selection 
system yielding stable cell lines with GFP producer rates of over 90% in less than 16 days. As 
described previously, CHO-S cells have a lower tendency to reverse to a proline prototroph 
phenotype and corresponding Pro+ cells express much lower amounts of P5CS compared to 
CHO-K1 Pro+ cells resulting in slower growth rates in proline-free medium. CHO-S proline 
prototroph cells spontaneously formed during the selection process in proline-free medium 
therefore have a growth disadvantage and are more frequently overgrown by cells with 
stable integration of the expression vector. In contrast, the CHO-K1 Pro+ cells spontaneously 
formed during selection are able to overgrow transfected cells with stable integration of the 
expression vector into the genome, because these Pro+ cells express sufficiently high 
amounts of P5CS to allow normal growth rates. Apart from the cell line used, another crucial 
factor for the P5CS selection system was found to be the amount of dialyzed FBS in the 
selection medium. The used lot of dialyzed FBS contained 3.9x10-4 M proline. Using a 
medium supplemented with 10% of the dialyzed FBS resulted in a proline concentration of 
3.9x10-5 M. In comparison, Kao and Puck (1967) determined proline requirements of CHO 
cells to be 3x10-5 M for a normal plating efficiency and colony size in plating tests with 
different proline concentrations. The medium Kao and Puck (1967) used was supplemented 
with 2% non dialyzed FBS and 1.5g/L of the macromolecular fraction of BSA, which both 
presumably contained traces of proline, therefore the actual proline concentrations might 
have been higher. A reduction of the supplementation with dialyzed FBS in the selection 
medium from 10% to 5% reduced proline concentration to 1.95x10-5 M, a level at which no 
normal colony formation was observed in studies of Kao and Puck (1967).  
 
To validate the P5CS selection system for the expression of secreted recombinant proteins, 
the cytokine human transforming growth factor beta 1 (hTGF-β1) was chosen as one model 
protein. Human TGF-β1 is a homodimeric protein interacting with the latency associated 
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protein (LAP) in its latent form, which is encoded in the N-terminal region of the hTGF-β1 
gene and is cleaved of during maturation. This cytokine plays an important role in 
immunosuppression and immunotolerance, development and differentiation as well as 
mutagenesis (Beatson et al, 2011). To determine secreted hTGF-β1 concentrations in the cell 
culture supernatant, the latent form bound to LAP had to be activated by acid: Hydrochloric 
acid was thus added to activate the hTGF-β1. The activation was followed by a 
neutralization with sodium hydroxide to ensure a pH range suitable for binding to an ELISA 
plate. Practical application revealed one challenge: In particular, samples were wither not 
acidified enough leading to incomplete activation or the neutralization was not accurate 
enough leading to a pH not optimal for binding of the samples to the ELISA plates. Both 
factors led to high variations between doublet samples. Using commercially available 
standard acid and base solutions, it was possible to reduce problems of variations between 
sample doublets and ensure a suitable pH after neutralization. However, since there does not 
exist a latent hTGF-β1 standard as an activation control, it could not be guaranteed that the 
activation of latent samples was 100% efficient, which might have led to an underestimation 
of secreted hTGF-β1 concentrations.  
Since hTGF-β1 is a homodimer encoded by only one gene, it is a suitable model protein to 
directly compare different selection systems in a one-vector strategy. Therefore, the novel 
P5CS selection system was compared with three antibiotic selection systems.  Expression 
levels of all tested stable CHO-S cell lines selected by P5CS or by antibiotic selection 
(neomycin, hygromycin B or zeocin selection) confirmed the fast selection time observed 
expressing GFP. Less than 20 days after transfection, cell lines already secreted hTGF-β1 at 
levels, which remained stable over the following 30 days of culture. The novel P5CS selection 
system led to secreted hTGF-β1 amounts comparable to a conventional neomycin or 
hygromycin B selection. Zeocin selection enabled hTGF-β1 concentrations in the supernatant 
about three- to four-fold higher. Unfortunately, there are not many publications available, 
which compare the efficiency of different selection markers in CHO or other mammalian 
cells. Therefore, there are no results of other antibiotic selection systems to compare the 
superior expression of zeocin-selected cells to. Using the novel P5CS selection system hTGF-
β1 concentrations comparable to antibiotic selection systems routinely used to select stably 
transfected cells for research applications could be obtained. Thus, the P5CS selection system 
might be a promising alternative due to the major advantages of being a metabolic system 
without the need for any cytotoxic substances. This might also be of special interest for the 
modification of parental CHO cell lines used for recombinant protein production. In contrast 
to the selection systems for the recombinant protein expression requiring amplifiable system 
with extremely high yields, overexpressing genes to modify the cell line requires only a 
moderate level of expression. Targets for engineering might include anti-apoptosis factors 
such as Bcl-2, Bcl-xL or Aven or metabolic enzymes such as pyruvate carboxylase or lactate 
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dehydrogenase to avoid lactate accumulation (Costa et al, 2009). Other host cell 
modifications are based on the ER secretory pathway by overexpressing chaperons, protein 
disulphide isomerase or the X-box binding protein 1 as a regulator of many critical genes of 
the secretory pathway (Costa et al, 2009). Also modification of the glycosylation pattern 
might make knock-in cell lines necessary. For example overexpression of 
galactosyltransferase, sialyltransferase and N-acetylglucosaminyltransferase have been 
reported (Costa et al, 2009). Selection of cells overexpressing these proteins is usually 
antibiotic-based. Neomycin (Mastrangelo et al, 2000; Sauerwald et al, 2002), puromycin 
(Figueroa et al, 2007; Figueroa et al, 2004) and hygromycin B (Jung et al, 2002; Sauerwald et 
al, 2002; Mohan et al, 2007) have been reported to be used as selection markers. As described 
above, antibiotic selection has negative effects on cell growth, even in cells expressing 
resistance genes (Rodolosse et al, 1998; McDaniel and Schultz, 1993). In addition to the 
selection marker needed to modify the parental cell line, further selection markers for the 
expression of the recombinant target protein have to be used, adding up to an increased toxic 
burden for the cells. Using the enzyme P5CS as a selection marker, which leads to similar 
expression levels as mentioned antibiotic systems, would only require the use of a proline-
free medium to generate and maintain the parental cell line. Thereby, the modification 
would not bring any additional cytotoxic burden. In addition the enzyme P5CS has been 
reported to be connected to oxygen stress response. P5CS expression is increased in plants 
(Kishor et al, 1995; Verbruggen and Hermans, 2008) as well as human cells (Krishnan et al, 
2008) challenged with oxygen stress by direct treatment with H2O2 and in plants drought or 
salt stress leading to formation of reactive oxygen species (Verbruggen and Hermans, 2008). 
Recombinant overexpression of P5CS can rescue plant and mammalian cells from oxygen 
stress (Kishor et al, 1995; Krishnan et al, 2008). Reactive oxygen species are known to induce 
apoptosis (Yun et al, 2003 A). Generation of reactive oxygen species during the production 
process represents a potential inducer of cell death (Laken and Leonard, 2001) since 
apoptosis can account for a major part of cell death during a production (Majors et al, 2007). 
Addition of insulin, glutathione and iron chelators have been proven to reduce intracellular 
levels of reactive oxygen species and enhance cell survival and productivity (Yun et al, 2003 
A; Yun et al, 2003 B). A modified cell line overexpressing P5CS as a selection marker thereby 
might bring the additional advantage of rescuing cells from apoptosis. 
 
In addition to the expression studies with the cytokine hTGF-β1, three different monoclonal 
antibodies were produced as model proteins using the novel P5CS selection system: a human 
anti-CD303 antibody with humanized variable regions and chimeric anti-Biotin and anti-
CD14 antibodies with murine variable regions. All antibodies contained human constant 
IgG1 and kappa regions. Expressing recombinant proteins with two or more subunits gives a 
choice of different vector designs. Both subunits can either be expressed on two different 
expression vectors selected by different markers (two-vector strategy) (Pichler et al, 2011; 
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Sleiman et al, 2008; Brezinsky et al, 2003) or on one single expression vector (one-vector 
strategy) by different promoters (dual-gene vector) (Schlatter et al, 2005; Hung et al, 2010) or 
in a dicistronic construct coupled by IRES elements (Li et al, 2007), 2A peptides (Fang et al, 
2005), alternative splicing (Fallot et al, 2009) or intein-mediated protein splicing (Kunes et al, 
2009). Although a one-vector strategy brings the advantage of correlating expression levels 
(Li et al, 2007) especially when using coupled expression of the two GOIs again, it was 
decided two use a two-vector strategy in this study. As described above, the generated 
pMACS-CHO expression vector already contains a dicistronic cassette with coupled 
expression of GOI and selection marker to facilitate an increase in producer rates. To ensure 
coupling of GOI and selection marker expression, the expression of both antibody chains on 
one vector would create the need for a tricistronic construct. But all of the aforementioned 
coupling elements have some major drawbacks for coupling of two recombinant protein 
subunits. Using 2A elements, equimolar expression of first and second gene is caused, which 
is not wanted for all recombinant proteins. For example, some publications describe that for 
the expression of antibodies an excess of light chain leads to an increased production (Bibila 
and Flickinger 1991; Schlatter et al, 2005). In addition, after the “cleavage” at the 2A element, 
the 2A residue amino acids remain on both chains, which might be unwanted for therapeutic 
applications. Using an IRES element, it is possible to vary heavy and light chain expression 
(Li et al, 2007), but the efficiency of the IRES element is dependent on the surrounding 
sequences (Davies and Kaufman, 1992). Therefore, optimization might be necessary for 
different antibody constructs. Splicing-based vectors have only been described in few 
publications for antibody expression and do not seem to be commonly used. In addition to 
the mentioned problems with a one-vector strategy, using a two-vector strategy brings the 
advantage to balance heavy and light chain expression levels or other proteins´ subunit 
expression via the used selection marker combination. To identify such an optimal 
combination of P5CS with another selection marker, the anti-CD303 antibody was expressed 
using different combination of P5CS, GS and antibiotic selection markers. The highest 
secreted antibody concentrations were reached with a combination of heavy chain selection 
by P5CS and light chain selection by zeocin. This correlates to the result of the hTGF-β1 
expression in this study; at which zeocin was the stronger selection marker, and also with 
several publications indicating that a higher light chain expression might be advantageous 
(Bibila and Flickinger, 1991; Schlatter et al, 2005). To compare the P5CS selection system to an 
antibiotic system again, it was decided to keep the zeocin selection for the light chain 
expression and replace the P5CS by neomycin selection for the heavy chain expression. 
Stable producer cell lines expressing the three different antibodies revealed for all tested 
constructs that the combination of P5CS and zeocin selection led to similar antibody 
concentrations as the neomycin and zeocin selection. Expressing the anti-Biotin and anti-
CD14 antibodies, the use of neomycin and zeocin selection resulted in slightly higher 
antibody productivity regarding the stable cell lines as well as the clone distribution after 
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limiting dilution. In contrast, expressing the humanized anti-CD303, the P5CS and zeocin 
selection led to higher antibody concentrations. In general, expressing the chimeric 
antibodies consisting of murine variable regions and human constant regions led to 
significantly lower antibody concentrations compared to the humanized antibody. Both, 
intracellular staining of the heavy and light chains as well as the clone distribution after 
limiting dilution revealed low numbers of non-producing cells, for all tested antibody 
constructs and selection marker combinations. Double producer rates, defined as cells 
expressing heavy and light chain intracellularly or secreting complete antibody, were 
determined to be higher than 75% proving the potency of the dicistronic vector design.   
Isolated clones expressing the anti-CD303 antibody and selected by the novel selection 
system P5CS in combination with zeocin were used for expression studies in shake flasks in 
batch and fed-batch processes. A batch process is the most simple and therefore most reliable 
process for clone screening. The shake flask or bioreactor is initially inoculated with cells in 
appropriate production medium and cells are allowed to grow to determined cell numbers 
and viabilities until the supernatant is harvested. During culture nutrients decrease and toxic 
waste increases limiting the maximum cell density (Rodrigues et al, 2010). In a fed-batch 
process, the culture is fed with concentrated feed supplements continuously or once daily. 
This reduces nutrient limitations and thereby enables higher cell densities and prolongs 
culture time. Thereby higher final product concentrations are enabled. Although 
accumulation of growth-inhibitory waste cannot be avoided, fed-batch processes are still a 
common production mode due to their scalability, ease of operation and increased product 
yields compared to batch processes (Rodrigues et al, 2010). 
In a batch process, two of the ten analyzed clones expressed more than 50 mg/L 
recombinant antibody with specific productivities of up to 10 pcd in the proline-free 
production medium CHO MACS CD, which contained zeocin concentrations as also used for 
the selection process. To find a more suitable production medium, the two highest 
producing clones were adapted to five different commercially available production media all 
containing proline. This led to a cultivation time of about three to four weeks in the presence 
of proline. The following batch production was carried out in the presence of proline and 
without zeocin. Analysis of the antibody concentrations revealed about three-fold reduced 
productivities compared to the previous batch process with selection pressure indicating 
instability of the clones, although it cannot be said whether the titer decrease was mainly due 
to an instability of the P5CS or zeocin selection systems or a combination of both. These 
observations about instability of clones in medium without selection pressure will be 
discussed later. The previously used CHO MACS CD, in this batch process supplemented 
with proline, facilitated growth in highest viable cell densities with antibody concentrations 
similar to those of the HyClone SFM4CHO medium, which led to highest antibody 
concentrations in this experiment.   
 
Discussion 
 72 
A high stability of production clones is a desirable goal of cell line development. Upscaling 
cells for a 1,000 L bioreactor requires about 50 to 60 cell generations (Dorai et al, 2012; Bailey 
et al, 2012) and necessitates a stable productivity over at least this time frame to ensure 
predictable and constantly high recombinant protein yields (Wurm, 2004). In addition, clonal 
instability may compromise regulatory approval of proteins manufactured for therapeutic 
applications (Kim et al, 2011). Loss of productivity may occur rapidly or gradually over 
several passages in absence but also in presence of selection pressure (Kim et al, 2011; Jun et 
al, 2006) and has been reported in CHO cells both for the DHFR (Chusainow et al, 2008; Kim 
et al, 1998 A; Kim et al, 1998 B) and the GS selection system (Jun et al, 2006; Kim et al, 2011; 
Bailey et al, 2012; Dorai et al, 2012). According to Kim et al (2011) and Dorai et al (2012), 
clonal instability is a widespread problem affecting 40 to 60% of all production cell lines, in 
which instability is defined as a 30% decline in productivity over a period of 60 generations 
(Dorai et al, 2012; Bailey et al, 2012). The molecular mechanisms that cause instability are 
diverse and range from loss of transgene copies (Kim et al, 1998 A; Kim et al, 2011) to a 
decline in recombinant gene transcription with gene silencing. This is mainly due to 
promoter methylation (Chusainow et al, 2008; Kim et al, 2011) and leads to selection system- 
but also clone-dependent instabilities (Kim et al, 2011). 
The fed-batch production in this study was carried out in CHO MACS CD initially without 
proline. From day 3 on daily feeds supplemented the culture medium with proline. Different 
zeocin concentrations revealed that both tested clones showed a reduction in the maximal 
reached titer of 5 to 12 % when cultivated in halved zeocin concentration and 25 % to 54 % 
respectively when cultivated without zeocin. The influence of the proline supplementation 
due to the daily feed with CHO MACS Feed Supplement could not be addressed in this 
experiment. Batch experiments with different media containing proline (for over 4 weeks) 
and no zeocin (only for the batch process) revealed a reduction in final antibody 
concentration by 75%. Again both selection markers might have caused this instability. To 
specifically analyze the stability of the P5CS selection system, CHO-S clones expressing 
hTGF-β1 were used. The clones were selected by only P5CS in a one-vector strategy and 
isolated by FACS using the coexpressed GFP. For stability tests clones were cultivated in 
parallel in media with and without proline. After 17 days in culture, a time frame that would 
be sufficient for a usual batch or fed-batch production, no significant titer reduction could be 
observed. In contrast, all clones showed productivities reduced by up to 42% decrease after 
40 days without selection pressure. These results combined indicate that the addition of 
proline due to a feed in a fed-batch process would probably not have a negative effect on the 
productivity since the P5CS selection system seemed to be stable in all tested hTGF-β1-
expressing clones for this time period. Since no cytotoxic substances are needed for the P5CS 
selection system, removal of selection pressure for the production process only would be 
practical. The removal or even reduction of zeocin selection pressure immediately led to a 
decrease in productivity indicating that the analyzed clones might be more instable for the 
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zeocin selection than for the P5CS selection. The massive maximal titer decrease observed 
during the batch production in different media fits into this picture. Clones were cultivated 
for over 4 weeks in proline-containing media and the zeocin was removed during the batch 
process, which might have led to an added decrease in productivity. Although instabilities 
were tested with different systems (antibody in a two-vector system and cytokine in a one-
vector system), instabilities of both selection systems caused productivity decrease in the 
range of added decreases for both rapid zeocin and delayed P5CS instability. To further 
characterize the P5CS selection system, a comparison of the stability of different selection 
systems to each other directly in a one-vector system to obtain more reliable results would be 
an interesting aspect.  
 
In the fed-batch process, antibody concentrations of over 140 mg/L could be reached for 
both tested clones. This equates to an increase from batch to fed-batch process of 2.3- to 2.5-
fold. Maximally reached viable cell densities could also be massively improved by the daily 
feeds. Compared to the batch process the increases range between 3.8- and 3.9-fold with 2-
fold prolonged culture times. Both antibody titers as well as viable cell numbers increases 
were remarkably comparable between the tested clones. Several publications compare batch 
and fed-batch processes with differing results. The final product concentration can be 
enhanced in all studies, but increases regarding viable cell concentration and culture 
prolongation differs. Han et al (2011) producing antibody in CHO cells in a 2 L bioreactor 
with oxygen and pH control and daily feeds during the fed-batch and Altamirano et al (2004) 
expressing tPA in CHO observed no increase of cell number, but doubled culture time and 
an antibody concentration increase of about 1.5-fold in the fed-batch process. In contrast, 
Jardon et al (2012) also producing tPA in CHO cells in shake flasks with manual pH control 
saw an increase in culture time (about 2-fold), product concentration (about 4-fold) and also 
cell concentration (1.8-fold) using a high-feed protocol. Invitrogen reports an antibody titer 
increase of about 6-fold for the CD OptiCHO system with highest feed concentrations, but 
only low viable cell density increase and low culture time elongation5. Comparing these 
improvements from batch to fed-batch with the results from this study reveals that the 
observed product concentration increase and culture time prolongation is in the range of 
reported enhancement. However, the nearly 4-fold increase in viable cell density, which is 
higher than in any of the mentioned comparisons of batch and fed-batch, was unexpected.  
The maximal antibody concentration reached using the P5CS and zeocin selection for 
antibody expression in a first fed-batch process was 140 mg/L for two individual clones 
isolated by limiting dilution with screening of a low amount of clones. These productivities 
                                                      
5 http://www.invitrogen.com/etc/medialib/en/filelibrary/bioproduction/pdfs.Par.7260.File.dat/  
CHO%20CD%20EfficientFeed%20Product%20Flyer.pdf, 25.10.2012 
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are much lower than reported titers for amplified systems. For the GS system6 as well as for 
the DHFR system (Gagnon et al, 2011; Schulz et al, 2010) antibody concentrations produced 
by stable CHO clones in improved production processes of over 8 g/L have been reported. 
But these maximal titers are obtained from clones manufactured for therapeutic antibody 
production, implying the need of high productivities in order to reduce costs during the 
production process. These high-producing clones are generated by optimized selection 
systems and, in addition, by optimized high-throughput clone isolation. Production 
processes in bioreactors are optimized specifically for each clone (Gagnon et al, 2011; Schulz 
et al, 2010). As an example for this laborious and time-consuming effort to push clones to 
these productivities, Gagnon et al (2011) described a pH-controlled delivery of glucose 
during fed-batch bioreactor productions enabling a DHFR-selected clone previously 
producing 0.9 g/L to reach titers of 5.4 g/L. In comparison, Lee and Lee (2012) also used 
amplified DHFR-selected clones in a standard batch process and obtained significantly lower 
antibody titers of only 600 mg/L emphasizing the importance of an optimized production 
process. Not only the standard production process used is a factor that has to be taken into 
account for the lower titers observed in this study. The P5CS system is a non-amplified 
selection system. The amplification during DHFR selection using MTX can lead to a 6-fold 
titer increase as observed by Surabattula et al (2011) and 10-fold increase in specific 
productivities as observed by Lipscomb et al (2005). Agrawal and Bal (2012) described an up 
to 200-fold increase in GS copy numbers after MSX amplification. In general, gene 
amplification of GOI and selection marker should correlate as well as the amplification and 
expression level, although there are limitations at high amplification rates (Chusainow et al, 
2009). 
Usually, DHFR-deficient CHO strains are used for a DHFR amplification (Kim et al, 1998 A 
and B). Recently, Invitrogen described the use of CHO-S cells in combination with a DHFR 
amplification applying a double selection with puromycin and MTX directly after 
transfection7. Similar to this Invitrogen protocol, the DHFR gene controlled by a SV40 
promoter was integrated into a pMACS-CHO II vector encoding the anti-CD303 light chain, 
a zeocin resistance protein and RFP. This novel pAS-158 vector was cotransfected into CHO-
S cells with a P5CS-selected heavy chain–vector (pAS-131). Although using similar 
concentrations of MTX as proposed by Invitrogen and testing different selection strategies 
(P5CS, zeocin and MTX selection; P5CS and MTX selection; zeocin and P5CS selection 
followed by MTX amplification), only few cells were able to recover to stable cell lines. These 
stable cell lines had lower productivities than MTX-untreated cell lines. Flow cytometry 
analysis indicated that the RFP, which was encoded on the light chain vector, was amplified, 
but GFP expression, which was encoded on the heavy chain vector, was lost. During the long 
                                                      
6 http://www.lonza.com/custom-manufacturing/development-technologies/gs-gene-expression-
system/advantages-of-the-gs-system.aspx, 25.10.2012 
7 http://products.invitrogen.com/ivgn/product/A1369601?ICID=search-product, 25.10.2012 
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recovery time, the P5CS selection might have been too weak to avoid loss of GFP and heavy 
chain expression. To improve these first approaches with a combination of P5CS and DHFR 
selection, a first step must be the improvement of the selection protocol to reduce the time 
needed. In addition, it might be favorable to test different vector settings: with the P5CS and 
DHFR on one vector and zeocin resistance gene on the other; with DHFR on both the P5CS- 
and zeocin-selected vector or even on one vector. In such a one-vector strategy a dual-
promoter strategy might be promising to keep the coupling of GOI and selection marker, 
which has been proven to be very successful in this study. 
In all probability, an optimized process could increase the currently reached titers with a 
combination of P5CS and zeocin selection, but the focus of this project was a novel 
expression system for cell line development. For the purpose of validating the generated 
clones the used process was suitable. To further enhance the productivity of the P5CS 
selection system, the cell line development still offers room for improvement: First, as 
described, a combination of P5CS selection with an amplifiable system such as DHFR might 
be favorable to establish a fast system for medium scale productivities and, if necessary, 
clones might be further optimized by amplification. Second, a P5CS- and OAT-knockout cell 
line might further improve the selection as described for GS-knockout mutants used in the 
GS selection system (Fan et al, 2012). Third, optimizing the high-producer identification and 
isolation can greatly enhance productivity. Developing such an enrichment system for FACS 
as well as MACS was addressed in the second part of this study. 
 
4.3 Development of a novel cell enrichment system 
In addition to a suitable selection system, the generation of cell lines with high productivities 
crucially depends on the isolation of clones with extraordinary high productivities. Limiting 
dilution as a traditional clone isolation process has the drawback of being very time-
consuming. Even automation of this process allows only relatively low numbers of cells to be 
analyzed (Chartrain and Chu, 2008). Therefore, several techniques have been developed 
allowing screening of larger cell numbers and isolating only those cells with productivities 
above average. Identification of high-producing cells is mainly accomplished by two 
alternatives, the detection of produced recombinant protein or by coexpression of a reporter 
protein (Carroll and Al-Rubeai, 2004). Currently, high-producer isolation systems mainly 
focus on FACS for clone isolation and only few enrichment systems based on magnetic 
separation have been described. Carroll and Al-Rubeai (2005) describe a MACS-based high-
producer enrichment protocol using affinity capture surface display (ACSD). Hoch (2010) 
established an “Antibody CHO Capture Assay” detecting the secreted recombinant 
antibodies with a capture antibody in combination with MACS enrichment. The second aim 
of this study was thus the establishment of an enrichment process for high-producers that 
can be used for FACS and also MACS and is suitable to be used in combination with the 
P5CS selection system. Instead of detecting the secreted antibody as tested by Hoch (2012) 
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and Carroll and Al-Rubeai (2005), the approach was based on the coexpression of a 
fluorescent reporter protein. This had several advantages: First, due to its fluorescence no 
additional labeling was necessary thereby reducing handling steps and subsequently cell 
stress during the FACS sort. Second, the fluorescent protein could be targeted to the 
membrane allowing staining with microbead-coupled antibodies for MACS enrichment. 
Third, the fluorescent protein might be additionally used to monitor the cell lines production 
levels and stability by flow cytometry without the need for any additional staining making 
this an easier and faster monitoring tool than ELISA screens.  
The coupled expression of GOI and selection marker has been proven to successfully 
facilitate high producer rates in the selection process. Therefore, the dicistronic pMACS-
CHO expression vector was used as a backbone. The additional reporter protein had to be 
coupled to the GOI as well to reach correlating expression intensities to make the reporter 
protein usable to predict expression levels. A 2A peptide sequence was chosen as a coupling 
element to obtain a tricistronic expression cassette with the additional reporter protein. The 
expression of IRES-controlled genes is considerably lower when compared to cap-translated 
genes (Szymczak and Vignali, 2005), which is wanted in case of the selection marker. But a 
second IRES might lead to expression levels of selection marker or reporter protein 
depending on the order, which might be to low to survive selection or to be detected. A 2A 
element leads to about equimolar expression ratios of the gene up- and downstream of the 
2A peptide since both genes are encoded as one fusion gene and are separated during 
translation (Szymczak and Vignali, 2005). Several problems were observed using the first 
tricistronic vector pMACS-CHO-2A with the order GOI – IRES - selection marker - F2A – 
reporter protein: Transfected cells did not survive the standard applied selection pressure, 
and, in addition, expressing a membrane-bound GFP as a reporter protein, it was not 
possible to stain GFP on the cell surface. Both observations indicated that selection marker 
and reporter protein were not properly cleaved resulting in a fusion protein that was not 
active as a selection marker and not localized at the membrane. This problem was solved by 
the use of a different 2A peptide that had proven to facilitate cleavage (Lock, 2012) with an 
additional serine-glycine linker allowing more flexibility in confirmation and improving the 
ribosomal-skip mechanism (Szymczak and Vignali, 2005). In addition, the order of reporter 
protein and selection marker was switched since stable cell lines with loss of reporter protein 
had been observed. Having the selection marker at the end of the expression cassette 
ensured that the whole cassette had to be expressed to gain resistance. With this novel 
tricistronic expression vector pMACS-CHO II with the order GOI – IRES- reporter protein – 
T2A – selection marker, it was possible to generate stable cell lines according to the standard 
protocol. This indicated that cells were able to generate sufficient amounts of functional 
selection marker. The membrane-bound GFP was detectable in a surface staining also 
indicating a proper cotranslational cleavage and correct localization. By monitoring GFP and 
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RFP coexpression of an antibody-producing stable cell line, it could be proven that the 
developed selection system delivered high producer rates of over 90% in less than 20 days. 
Getting the cotranslationally separated proteins to their intended localization might be an 
issue when using 2A peptides. De Felipe and Ryan (2004) studied the effect of proteins with 
different localizations coupled by 2A peptide sequences and observed several 
mislocalizations of the second protein. For example, a setting where only the first protein 
contained a signal sequence resulted in translocation of both proteins into the ER, 
presumably due to the second protein “slipstreaming” through the translocon formed by the 
first protein. But this incorrect localization is dependent on the order and intended 
localization of proteins. Other studies describe cleavage events resulting in correct 
localization. For example, expression of two secreted subunits of the cytokine IL-12 resulted 
in efficient secretion (Chaplin et al, 1999). Tang et al (2009) also used some additional amino 
acids to improve the cleavage environment and were able to express a nucleus-localized Cre 
recombinase, a secreted Noggin or two light-activated membrane-bound proteins 
(Channelrhodopsin2 and Halorhodopsin) at the first position coupled to a second cytosolic 
fluorescent protein, all resulting in correct distributions. Using the improved tricistronic 
pMACS-CHO II vector, no further indications for mislocalized proteins expressing a 
cytosolic or membrane-bound fluorescent protein before the 2A peptide in combination with 
the cytosolic zeocin resistance protein or the mitochondrial P5CS could be observed in this 
study.  
The influence of a di- or even tricistronic construct on the expression of the GOI is not clearly 
defined. Chinnasamy et al (2006) compare a monocistronic construct expressing O6-
methylguanine-DNA-methyltransferase (MGMT) to two different dicistronic constructs with 
an IRES element or a 2A peptide. In the dicistronic construct, the MGMT expression was 
reduced by about 15% to 20%. Studies with the dicistronic pMACS-CHO vector expressing 
fluorescent proteins as GOI with different genes at the second position behind the IRES 
element revealed similar reduction rates in transient transfections. In stable transfections, 
however, the advantage of the coupled expression of GOI and selection marker led to 
dramatically higher producer rates and about 3-fold higher expression levels compared to a 
two-promoter vector. For a tricistronic construct consisting of MGMT-2A-HOXB4-IRES-GFP, 
Chinnasamy et al (2006) reported an even higher reduction of MGMT expression levels of 
about 80% compared to a monocistronic constructs. Similarly, Osborn et al (2005) showed 
that expressing iduronidase  (IDUA), a lysosomal enzyme involved in glycosaminoglycan 
(GAG) degradation, in a monocistronic construct or a tricistronic construct with coexpression 
of luciferase and a fluorescent protein coupled by two different 2A peptides resulted in a 
nearly 3-fold lower activity of IDUA in the tricistronic constructs. Whereat measuring the 
activity, it is not clear whether it was reduced due to lower expression levels or due to 
reduced activity, for example, caused by the additional 2A peptide amino acids. Such a 
dramatic reduction of GOI expression would not be suitable for an expression vector made 
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for high-level recombinant protein reduction. One more promising result regarding 
tricistronic vectors was published by Bouabe et al (2008), who expressed luciferase in a 
monocistronic construct compared to di- and tricistronic constructs containing one or two 
additional IRES-GFP blocks. Bouable et al (2008) did not see any effect of these multiple 
tandem-IRES on the upstream cap-dependent gene expression. Expression experiments with 
hTGF-β1 selected by P5CS in a dicistronic pMACS-CHO vector or tricistronic pMACS-CHO 
II vectors coexpressing GFP or the membrane-bound GFP showed usual variations between 
stable cell lines, but no negative effect of the tricistronic vector of the GOI expression. These 
results indicate that this vector might be suitable for recombinant protein expression. These 
inconsistencies in the results of different studies demonstrate that a reduction of GOI 
expression might strongly depend on the used elements and their combination as well as on 
whether the expression is transient or stable since the stringency of selection marker 
expression has an impact on the GOI expression.  
Once the applicability of the tricistronic vector pMACS-CHO II was proven, FACS-sorted 
clones using the coexpressed fluorescent reporter proteins for sorting were directly 
compared to clones isolated by a traditional limiting dilution. Expressing a humanized 
antibody, the enrichment regarding the highest producing clone from the starting cell line 
was 10-fold for the FACS-sorted clones and 5.7-fold for the limiting dilution clones. This 
resulted in a 1.8-fold higher increase from FACS compared to the limiting dilution. During 
the initial screen in 96-well plates, even higher titers of FACS isolated clones correlating to an 
enrichment of 27-fold could be observed. But nearly all clones lost productivity even under 
selection pressure. As discussed above, instability of production cell lines is a major and very 
common issue. To get further evidence whether the instability observed in this study was 
caused by the FACS enrichment process, since such rapid productivity loss under selection 
pressure has not been seen before in any limiting dilution, the clone isolation process by 
FACS was repeated with a pre-enriched cell line as well as cell lines expressing hTGF-β1. In 
none of the following clone isolations by FACS an increased instability of clones could be 
observed. Repeating the FACS-based clone isolation for an hTGF-β1-expressing, P5CS-
selected and GFP-coexpressing cell line could confirm the obtained enrichment rates from 
the first sort with a 8.8-fold enrichment. These hTGF-β1 clones were also tested in a batch 
process to ensure the ability of adaptation to serum-free conditions in the shake incubator 
and stability of productivity. As in a batch process with antibody-producing clones isolated 
by limiting dilution, viable cell densities of up to 1x107 cells/mL were reached. Compared to 
the production of recombinant antibodies, maximal titers of up to 0.27 mg/L as well as 
specific productivities of up to 0.03 pcd were significantly lower. This observation has 
already been made during stable cell line generation and fits to published hTGF-β1 
productivities: Ramani and Kondaiah (1998) report titers of 0.97 mg/L in a non-amplified, 
neomycin-selected clone. Amplified clones either isolated by DHFR selection (Bourdrel et al, 
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1993) or GS selection (Zou and Sun, 2004) reach titers between 7 and 30 mg/L. 
Not for all enrichment systems described in the introduction, details about their enrichment 
factors are given. But comparing the stated enrichment factors of other FACS-based 
enrichment systems to the system developed in this study reveals a similar range. Brezinsky 
et al (2003) reported an increase in specific productivity of 10-fold expressing recombinant 
antibodies using a surface fluorescent antibody staining for detection. Lower enrichment 
factors were reported by Meng et al (2000), who expressed the vascular endothelial growth 
factor  (VEGF) in a vector setting with coupled GOI and selection marker expression and a 
separate expression unit for a fluorescent marker reaching an enrichment for FACS-sorted 
clones of 6-fold regarding the specific productivity. Cairns et al (2011) expressed both a 
soluble Fc fusion protein and a monoclonal antibody coexpressing CD52 and CD59 by a non-
AUG initiation codon with selection markers controlled by a separate promoter. Next, Cairns 
et al (2003) sorted the top 0.5% cells and compared these clones to clones obtained by 
limiting dilution. The improvement from the starting cell line to the top limiting dilution 
(1.5- to 2.9-fold) or FACS-sorted clones (2.4- to 3.5-fold) is much lower than the enrichment 
rates obtained in this study. In contrast, there is one group describing higher enrichment 
rates. Sleiman et al (2008) were able to improve titers of an antibody-expressing cell line 
coexpressing fluorescent proteins via IRES elements with separate promoters for the 
selection markers up to 30-fold from the starting cell line to the top FACS clone.  
The increased enrichment rates of the developed FACS-clone isolation system demonstrate 
the potency and applicability of this method. In a further characterization step, the 
correlation of GFP fluorescence, secreted hTGF-β1 and intracellular hTGF-β1 of FACS-sorted 
hTGF-β1-expressing, P5CS-selected and GFP-coexpressing clones were analyzed. A strong 
correlation between intracellular hTGF-β1 levels and GFP fluorescence (R2= 0.83), but not 
between secreted hTGF-β1 levels and GFP fluorescence (R2= 0.07) due to a missing 
correlation of intracellular and secreted hTGF-β1 levels (R2= 0.09) could be observed. The 
question whether intracellular and secreted protein levels correlate, has been addressed in 
several studies with differing results. The intracellular amount of recombinant proteins has 
been found to correlate in some cases with production rates (Borth et al, 2000). For example, 
Borth et al (1996) and Strutzenberger et al (1999) found that the intracellular light chain levels 
correlated better to the overall antibody secretion than the heavy chain levels. In contrast, 
there are some publications that suggest different levels of intracellular and secreted product 
in stable CHO cell lines and clones supporting the results obtained in this study (Pendse et 
al, 1992; Pichler et al, 2011). 
Publications of different FACS-based clone enrichment systems state the coefficient of 
determination R2 as an indication how well high-producing clones can be isolated according 
to the flow cytometry signal. Since different systems calculate the coefficient of 
determination from different parameters, a one-to-one comparison is not possible. From the 
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previously described systems coefficients of determination were R2= 0.7 in the separate 
expression unit GFP-based system of Meng et al (2000) or R2= 0.9 in YFP/-CFP-based system 
of Sleimann et al (2008) both correlation fluorescence protein intensity and specific 
productivity. The coefficients of determination in the non-AUG initiation codon based 
system of Cairnes et al (2011) was R2= 0.7 correlation fluorescence protein intensity and titer. 
Other systems with even lower coefficients of determination also enabled high producer 
enrichment. For example both Freimark et al (2010) using GFP-coexpression to identify high-
producers by a plate reader and Kober et al (2012) using a fluorescent ER reporter CHO cell 
line reported a correlation of fluorescence intensity and recombinant protein titer with a 
coefficients of determination R2= 0.6. The system developed in this study with a coefficient of 
determination R2= 0.8 correlating fluorescent intensity and intracellular protein levels is in 
the range of the mentioned publications. To further improve the clone selection with the 
developed tricistronic pMACS-CHO II expression vector, it might be favorable to use a 
fluorescent reporter protein that enters the secretory pathway to closer mimic the secreted 
recombinant proteins and get a better correlation to the final secreted product by the 
identification of cells with not only high production levels but also high secretion capacities. 
One strong indicator that this strategy might be very successful is based on the data from 
antibody-producing clones isolated by two rounds of subcloning by FACS according to their 
GFP and RFP fluorescence compared to clones obtained first by four MACS-enrichment 
steps followed by a FACS-cloning according to the membrane-bound GFP and RFP 
fluorescence wherein the GFP fluorescence was encoded on the light chain vector. Although 
only one of the antibody chains has been switched from a cytosolic to a membrane-bound 
fluorescent protein, the amount of antibody secretion in relation to the GFP fluorescence 
intensity could be increased from a coefficient of determination R2= 0.0, indicating no 
correlation, to R2= 0.5, a coefficient of determination that is comparable to some publications 
(Freimark et al 2010; Kober et al, 2012) with successful enrichment systems. 
Using a membrane-bound fluorescent reporter protein allows the combination of clone 
isolation by FACS with previous MACS enrichment steps. Using magnetic assisted cell 
enrichment for high-producer selection, it is important to have an optimized level of reporter 
protein expression. All cells expressing the reporter protein are labeled with magnetic beads. 
A too low amount of reporter proteins leads to a magnetic load too low to retain cells on the 
column. A too high reporter protein amount results in sufficient labeling and but retainment 
of all cells not leading to any enrichment. Expressing a recombinant antibody using a 
combination of zeocin selection and the membrane-bound GFP on one vector, the GFP levels 
were usable for MACS enrichment. Titers of an antibody-expressing cell line could be 
improved in each MACS step up to 1.7-fold. Using a combination of P5CS and the 
membrane-bound GFP on one vector to express hTGF-β1, the enrichment protocol had to be 
optimized. But using a monoclonal antibody for direct labeling, enrichment rates of 10.6-fold 
could be reached. The direct labeling with the monoclonal antibody led to higher labeling 
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intensities of cells compared to the polyclonal indirect approach, thereby being more suitable 
for cells expressing low amounts of surface reporter. For a higher amount of surface 
molecules, the polyclonal indirect labeling might be favorable to reach the optimal intensity 
of magnetic labeling. Expressing a recombinant antibody in a two-vector strategy and 
enriching only one chain already led to enrichment factors of up to 1.7-fold. This method 
could be improved using a releasable magnetic labeling system (Miltenyi, EP 0819250B1), 
thereby having the ability to enrich two different surface reporter proteins in a sequential 
manner. 
Carroll and Al-Rubeai (2005) described a MACS-based high-producer enrichment protocol 
using affinity capture surface display (ACSD). They were able to enrich NS0 cells expressing 
a recombinant antibody about 4-fold and stated the very rapid and simple protocol as one 
major advantage in contrast to FACS. Bort et al (2010) using FACS as well as MACS to select 
a CHO-K1 cell line growing in glutamine-free medium found that both sorting systems gave 
similar results and confirmed the MACS protocol being faster and easier to handle. The 
FACS protocol brings the advantage of being able to set cut-offs and to finer discriminate 
between healthy and dead cells (Bort et al, 2010), although dead cells have never been an 
issue during MACS enrichment in this study if a starting cell line with a suitable viability of 
over 90% was used. Combining the advantages of both enrichment systems using MACS to 
pre-enrich the stable cell line and FACS to isolate high-producing clones enabled to enrich 
20.9-fold in this study, which comparable to the enrichment rate of two FACS subcloning 
steps. Analysis of MACS-enriched and FACS-sorted clones in a shake flask batch process led 
to titers of 130 mg/L. The stable starting cell line as well as the MACS-enriched stable cell 
line were also cultivated in this batch process both leading to comparable titers. As seen 
during the previous cultivation times of all MACS-enriched cell lines, the productivity 
dropped during the following cultivation period. Only using MACS does not lead to a stable 
high-producing cell line, but in combination with clone isolation it is a good tool to improve 
timelines as well as the amount of work of cell line development: A MACS enrichment step 
allows enrichment from 2x1010 cells in less than 2 hours with an additional week for 
expansion of cells. Using FACS it is only possible to screen about 1x107 cells per hour and 
handling cell numbers of 2x1010 is not feasible (Philipps, 2004).  
The batch results of up to 130 mg/L of the MACS-enriched and FACS-sorted clones are very 
promising. As seen before for clones isolated by limiting dilution, a further increase in 
maximal titer can to be expected for production in a fed-batch process. Several publications 
(Combs et al, 2011; Gorfien et al, 2003; Tabuchi et al, 2010, Strnad et al 2010) indicate that a 
further improvement in titer of about 2-fold are realistic for fed-batch production in 
bioreactors due to better control of temperature, culture pH, dissolved oxygen and 
continuous feed (Rodrigues et al, 2010). 
A traditional cell line generation process using a DHFR amplification and clone isolation by 
limiting dilution takes at least 6 month (Butler, 2005; Wurm, 2004; Haines, 2009). Using the 
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non-amplifiable P5CS selection system in combination with a MACS-enrichment and clone 
isolation by FACS reduces the timeline to find a suitable clone to 3 month. In addition, the 
application of the tricistronic pMACS-CHO II vector for the expression of recombinant 
proteins coexpressing fluorescent reporter proteins is not limited to the use in combination 
with the P5CS selection system in CHO cells. The established system can be easily 
transferred to other selection markers and also other production cell lines. 
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5 Outlook 
In the first part of the presented thesis the development of a novel selection system based on 
the enzyme pyrroline-5-carboxylate synthetase (P5CS) has been described. The P5CS 
selection system enables fast generation of stable cell lines expressing different recombinant 
proteins with high producer rates and can be combined with antibiotic selection systems for 
the use in a two-vector strategy. Neither during initial selection process nor during long-time 
cultivation of P5CS-selected cell lines any addition of cytotoxic drugs is necessary. Thereby, 
the P5CS selection system is optimal to modify parental CHO cell lines by overexpression of 
additional genes for modified glycosylation, ER secretion capacities or any other application. 
The currently reached titers of 140 mg/L in a fed-batch shake flask process are suitable for 
research applications, but not for high-level therapeutic protein production. To further 
improve the P5CS selection system, several approaches might be promising: The generation 
of a knock-down CHO cell line with deficiencies in both key enzymes for proline synthesis, 
OAT and P5CS, as well as a serum-free selection medium without traces of proline could 
greatly enhance the applied selection pressure and prevent recovery of non-producing cells. 
Furthermore, a combination of P5CS selection and a DHFR selection on one vector would 
allow an additional amplification step if required for further applications. A first test 
revealed an amplification of one vector and loss of the other. Therefore, the vector setting as 
well as the selection protocol would need to be improved. The amino acid proline has been 
reported to play an important role in protection of plant as well as mammalian cells against 
oxygen stress and overexpression of proline-forming enzymes has been proven to prevent 
reactive oxygen species (ROS)-induced apoptosis and to enhance cell survival. Apoptosis can 
account for a major part of cell death during the production process. Modified cell lines have 
shown improved performances in bioreactors. Analyzing the influence of the P5CS 
expression on the intracellular ROS levels and apoptosis might help to understand whether 
the endogenous proline synthesis increases apoptosis resistance.  
In the second part of this thesis a tricistronic expression vector to enrich high-producers by 
the coexpression of fluorescent reporter proteins for both FACS as well as MACS was 
developed. The use of magnetic labeling allows a very fast and simple enrichment of high-
producing cell lines. In addition, the clone selection by FACS has been proven to be superior 
compared to limiting dilution. The combination of MACS and FACS leads to clones with the 
same productivity as clones isolated by two FACS subcloning steps with an improved 
timeline and manual amount of work. One issue is the low correlation of secreted 
recombinant protein and cytosolic reporter protein. First experiments with membrane-bound 
fluorescent proteins processed in the secretory pathway as the secreted recombinant proteins 
already show an improved correlation. Therefore, switching both reporter proteins for 
recombinant antibody expression to membrane-bound reporter proteins seems to be very 
promising. For these two different surface markers, a MACS enrichment process with 
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releasable magnetic beads should be established to further improve the system by enabling 
enrichment of both antibody chains. The tricistronic expression vector is not limited for the 
use with the P5CS selection system in CHO cells. In general, an application in other 
expression hosts is possible and might be established.  
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6 Material and Methods 
6.1 Materials 
6.1.1 Technical devices 
Analytical balances CP224S Satorius, Göttingen 
506-2 Kern, Balingen-Frommern 
Autoclave Varioklav® VI 500 EP H+P Labortechnik, 
Oberschleißheim 
Systec V-95 Systec, Wettenberg 
Blotting apparatus Flastblot B34 Biometra, Göttingen 
Cryo freezing container Nalgene® Cryo 1°C Freezing 
Container Mr. Frosty® 
Thermo Scientific, Bonn 
Dispenser Easypet® Eppendorf, Hamburg 
Electrophoresis apparatus Horizon® 11.14 Biometra, Göttingen 
Horizon® 58 Biometra, Göttingen 
Xcell SureLockTM Invitrogen, Karlsruhe 
Consort E 865 Protrans, Hockenheim 
EPS 200 Amersham GE Healthcare, 
Freiburg 
ELISA washer HydroFlexTM Tecan, Männedorf 
Flow cytometer MACSQuant® Analyzer Miltenyi Biotec, Bergisch 
Gladbach 
MACSQuant® VYB Miltenyi Biotec, Bergisch 
Gladbach 
BD InfluxTM Becton-Dickinson, Heidelberg 
FACSVantageTM SE DIVA Becton-Dickinson, Heidelberg 
Gele documentation Gel Doc 1000 BioRad, München 
Ice flaker Scotsman AF 100 Hubbard Ice Systems, Ipswich 
Incubator Heracell® 240i Heraeus, Hanau 
Heracell® BB6620 Heraeus, Hanau 
Heraeus® B6030 Heraeus, Hanau 
Binder C 150 Binder, Tuttlingen 
Magnetic separator  OctoMACSTM Separator Miltenyi Biotec, Bergisch 
Gladbach 
thermoMACSTM Separator Miltenyi Biotec, Bergisch 
Gladbach 
Microscope Leica DM IL Leica, Wetzlar 
 Leica TCS SP2 Leica, Wetzlar 
Mixer Thermomixer compact Eppendorf, Hamburg 
MACSmixTM Tube Rotator Miltenyi Biotec, Bergisch 
Gladbach 
Vortex Genie Scientific Industries, Portland 
C-MAG HS 4 IKAMAG® IKA-Werke, Staufen 
GFL 3015 GFL, Burgwedel 
PCR-cycler Mastercycler® Gradient Eppendorf, Hamburg 
AbiPrism® 7000 Applied Biosystems/Life 
Technologies, Darmstadt 
pH meter Labor-pH-Meter 765 Calimatic® Knick, Berlin 
Photometer NanoDrop ND-1000 Thermo Scientific, Bonn 
Pipet Research® 10/100/200/1000 µL Eppendorf, Hamburg 
Research® plus 8x 100/300 µL Eppendorf, Hamburg 
Xplorer® 12x300 µL Eppendorf, Hamburg 
HandyStep® Repeating Pipette Brand, Wertheim 
Plate reader Emax Molecular Devices, Biberach an 
der Riss 
Infinite® 200 PRO Tecan, Männedorf 
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VICTORTM X4 PerkinElmer, Rodgau 
Shake incubator Certomat® CT plus Satorius, Göttingen 
Forma Orbital Shaker Thermo Scientific, Bonn 
Sonificator Sonoplus HD 2200 Brandelin electronic, Berlin 
Sterile workbench HERAsafe® HS Thermo Scientific, Bonn 
HERAsafe® KSP Thermo Scientific, Bonn 
Biowizard Golden Line Kojar, Vilppula 
Thermostat water bath Type EC-5 Julabo, Seelbach 
Water Purification Milli-Q® Integral Water 
Purification System 
Millipore/Merck, Darmstadt 
Centrifuge Heraeus® Multifuge 4Kr Thermo Scientific, Bonn 
Heraeus® Biofuge Pico Thermo Scientific, Bonn 
Centrifuge 5424 Eppendorf, Hamburg 
Centrifuge 5415 R Eppendorf, Hamburg 
Centrifuge 5417 R Eppendorf, Hamburg 
 
6.1.2 Software & Databases 
AbiPrism® 7000 SDS PCR-cycler software Applied Biosystems/Life 
Technologies, Darmstadt 
ApE v2.0.15 to 45 Plasmid editor Wayne Davis, University Utah, 
Salt Lake City 
Clone Manager Professional 
version 9.x 
Plasmid editor Sci-Ed Software, Cary 
Gel Doc 1000/PC Gel Doc software BioRad, München 
i-control Microplate reader software Tecan, Männedorf 
MACSQuantify Professional 
version 1.0 
Analysis MACSQuant data Miltenyi Biotec, Bergisch 
Gladbach 
Microsoft Office version 12/14 Office suite Microsoft, Redmont 
NanoDrop 1000 V3.8.1 NanoDrop software Thermo Scientific, Bonn 
New WorkOut 2.5 Microplate reader software PerkinElmer, Rodgau 
SoftMax Pro ELISA reader software Molecular Devices, Biberach an 
der Riss 
http://bioinfo.clontech.com/inf
usion/molarRatio.do 
 
Cloning tool, insert: vector ratio Clontech, Saint-Germain-en-
Laye 
http://blast.ncbi.nlm.nih.gov/B
last.cgi 
 
Sequence blast National Center for 
Biotechnology Information, 
Bethesda 
http://www.ncbi.nlm.nih.gov/ Sequence and literature database National Center for 
Biotechnology Information, 
Bethesda 
http://www.promega.com/tec
hserv/tools/biomath/calc11.ht
m#melt_results 
 
Primer design Promega, Mannheim 
http://www.uniprot.org/ Sequence database UniProt consortium 
 
6.1.3 Consumables  
4 - 20 % Tris-glycine-gel, 10 slots Anamed Elektrophorese, Groß-Bieberau 
ABsoluteTM QPCR Seal Thermo Scientific, Bonn 
Amersham HybondTM ECLTM  GE Healthcare, Freiburg 
Cell Strainer 40 µm BD, Heidelberg 
Conical centrifuge tube, 225 mL BD, Heidelberg 
Cryogenic vials 1.5/2.0 mL Nalgene/Nunc, Langenselbold 
Dispenser tips, Plastibrand PD-tips 1.25/2.5/5/12.5 mL Brand, Wertheim 
Erlenmeyer flask, vented cap, 125 mL Corning, Hagen 
Extra Thick Blot Paper BioRad, München 
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Falcon tubes 15/50 mL BD, Heidelberg 
Filter pipet tip, ART, 1000 µL, sterile Molecular Bio Products, San Diego 
Filter pipet tip, Quali-tips 10/100/200 µL, sterile Kisker Biotec, Steinfurt 
Filter Unit Millex PVDF 0.22 µm Millipore/Merck, Darmstadt 
Immuno-plates MaxiSorp® 96-well Nunc, Langenselbold 
Latex glove Kimtech PFE KIM Jarolim, Sulzdorf 
Microcentrifuge tubes 1.5/2.0 mL Starlab, Hamburg 
Microtiter plate pureGradeTM, 96-well, PS, V-bottom Brand, Wertheim 
Neubauer Improved Brand, Wertheim 
Nitrile gloves Supreno SE Microflex, Reno 
PCR tubes strip, 8x 0.2 mL, individual flat cap Brand, Wertheim 
Petri dish  Greiner Bio-One, Frickenhausen 
Pipet tip, TipOne 10/200/1000 µL Starlab, Hamburg 
Pre-separation filters, 30 µm Miltenyi Biotec, Bergisch Gladbach 
Scalpel blades Bayha, Tuttlingen 
Separation columns MS Miltenyi Biotec, Bergisch Gladbach 
Serological pipettes 5/10/25 mL, unsterile Sarstedt, Nümbrecht 
Serological pipettes 5/10/25/50 mL, sterile Sarstedt, Nümbrecht 
Storage bottle 250/500/1000 mL  Corning, Hagen 
Syringe, 1/5/10/50 mL, Plastipak BD, Heidelberg 
Thermo-Fast® 96 PCR detection plate Thermo Scientific, Bonn 
Tissue culture flask, 25 cm2, screw cap with filter TPP, Trasadingen 
Tissue culture flask, 75/175 cm2, vented cap BD, Heidelberg 
Tissue-culture plates 6-/12-/24-/96-well, flat bottom BD, Heidelberg 
 
6.1.4 Chemicals 
2-propanol, molecular biology grade AppliChem, Darmstadt 
Acetic acid, 100% AppliChem, Darmstadt 
Agarosis, electrophoresis grade Invitrogen, Karlsruhe 
Ampicillin, sodium salt AppliChem, Darmstadt 
Bromphenol blue Sigma-Aldrich, München 
BSA fraction V Serva Electrophoresis, Heidelberg 
BSA Stock Solution, 10% Miltenyi Biotec, Bergisch Gladbach 
cOmplete Mini Protease Inhibitor Cocktail Tablets Roche, Penzberg 
Developer solution, Roentogen liquid Tetenal, Norderstedt 
EDTA, molecular biology grade Sigma-Aldrich, München 
Erythrosine B Sigma-Aldrich, München 
Ethanol, molecular biology grade AppliChem, Darmstadt 
Ethidium bromide solution, molecular biology grade Sigma-Aldrich, München 
Fixation solution, Roentogen Superfix Tetenal, Norderstedt 
Glycerin, molecular biology grade Sigma-Aldrich, München 
Glycine Sigma-Aldrich, München 
H2SO4, 95-97 % analysis grade AppliChem, Darmstadt 
HCl, 37%  Carl Roth, Karlsruhe 
ImmubilonTM Western Chemiluminescent HRP Substrate Millipore, Schwalbach/Ts. 
Kanamycinsulfat AppliChem, Darmstadt 
KCl, cell culture grade AppliChem, Darmstadt 
KH2PO4, cell culture grade AppliChem, Darmstadt 
MACSQuant Running Buffer Miltenyi Biotec, Bergisch Gladbach 
MACSQuant Storage Solution Miltenyi Biotec, Bergisch Gladbach 
MACSQuant Washing Solution Miltenyi Biotec, Bergisch Gladbach 
Methanol, analysis grade AppliChem, Darmstadt 
Milk powder Sigma-Aldrich, München 
Na2HPO4, cell culture grade AppliChem, Darmstadt 
NaCl, analysis grade AppliChem, Darmstadt 
NaOH, analysis grade VWR, Darmstadt 
Peptone, from soy bean, for microbiology Merck, Darmstadt 
Propidium iodide Sigma-Aldrich, München 
SDS running buffer Anamed Elektrophorese, Groß-Bieberau 
SDS, biochemistry grade Carl Roth, Karlsruhe 
Select agar Sigma-Aldrich, München 
SeramunBlau® fast TMB Substrate Seramun, Heidesee 
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SOC New England Biolabs, Frankfurt am Main 
Sodium Deoxycholate Sigma-Aldrich, München 
Tris (Trizma base), molecular biology grade Sigma-Aldrich, München 
Triton X-100, laboratory grade Sigma-Aldrich, München 
Tween 20 Sigma-Aldrich, München 
Water, molecular grade Sigma-Aldrich, München 
Yeast extract, for biotechnology Merck, Darmstadt 
β-mercaptoethanol, molecular biology grade Sigma-Aldrich, München 
 
6.1.5 Buffers & Solutions 
Agarosis gel loading buffer (6x) 10% (v/v) 50x TAE buffer, 25% (v/v) glycerin, 0.2% (w/v) 
bromphenol blue 
 
Ampicillin solution (1000x) 50 mg/mL ampicillin 
 
ELISA Assay buffer PBS, 1% (w/v) BSA 
 
Erythrosine B solution (2x) 1 mg/mL in 1x PBS 
 
Ethidium bromide solution (100x) 50 µg/mL ethidium bromide 
 
Kanamycin solution (1000x) 50 mg/mL kanamycin 
 
Laemmli buffer (5x) 250 mM Tris pH 6.8, 10% (w/v) SDS, 40% (v/v) glycerin, 
0.025% (w/v) bromphenol blue, 3.3% (v/v) β-mercaptoethanol 
 
LB-agar 1% (w/v) peptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl 
 
LB-agar plates 1% (w/v) peptone, 0.5% (w/v) yeast extract, 1% (w/v) NaCl, 
1.5% (w/v) agarosis 
 
MSX 1 mM, use aliquot immediately, do not refreeze 
 
MTX 25 mM MTX 
 
PBS 137 mM NaCl, 8.1 mM Na2HPO4, 2.6 mM KCl, 1.4 mM KH2PO4 
 
PBST PBS, 0.05 % (v/v) Tween 20 
 
PE PBS, 2 mM ETDA 
 
PEB PBS, 2 mM ETDA, 0.5 % (w/v) BSA 
 
Propidium iodide solution (1000x) 1 mg/mL propidium iodide 
 
RIPA 150 mM NaCl, 0.5% (w/v) sodium deoxycholate, 0.1%(w/v) 
SDS, 50 mM Tris pH 8.8, 1 % (v/v) Triton X-100, 1x protease 
inhibitors 
 
TAE  40 mM Tris, 20 mM acetic acid, 2 mM EDTA, pH 8.5 
 
TBS 150 mM NaCl, 50 mM Tris, pH 7.0 
 
TBST TBS, 0.1% (v/v) Tween 20 
 
Western Blot blocking buffer TBS, 5% (w/v) milk powder 
 
Western Blot transfer buffer 48 mM Tris, 39 mM glycine, 1.3 mM SDS, 10% (v/v) methanol 
 
If not stated otherwise buffers were made with pure water. 
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6.1.6 Buffer, media and supplements for cell culture 
6.1.6.1 Reagents 
10x MEM (proline-free) Sigma-Aldrich, München 
BSA 30% solution PAA, Cölbe 
CD FortiCHOTM Invitrogen, Karlsruhe 
Chemically defined lipid concentrate (1000x) Invitrogen, Karlsruhe 
CHO MACS CD Miltenyi Biotec, Bergisch Gladbach 
CHO MACS CD without proline TeutoCell, Bielefeld 
CHO MACS Feed Supplement Miltenyi Biotec, Bergisch Gladbach 
Dialyzed FBS PAA, Cölbe 
DL-methionine, insect cell culture grade Sigma-Aldrich, München 
DMSO, cell culture grade Sigma-Aldrich, München 
Erythrosine B Sigma-Aldrich, München 
ExCell® CD CHO Sigma-Aldrich, München 
FugeneHD® Roche, Penzberg 
G418 sulphate solution (50 mg/mL) PAA, Cölbe 
Genetix CloneMatrix Molecular Devices, Biberach an der Riss 
Gibco® FreeStyleTM CHO  Invitrogen, Karlsruhe 
Glycine, cell culture grade Sigma-Aldrich, München 
HT supplement (100x) Invitrogen, Karlsruhe 
HyClone SFM4CHO (contains 4 mM glutamine) Thermo Scientific, Bonn 
Hygromycin B solution (50 mg/mL) PAA, Cölbe 
ITS PAA, Cölbe 
ITS+3 Sigma-Aldrich, München 
L-alanine, cell culture grade Sigma-Aldrich, München 
L-arginine monohydrochloride, cell culture 
grade 
Sigma-Aldrich, München 
L-asparagine monohydrate, cell culture grade Sigma-Aldrich, München 
L-aspartic acid, cell culture grade Sigma-Aldrich, München 
L-cysteine hydrochloride, cell culture grade Sigma-Aldrich, München 
L-glutamic acid, cell culture grade Sigma-Aldrich, München 
L-glutamine (200 mM) PAA, Cölbe 
L-isoleucine, cell culture grade Sigma-Aldrich, München 
L-leucine, cell culture grade Sigma-Aldrich, München 
L-lysine monohydrochloride, cell culture grade Sigma-Aldrich, München 
L-methionine sulphoximine Sigma-Aldrich, München 
L-phenylalanine, cell culture grade Sigma-Aldrich, München 
L-proline, cell culture grade Carl Roth, Karlsruhe 
L-serine, cell culture grade Sigma-Aldrich, München 
L-threonine, cell culture grade Sigma-Aldrich, München 
L-tryptophan, cell culture grade Sigma-Aldrich, München 
L-tyrosine disodium salt hydrate, cell culture 
grade 
Sigma-Aldrich, München 
L-valine, cell culture grade Sigma-Aldrich, München 
MEM (proline-free) Sigma-Aldrich, München 
L-MSX Sigma-Aldrich, München 
MTX Sigma-Aldrich, München 
Penicillin/Streptomycin PAA, Cölbe 
Pluronic® F-68 solution, 10% Sigma-Aldrich, München 
RPMI Vitamins Solution (100x) PAA, Cölbe 
Sodium bicarbonate solution, 7.5 %  Sigma-Aldrich, München 
Sodium pyruvate (100 mM) PAA, Cölbe 
Trace Elements A (1000x) Cellgro, Manassas 
Trace Elements B (1000x) Cellgro, Manassas 
TrypLETM Select (1x) Invitrogen, Karlsruhe 
Trypsin PAA, Cölbe 
ZeocinTMsolution (100 mg/mL) Invivogen, Toulouse 
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6.1.6.2 Media 
MEM  MEM +/- 40 mg/L proline, 2 mM glutamine, 10% (v/v) dialyzed FBS 
 
 
Serum-reduced MEM MEM +/- 40 mg/L proline, 2 mM glutamine, 1:100 ITS+3, 5% (v/v) 
dialyzed FBS 
 
CHO-MEM MEM +/- 40 mg/L proline, 6 mM glutamine, 5% (v/v) dialyzed FBS, 
1:100 ITS, 3 mM sodium pyruvate, 1x amino acid mixture, 1x RPMI 
vitamins solution, , 1x trace elements A and B, 1 % (v/v) Pluronic F-68, 
2x chemically defined lipid concentrate, 0.05% (w/v) BSA 
 
Amino acid mixture (50x) 0.85 g/L L-alanine, 4.25 g/L L-arginine hydrochloride, 5.5 g/L L-
asparagine monohydrate, 1.75 g/L L-aspartic acid. 1.75 g/L L-cysteine 
hydrochloride, 4 g/L glutamine acid, 3 g/L glycine, 5.25 g/L L-
isoleucine, 5.25 g/L L-leucine, 2.5 g/L L-lysine monohydrochloride, 1.05 
g/L DL-methionine, 0.9 g/L L-phenylalanine, 2.6 g/L L-serine, 1.45 g/L 
L-threonine, 0.25 g/L L-tryptophan, 0.65 g/L L-tyrosine disodium salt 
hydrate, 1.2 g/L L-valine in water, sterile filtered 
 
CHO MACS CD without 
proline 
CHO MACS CD without proline, 6-8 mM glutamine, (8 mM batch, 6 mM 
fed-batch) 
 
CHO MACS CD CHO MACS CD, 8 mM glutamine 
 
ExCell CD CHO ExCell CD CHO, 8 mM glutamine 
 
CD FortiCHO CD FortiCHO, 8 mM glutamine 
 
Gibco FreeStyle CHO Gibco FreeStyle CHO, 8 mM glutamine 
 
2x MEM  20% (v/v) 10x MEM, 0.45% (w/v) sodium bicarbonate, 20% (v/v) 
dialyzed FBS, sterile filtered 0.22 µm 
 
ClonePix base 50 mL 2x MEM, 40 mL Genetix Clone Matrix 
 
ClonePix medium ClonePix base supplemented with 2 mM glutamine, 400 µg/mL G418 
and 1:100 CloneDetect Agent 
 
For the cultivation of CHO DG 44 cells, HT supplement (1x) was added to the media.  
 
6.1.7 Cells 
6.1.7.1 Bacterial cells 
dam-/dcm- Competent E. coli New England Biolabs, Frankfurt am Main 
NEB 5-alpha Competent E. coli (High Efficiency) New England Biolabs, Frankfurt am Main 
 
6.1.7.2 Mammalian cells 
CHO-S Invitrogen, Karlsruhe   
CHO-K1 (ATCC-CCL-61) American Type Culture Collection, Manassas   
CHO DG44 Invitrogen, Karlsruhe   
HEK EBNA (ATCC-CRL-10852) American Type Culture Collection, Manassas   
 
 
 
 Material and Methods 
 91 
6.1.8  Enzymes  
Antarctic phosphatase New England Biolabs, Frankfurt am Main 
Eurogenec qPCR Core kit for SYBR® Green I Eurogentec, Liège 
MACSscript Miltenyi Biotec, Bergisch Gladbach 
PicoMaxx High Fidelity PCR System Agilent Technologies, Böblingen 
Quick Blunting KitTM New England Biolabs, Frankfurt am Main 
Rapid DNA Ligation Kit Roche, Penzberg 
Restriction endonucleases New England Biolabs, Frankfurt am Main 
 
6.1.9 Others Kits and materials for molecular and biochemical applications 
2-Log DNA Ladder (0.1–10.0 kb) New England Biolabs, Frankfurt am Main 
BCATM Protein Assay Kit Thermo Scientific, Bonn 
BSA standard pre-diluted set Thermo Scientific, Bonn 
dNTPs (10 mM) Fermentas, St. Leon-Rot 
DTT (0.1 M) Invitrogen, Darmstadt 
FcR Blocking reagent Miltenyi Biotec, Bergisch Gladbach 
First strand buffer (5x) Invitrogen, Darmstadt 
High Pure PCR Product Purification Kit Roche, Penzberg 
Human/Mouse TGF beta 1 ELISA Ready-SET-
Go!® (2nd Generation) 
eBioscience, Frankfurt am Main 
Inside Staining Kit  Miltenyi Biotec, Bergisch Gladbach 
Invisorb® Spin Plasmid Mini Two Stratec Molecular, Berlin 
Low Molecular Weight DNA Ladder New England Biolabs, Frankfurt am Main 
NucleoBond® Xtra Maxi EF 
 
Macherey-Nagel, Düren 
PageRulerTM Prestained Protein Ladder Fermentas, St. Leon-Rot 
pGEM®-T Easy Vector System Promega, Mannheim 
Primer mix (as)  Miltenyi Biotec, Bergisch Gladbach 
RNeasy® Mini Kit Qiagen, Hilden 
"MACSTM One-step cDNA Kit Miltenyi Biotec, Bergisch Gladbach 
 
6.1.10 Vectors 
6.1.10.1 Commercial vectors & vectors from collaborations 
pTagRFP-N Source of RFP sequence, used as control 
vector 
Evrogen, Moscow 
pEGFP-C1 Source of GFP and neoR sequence, used as 
control vector 
Clontech, Saint-Germain-en-Laye 
pMACS 4-IRES.II Backbone of pMACS-CHO Miltenyi Biotec, Bergisch Gladbach 
pGEM®-T Easy Cloning vector for PCR products Promega, Mannheim 
pSV2neo-hCMV Backbone of pSV2neo vector with hCMV 
promoter, backbone for pSV2neo-hCMV-GFP 
Busch, 2005 
pDisplay-GFP Source of membrane-bound GFP sequence, 
used as control vector 
Knöbel, 2006 
 
6.1.10.2 Constructed vectors  
6.1.10.2.1 Vectors with pSV2neo-hCMV backbone 
Table 13: Vectors with pSV2neo-hCVM backbone 
Vector 1. GOI hCMV promoter 2. GOI SV40 promoter 
pSV2neo-hCMV-GFP GFP neoR 
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6.1.10.2.2 Vectors with pGEM-T Easy backbone 
Table 14: Vectors with pGEM-T Easy backbone 
Vector Insert 
pGEM-GAPDH  CHO GAPDH ORF 
pGEM-OAT  CHO OAT ORF first 939 bp 
pGEM-P5CS  CHO P5CS ORF 
pGEM-GAPDH  CHO GAPDH ORF 
pGEM-GS  CHO GS ORF 
pGEM-mGFP F2A mGFP for F2A vector (pMACS-CHO 2A) 
pGEM-zeoR F2A zeoR for F2A vector (pMACS-CHO 2A) 
pGEM-GFP T2A  GFP for T2A vector (pMACS-CHO II) 
pGEM-mGFP T2A  mGFP for T2A vector (pMACS-CHO II) 
pGEM-RFP T2A  RFP for T2A vector (pMACS-CHO II) 
pGEM- zeoR T2A  zeoR for T2A vector (pMACS-CHO II) 
pGEM- P5CS T2A  P5CS for T2A vector (pMACS-CHO II) 
 
6.1.10.2.3 Vectors with pMACS-backbone 
Table 15: Vectors with pMACS-backbone 
Vector Backbone 1. GOI 
before 
IRES 
2. GOI behind 
IRES 
2A 
peptide 
3. GOI 
behind 2A 
peptide 
Additional 
elements 
pAS-5 pMACS-CHO GFP - - -  
pAS-8 pMACS-CHO GFP neoR - -  
pAS-9 pMACS-CHO - GFP - -  
pAS-16 pMACS-CHO GFP P5CS - -  
pAS-17 pMACS-CHO GFP GS - -  
pAS-18 pMACS-CHO GFP hygroR - -  
pAS-19 pMACS-CHO hum anti-
CD303 HC 
neoR - -  
pAS-20 pMACS-CHO hum anti-
CD303 HC 
hygroR - -  
pAS-21 pMACS-CHO hum anti-
CD303 HC 
P5CS - -  
pAS-23 pMACS-CHO hum anti-
CD303 LC 
neoR - -  
pAS-24 pMACS-CHO hum anti-
CD303 LC 
hygroR - -  
pAS-25 pMACS-CHO hum anti-
CD303 LC 
P5CS - -  
pAS-31 pMACS-CHO hum anti-
CD303 HC 
GFP - -  
pAS-32 pMACS-CHO hum anti-
CD303 LC 
GFP - -  
pAS-46 pMACS-CHO hum anti-
CD303 HC 
GS (CHO-K1) - -  
pAS-47 pMACS-CHO hum anti-
CD303 LC 
GS (CHO-K1) - -  
pAS-54 pMACS-CHO hum anti-
CD303 HC 
zeoR - -  
pAS-55 pMACS-CHO hum anti-
CD303 LC 
zeoR - -  
pAS-83 pMACS-CHO-2A hum anti-
CD303 LC 
neoR w/o 
Stop 
F2A mGFP  
pAS-84 pMACS-CHO-2A hum anti-
CD303 LC 
neoR w/o 
Stop 
F2A RFP  
pAS-85 pMACS-CHO-2A hum anti-
CD303 HC 
P5CS w/o 
Stop 
F2A mGFP  
pAS-86 pMACS-CHO-2A hum anti-
CD303 HC 
P5CS w/o 
Stop 
F2A RFP  
pAS-97 pMACS-CHO chim anti-
Biotin HC 
neoR - -  
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pAS-98 pMACS-CHO chim anti-
Biotin HC 
P5CS - -  
pAS-100 pMACS-CHO chim anti-
Biotin LC 
zeoR - -  
pAS-102 pMACS-CHO chim anti-
CD14 HC 
neoR - -  
pAS-103 pMACS-CHO chim anti-
CD14 HC 
P5CS - -  
pAS-105 pMACS-CHO chim anti-
CD14 LC 
zeoR - -  
pAS-107 pMACS-CHO-2A hum anti-
CD303 LC 
zeoR w/o Stop F2A mGFP  
pAS-125 pMACS-CHO II hum anti-
CD303 LC 
GFP w/o Stop T2A zeoR  
pAS-126 pMACS-CHO II hum anti-
CD303 LC 
mGFP w/o 
Stop 
T2A zeoR  
pAS-130 pMACS-CHO II hum anti-
CD303 LC 
RFP w/o Stop T2A zeoR  
pAS-131 pMACS-CHO II hum anti-
CD303 HC 
GFP w/o Stop T2A P5CS  
pAS-132 pMACS-CHO II hum anti-
CD303 HC 
mGFP w/o 
Stop 
T2A P5CS  
pAS-133 pMACS-CHO II hum anti-
CD303 HC 
RFP w/o Stop T2A P5CS  
pAS-158 pMACS-CHO II hum anti-
CD303 LC 
RFP w/o Stop T2A zeoR DHFR with 
SV40 
promoter 
pJN-1 pMACS-CHO hTGFβ1-
FGA SP 
P5CS -   
pJN-2 pMACS-CHO hTGFβ1-
FGA SP 
neoR -   
pJN-3 pMACS-CHO hTGFβ1-
FGA SP 
hygroR -   
pJN-4 pMACS-CHO hTGFβ1-
FGA SP 
zeoR -   
pJN-5 pMACS-CHO II hTGFβ1-
FGA SP 
GFP T2A P5CS  
pJN-6 pMACS-CHO II hTGFβ1-
FGA SP 
mGFP T2A P5CS  
 
6.1.11 Oligonucleotides 
Table 16: List of used oligonucleotides 
Name Sequence (5´!3´) Annealing 
temperature 
Application 
OAT deg f CRYVATGYTYTCYARRYTAGC 55°C P 
OAT deg r CTCAGAARGACARGAYRGTC 55°C P 
OAT 3 ATGAATACAGGAGTGGAGGC 55°C P, S 
OAT 4 r GGTCAGCATTATCTCATCATCAC 55°C P, S 
OAT 5 r GAAGGACAAGATGGTCTTGTT 55°C P 
OAT 6 r TGCAACAGATGCAGCAGAGG  S 
OAT 7 r GCCTTGGACTGTCTTCTTAG  S 
P5CS deg f AYATCDCAVSATGYTGAGWCA 55°C P, S 
P5CS deg r TCARYTGRWRTKYCKCTGRGG 55°C P, S 
P5CS 2 GTACCCCTCAGTCGTGC 45°C P, S 
P5CS 4 r CAGCCAGGCTATCATTATC 45°C P, S 
P5CS 7 GAACAAGTGACTGTCCCAAT 50°C P, S 
P5CS 8 r GACGATGACATCTGTGTG 50°C P, S 
P5CS 11 r AACGGCTCCGCTGGTGACC  S 
P5CS 12 f TCATCGATATGCTGCGAGTGG  S 
OAT ORF f ATGTTCTCCAGACTAGCAACTTTG 50°C P 
OAT ORF r TCAGAAGGGGCAGATGGTC 50°C P 
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P5CS ORF f ATGTTGAGACACATGCATCG 55°C P, S 
P5CS ORF r TCAGTTGGTGTTTCTCTGGG 55°C P, S 
GAPDH ORF f ATGGTGAAGGTCGGCGTGAAC 50°C P, S 
GAPDH ORF r TTACTCCTTGGAGGCCATGTAGG 50°C P, S 
GAPDH-84F TGTTGCCATCAATGACCCCT 60°C RT 
GAPDH-184R TCTCAGCCTTGACTGTGCCTT 60°C RT 
GAPDH-650F AAGTCATCCCAGAGCTGAACG 60°C RT 
GAPDH-750R AGGTTTCTCCAGGCGACATG  60°C RT 
OAT-825F GCTGGCTGTGGATCATGAGA  60°C RT 
OAT-925R CGTCATCACACAGCACTGCA  60°C RT 
OAT-670F GTTGCTGCCTTCATGGTGG 60°C RT 
OAT-770R TGGTGCCTGGTGCAGAGTT 60°C RT 
P5CS-519F CGAGGCCATGTTTACGCAGT 60°C RT 
P5CS-619R GTGTGCCGTTGAGATTCCG  60°C RT 
P5CS-920F GCATGGAAGCCAAGGTGAA 60°C RT 
P5CS-1022R GTGATGACGTGCCCAGACAC 60°C RT 
Seq IgG1 TTGGAGGGCTTATGGTTCAC  S 
Seq kappa CCTGGCTGTTTCCTGATTGC  S 
GS ohne Tag f GTGACTCTCGAGGCCGCCACCATGGCCA
CCTCAGCAAGTTC  
55°C C 
GS ohne Tag r GTGACTGGATCCTTATCATTAGTTTTTGTA
TTGAAGGGCTCG 
55°C C 
Zeocin vor 2A f GTGACTCTCGAGATGGCGAAGCTTACTTC
AGC 
50°C C 
Zeocin vor 2 A r GTGACTTCTAGAGTCCTGCTCCTCGGCCA
CG 
50°C C 
(m)GFP hinter F2A f GTGACTGCGATCGCGAGACAGACACACT
CCTGC 
50°C C 
(m)GFP hinter F2A r GTGACTCTTAAGATGCTAACGTGGCTTCT
TC 
50°C C 
RFP hinter F2A f GTGACTGCGATCGCATGGTGTCTAAGGG
CGAAGAG 
50°C C 
RFP hinter F2A r GTGACTCTTAAGTCAATTAAGTTTGTGCC
CCAG 
50°C C 
GFP vor T2A f GTGACTCTCGAGGCCACCATGGTGAGCA
AGGG    
60°C C 
GFP vor T2A r GTGACTTCTAGACTTGTACAGCTCGTCCA
TGCCG 
60°C C 
mGFP vor T2A f GTGACTCTCGAGGCCACCATGGAGACAG
ACACAC    
50°C C 
mGFP vor T2A r GTGACTTCTAGAACGTGGCTTCTTCTGCC
AAAG    
50°C C 
RFP vor T2A f GTGACTCTCGAGGCCACCATGGTGTCTA
AGGG  
50°C C 
RFP vor T2A r GTGACTTCTAGAATTAAGTTTGTGCCCCA
GTTTGC   
50°C C 
T2A f GTGACTTCTAGATCTGGCTCCGGAGAGG
GCC 
60°C C 
T2A r GTGACTGCGATCGCCGGGGCCGGGGTTC
TCCTCC   
60° C 
Zeocin hinter T2A f GTGACTGCGATCGCGCGAAGCTTACTTC
AGCGG   
45°C C 
Zeocin hinter T2A r GTGACTCTTAAGTCATCAGTCCTGCTCCT
CGG  
45°C C 
P5CS hinter T2A f GTGACTGCGATCGCCTTAGGCACATGCA
CAGATC 
55°C C 
P5CS hinter T2A r GTGACTCTTAAGTTATCAATGATGGTGGT
GGTG 
55°C C 
CMV-F CGCAAATGGGCGGTAGGCGTG  S 
pIRES-RP TATAGACAAACGCACACCG  S 
pcDNA1.1-RP CTCTGTAGGTAGTTTGTCC  S 
pcDNA-3.1-R CAAACAACAGATGGCTGGC  S 
M13 FP TGTAAAACGACGGCCAGT  S 
M13 RP CAGGAAACAGCTATGACC  S 
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D = A or T or G, K =  G  or T, R = A or G, S = G or C, V = A or C or G, W = A or T, Y = C or T 
S = sequencing, RT = real-time PCR, P = standard PCR (might be used for sequencing or cloning in 
pGEM®-T Easy vector), C = adding restriction enzyme sites for cloning in pGEM®-T Easy vector 
(addition of restriction enzymes sites in bold)  
 
6.1.12 Antibodies 
Table 17: List of used antibodies 
Antibody Distributor Dilution Application 
Alexa Fluor® 647 Goat Anti-
Rabbit IgG (H+L) 
Invitrogen, Darmstadt 1:2000 in PEB S 
anti-human kappa HRP In-house Miltenyi Biotec, 
Bergisch Gladbach 
1:2000 – 1:8000 ELISA 
Anti-Ig κ Light Chain-FITC, 
human 
Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB ICS 
Anti-IgG-APC, human Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB ICS 
Anti-LAP (TGF-β1)-APC, 
human 
Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB ICS 
Anti-Rabbit IgG Microbeads Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB MACS 
IgG (Fc) (anti- human, clone 
JDC-10) 
Beckman Coulter, Krefeld 1:150 in PBS ELISA 
Labeling Check Reagent-APC Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB S 
Living Colors® Full-Length 
A.v. Polyclonal Antibody 
(polyclonal rabbit anti-GFP) 
Clontech, Saint-Germain-en-
Laye 
1:1000 in PEB MACS 
Monoclonal anti-GAPDH 
HRP 
Sigma-Aldrich, München 1:2500 in blocking 
buffer 
WB 
rabbit anti-ALDH18A1 
(P5CS) 
Sigma-Aldrich, München 1:1000 in TBST WB 
rabbit anti-OAT Acris Antibodies, Herford 1:2500 in TBST WB 
Remicade® MSD Sharp & Dohme, Haar Standard, 0.976 to 
250 ng/mL 
ELISA 
Stemgent® HRP mouse anti-
rabbit 
Miltenyi Biotec, Bergisch 
Gladbach 
1:35000 in blocking 
buffer 
WB 
µMACSTM Anti-GFP 
MicroBeads (monoclonal) 
Miltenyi Biotec, Bergisch 
Gladbach 
1:10 in PEB MACS 
CloneDetect anti-human 
detection agent FITC-labeled 
Molecular Devices, Biberach 
an der Riss 
1:100 CP 
 
S= surface cell staining, ICS = intracellular staining, ELISA = ELISA, WB= Western Blot, CP= ClonePix 
 
6.2 Methods 
6.2.1 Molecular biological methods 
6.2.1.1 Isolation of plasmid DNA from E.coli 
For small-scale isolation of plasmid DNA from E.coli overnight cultures, the Invisorb Spin 
Plasmid Mini Two kit and for large-scale isolation of plasmid DNA, the Macherey-Nagel 
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NucleoBond® Xtra Maxi EF kit was used according to manufacture´s instructions. Plasmid 
DNA concentrations were determined by absorption measurement.  
 
6.2.1.2 Agarosis gel electrophoresis 
Using an agarosis gel electrophoresis, linearized DNA can be separated according to their 
size. A 0.8-1.5% TAE agarosis gel containing 500 ng/mL ethidium bromide was loaded with 
the DNA mixed with 6x loading buffer. The sample DNA and the marker were separated at 
10 V/cm2 for 30 to 60 minutes depending on the DNA molecular weight and the length of 
the gel. The DNA bands separated in the gel were visualized by the intercalating dye 
ethidium bromide under UV light (λ= 312 nm). DNA bands were cut out and the DNA was 
purified with the Roche High Pure PCR Product Purification Kit. 
 
6.2.1.3 Digestion of DNA by restriction endonucleases 
Typ II restriction endonucleases enable the sequence specific cutting of DNA. DNA samples 
(500 ng - 10 µg) were digested with up to two NEB restriction endonucleases using 
corresponding reaction buffers at optimal temperatures (generally 37°C) with varying 
incubation times of one hour (h) to overnight depending on the specific requirements. For 
not compatible enzymes, the digest was purified (Roche High Pure PCR Product Purification 
Kit) and carried out in separate steps. After the incubation, restriction enzymes were heat-
inactivated if possible.  
 
6.2.1.4 Plasmid DNA purification 
To purify PCR products, plasmid DNA from restriction enzyme digests or separated DNA 
from agarosis gels, the Roche High Pure PCR Product Purification Kit was used according to 
manufacturer´s instructions.  
 
6.2.1.5 Blunting of digested DNA 
For cloning of DNA fragments without compatible ends, DNA blunting was used to convert 
the incompatible 5´ or 3´overhangs to 5´ phosphorylated, blunt ends. The NEB Quick 
BluntingTM Kit was used according to manufacturer`s instruction following digestion. For 
restriction enzymes that could not be heat-inactivated, the digested DNA had to be purified 
in between.  
 
6.2.1.6 Dephosphorylation of digested DNA 
During DNA-dephosphorylation, the phosphate group at the 5´-end of the DNA is removed 
to avoid prevents religation of the vector. The dephosphorylation process carried out by the 
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NEB Antarctic Phosphatase according to manufacturer`s instruction was only performed, if 
the restriction enzymes produced compatible ends which would allow self-ligation. The used 
phosphatase can be completely inactivated by heat. Therefore, no purification step is 
necessary between dephosphorylation and ligation.  
 
6.2.1.7 DNA ligation 
DNA ligation was carried out with up to 200 ng DNA using the Roche Rapid DNA Ligation 
Kit at room temperature (RT) for 5 to 90 minutes (min). For ligation of ends with compatible 
overhangs (“sticky”), a molar ratio of vector to insert of 1:3 was chosen. For ligation of ends 
without overhangs (“blunt”), a molar ratio of vector to insert of 1:10 was used to increase 
probability of insert integration.  !"#$%&!!"#$!"! !" = !!"#$%&!!"#$%&!(!") ∗ !"#$!!"#$%&!(!")!"#$!!"#$%&!(!") ∗ !"#$%!(!"#$%& !"#$%&) 
For cloning of PCR products, the PCR product was isolated and purified by agarosis gel 
electrophoresis and gel extraction followed by a cloning step into the pGEM®-T Easy Vector 
System according to manufacturer’s instructions.  
 
6.2.1.8 Photometric determination of DNA concentrations 
DNA has the nature to absorb UV light at 260 nm. Measuring the absorbtion at 260 nm 
enables to calculate DNA concentration according to the Beer Lambert Law: 
Oligonucleotides:  OD260 nm= 1  ≈ 20 µg   
Single-strand DNA:  OD260 nm= 1  ≈ 40 µg/mL 
Double-strand DNA:  OD260 nm= 1  ≈ 50 µg/mL 
In addition, the absobtion at 280 nm, which is the absorbtion maximum of proteins, can be 
determined to calculate the 260:280 ratio, which is commonly used to analyze protein 
contaminations. A ratio of 1.8 indicates a DNA preparation relatively free of protein 
contaminations.  
 
6.2.1.9 PCR 
DNA-fragments were amplified using Polymerase chain reaction (PCR) (Mullis et al, 1986). 
The used PicoMaxx High Fidelity PCR System (Agilent Technologies) makes use of two 
different thermostable polymerases, Taq and Pfu. Due to the ability of proofreading activity 
the Pfu polymerase ensures higher fidelity. The mixture with Taq polymerase is commonly 
used to compensate for the reduced speed of Pfu polymerase. Complementary 
oligonucleotides (primers) flanking the amplified region were synthesized by Metabion. If 
degenerated primers were used, the primer concentration was increased depending on the 
number of degenerated bases.   
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Standard PCR cycle:    
Initial denaturation 95 °C 1 min  
Denaturation 95 °C 1 min  
Annealing as described for oligonucleotide 1 min 
 
34x 
Elongation 72 °C 1 min per 1 kb  
Final elongation 72 °C 10 min  
Hold 10 °C ∞  
 
6.2.1.10 Semi-quantitative real-time PCR 
To compare cDNA expression levels, a semi-quantitative real-time PCR approach was 
chosen using the Eurogenec qPCR Core kit for SYBR® Green I. All samples were measured as 
triplicates: 
 
 
 
 
 
 
Standard PCR cycle: 
   
Pre-heating 50°C 2 min  
Initial denaturation 95 °C 10 min  
Denaturation 95 °C 15 sec  
Annealing and Elongation 60°C 1 min 39x 
Mmelt curve 95°C ! 60°C   
 
Target genes´ cDNA (OAT, P5CS) and the reference gene´s cDNA (GAPDH) were PCR 
amplified and cloned into the pGEM®-T Easy Vector System. Real-time PCR using dilutions 
of these control vectors indicate that all three genes have similar efficiencies allowing a ΔΔ-
CT analysis.  
 
6.2.1.11 DNA sequencing 
For sequence verification, samples (plasmid DNA or PCR products) were sequenced at a 
commercial provider (GATC). DNA samples were dissolved in molecular grade water to a 
concentration of 50 ng/µL. Custom-made primers were diluted to a concentration of 10 
pmol/µL. 
Standard reaction mixture:  
Template DNA 1 µL 5-50 ng 
10x PCR buffer 10 µL 1x 
Sense primer 1 µL 200 pmol/µL 
Antisense primer 1 µL 200 pmol/µL 
dNTPs 1 µL 200 µM per nucleotide 
Polymerase 1 µL 0.05 U/µL 
Water, molecular grade ad 50 µL  
Standard reaction mixture:  
Template DNA 3 µL 15 ng 
10x PCR buffer 2 µL 1x 
Sense primer 0.4 µL 200 nM 
Antisense primer 0.4 µL 200 nM 
dNTPs 0.8 µL 200 µM per nucleotide 
Polymerase  0.1 µL 0.025 U/µL 
MgCl2 1.4 µL 3.5 mM 
SYBRGreen (1:2000) 0.6 µL  
Water, molecular grade ad 50 µL  
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6.2.1.12 Isolation of RNA from mammalian cells and cDNA synthesis 
For real-time PCR applications RNA was isolated using the Qiagen RNeasy® Mini Kit 
followed by a cDNA synthesis protocol:  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
For all other applications, mRNA isolation and subsequent cDNA synthesis was performed 
with the Miltenyi Biotec µMACSTM One-step cDNA Starting Kit according to manufacturer`s 
instruction. 
 
6.2.1.13 Cultivation of E.coli for plasmid preparation 
6.2.1.13.1 Transformation of E.coli 
E.coli were transformed by heat-shock transformation. In general NEB 5-alpha competent 
E.coli (high efficiency) were used. If subsequently the plasmid was going to be digested with 
methylation-sensitive restriction enzymes, the NEB dam-/dcm- competent E.coli were used. 
Half of a ligation reaction or 1-5 ng of a plasmid solution were mixed with the 50 µL 
competent E.coli and incubated on ice for 5 to 30 minutes. The heat-shock of 30 seconds (sec) 
at 42°C in a water bath was followed by cooling down on ice and addition of SOC medium. 
For re-transfections or sticky ligation with ampicillin selection, bacteria were directly spread 
on LB-agar plates containing appropriate selection antibiotics (50 µg/mL amplcillin or 50 
µg/mL kanamycin). For all other application, bacteria were first incubated for up to 1 hours 
shaken at 37°C. LB-plates were incubated overnight at 37°C. 
 
Standard reaction mixture:  
RNA 1 µL 1 µg 
Water, molecular grade 10 µL  
Primer mix (as) 1 µL  
 
1. Mix and incubate for 10 minutes at 70°C 
2. Immediately cool down on ice 
3. Add the following components: 
 
First strand buffer (5x) 4 µL 1x 
DTT (0.1 M) 2 µL 10 mM 
dNTPs (10 mM) 1 µL 0.5 mM 
 
4. Mix and incubate for 10 minutes at room temperature 
5. Incubate 2 minutes at 40°C 
6. Add the following components: 
 
MACSscript 1 µL  
 
7. Mix and incubate for 50 minutes at 42°C 
8. Heat-inactivate 15 minutes at 70°C 
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6.2.1.13.2 Overnight cultures for plasmid preparation 
A single colony from a LB-agar plate was transferred into LB-Medium with selection 
antibiotics and incubated overnight at 250 rpm (25 mm orbit) at 37°C in an Erlenmeyer flask 
with a volume five times larger than the culture volume.  
 
6.2.2 Biochemical methods 
6.2.2.1 Cell lysis 
Harvested cells were lysed in RIPA (Radioimmunoprecipitation assay) buffer to enable the 
extraction of membrane, cytoplasmic and nuclear proteins. Up to 1x107 cells harvested on ice 
were suspended in 1 mL ice-cold RIPA buffer containing protease inhibitors (Roche, 
Complete Protease Inhibitor Cocktail Tablets Mini) and were sonificated (3 times for 10 sec, 
30% pulses) on ice avoiding foaming. The lysate was incubated 10 minutes on ice on a shaker 
followed by a centrifugation step (10 min, 14,000 xg, 4°C) to remove cell debris. The protein 
lysate was split into several aliquots to avoid freezing-thawing cycles and stored at -20°C. 
 
6.2.2.2 Quantification of proteins  
Protein concentrations were determined by BCA assay using the Pierce BCATM Protein Assay 
Reagent and Bovine Serum Albumin (BSA) Standard Pre-Diluted Set in microtiter plates 
according to manufacturer´s instructions.  
 
6.2.2.3 SDS-PAGE 
SDS-PAGE (sodium dodecyl sulphate polyacrylamide gel electrophoresis) is used to separate 
proteins according to their size. Protein samples were mixed with 5x Laemmli sample buffer, 
heated to 95°C for 5 minutes and loaded on 4 – 20 % Tris-Glycine gels (Anamed). As a 
marker the PAGERulerTM Prestained Protein Ladder (Fermentas) and as running buffer a 
Tris-Glycine buffer (Anamed) was used. Gels were run at 200 V, 30 mA and 5 W per gel.  
 
6.2.2.4 Western Blot 
Using Western Blot, proteins separated by SDS-PAGE can be detected and identified by 
specific antibodies. The proteins separated by SDS-PAGE were transferred from the gel onto 
a nitrocellulose membrane (HyBond ECL, Amersham), which was pre-incubated in transfer 
buffer for 15 minutes. The nitrocellulose membrane was bedded on a blot paper soaked in 
transfer buffer in a semi-dry blotter. Avoiding air bubbles, the gel was put on top of the 
nitrocellulose membrane followed by another layer of soaked blot paper. By applying an 
electrical field (per gel 15 V, 100 mA, 2 W) for 30 minutes, proteins were transferred. After 
the transfer, membranes were washed to remove transfer buffer and, if blocking was 
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necessary for the used antibody, membranes were incubated for 1 hour at room temperature 
in blocking buffer. Incubations of membranes in antibody solutions were performed in the 
concentrations and buffers listed in Table 18 for 1 hour at room temperature. After each step, 
membranes were washed 3 times for 10 seconds and subsequently 3 times for 1 minute in 
TBST. Incubation and washing steps were performed using the MACSmixTM Tube Rotator.  
 
Table 18: Antibodies used for Western Blots 
Detected 
protein 
Blocking step Primary antibody Secondary antibody 
P5CS - rabbit anti-
ALDH18A1  
in TBST Stemgent® HRP 
mouse anti-rabbit 
in blocking buffer 
OAT - rabbit anti-
OAT  
in TBST Stemgent® HRP 
mouse anti-rabbit 
in blocking buffer 
GAPDH 1h blocking 
buffer 
- - monoclonal anti-
GAPDH HRP 
in blocking buffer 
in blocking buffer 
 
After immunolabeling, the washed membranes were incubated for 5 minutes with a HRP 
substrate (ImmobilonTM Western Chemiluminescent HRP Substrate, Millipore). A 
photographic film was exposed for 10 seconds to several minutes to the membrane, followed 
by an incubation in developer solution (Roentogen, Tetenal), washing in water, incubation in 
fixation solution (Roentogen, Tetenal) and another washing step in water. Each incubation 
step was performed for 1 minute.  
 
6.2.2.5 ELISA 
Concentration of secreted recombinant proteins were measured by ELISA (enzyme linked 
immunosorbent assay). Maximal titers were determined by seeding cells into an additional 
cell culture flask or plate and letting these cells overgrow. Supernatants were collected once 
cells had reached 100% confluence and the majority of cells already showed signs of dying, 
commonly after 5 to 7 day. Supenatants were centrifuged (5 min, 3,000 xg, RT) and the titer 
was determined directly or supernatants were stored at -80°C. 
 
6.2.2.5.1 Human IgG and kappa specific ELISA 
Nunc MaxiSorb® 96-well microtiter plates were coated with 100 µL mouse anti-human IgG 
(FC) antibody (Beckman Coulter) (3.33 µg/mL) in PBS and incubated at 4°C overnight. The 
plate was washed with 300 µL PBST for 3 times and to block free binding sites 100 µL ELISA 
Assay buffer were added for 1 hour at 37°C. Again the plate was washed. A standard 
antibody dilution series (Remicade®, 0.976 to 250 ng/mL) was prepared in Assay Buffer. 100 
µL per well of samples, supernatants of transfected cells, at different dilutions, blanks, 
recovery samples and the standard series were loaded as duplicates into the microtiter and 
incubated at 37°C for 1 hour. After washing, 100 µL horseradish peroxidase conjugated anti-
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human kappa specific antibody (Miltenyi Biotec, in-house, 1:2.000 – 1:8.000 in Assay Buffer) 
was added and incubated at 37°C for 1 hour. After washing, 100 µL TMB substrate 
(SeramunBlau® fast) was added and developed at room temperature for about 2 minutes 
(time course depends on the color development). The reaction was stopped by adding 100 µL 
1 N sulphuric acid and the absorbance at 450 nm was read with an ELISA reader. 
 
6.2.2.5.2 TGF-β  specific ELISA 
For detection of human TGF-β1 the human/mouse TGF beta 1 ELISA Ready-SET-Go!® 
(eBioscience) was used according to the manufacturer´s protocol. In short Nunc MaxiSorb® 
96-well microtiter plates were coated with an anti-TGF-β1 antibody, blocked and loaded 
with acid-activated samples, a standard series (0.62-16 ng/mL TGF-β1) and recovery 
samples. TGF-β1 was detected by a biotin-conjugated anti-TGF-β1 antibody and avidin-HRP 
followed by a 10 minute incubation at room temperature with TMB and stopping of the 
reaction with 1 N sulphuric acid. The absorbance at 450 nm was read with an ELISA reader.  
 
6.2.2.6 Intracellular staining 
1x106 cells were harvested as a single cell suspension, centrifuged (5 min, 300 xg, RT) and 
resuspended in 100 µL PEB. For fixation 400 µL Inside Fix (Miltenyi Biotec, Inside Stain Kit) 
was added and incubated for 30 minutes at room temperature. For washing, 3 mL Inside 
Perm (Miltenyi Biotec, Inside Stain Kit) were added and the cells were centrifuged (5 min, 
300 xg, RT). The supernatant was discarded. Cells were resuspended in appropriate amounts 
of Inside Perm (90 µL for staining with one antibody, 80 µL for staining with two antibodies) 
and incubated for 20 minutes at room temperature to make the cells permeable. After 20 
minutes, fluorescent dye-conjugated antibodies (Table 19) were added and incubated for 
another 20 minutes at room temperature in the dark. For washing, 1 mL Inside Perm was 
added, cells were centrifuged (5 min, 300 xg, RT) and the supernatant was discarded. Cells 
were resuspended in 1 mL PE and analyzed by flow cytometry using appropriate unstained 
and single-stained samples for compensation and gating.  
 
Table 19: Antibodies used for intracellular stainings 
Staining Antibody 
Human IgG/kappa antibody -
staining 
Anti-Ig κ Light Chain-FITC and human and Anti-IgG-APC, 
human 
LAP-staining Anti-LAP (TGF-β1)-APC, human 
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6.2.3 Cell culture methods 
6.2.3.1 Cultivation of cells 
6.2.3.1.1 Passaging of adherent cells 
Adherent CHO cells were routinely cultured in appropriate media such as MEM or the 
modified CHO-MEM. The cells were incubated at 37°C in a humid CO2 incubator in an 
atmosphere containing 5 % CO2. CHO cells were passaged every 3 to 4 days before reaching 
confluency by washing with PBS and incubating with trypsin-EDTA until the cells detached 
from the bottom of the cell culture flask. The cells were then diluted in fresh serum 
containing culture medium. If the trypsin-EDTA concentration in the fresh medium was 
lower than 5%, no centrifugation step was necessary. Otherwise cells were centrifuged (10 
min, 100 xg, RT), the supernatant was discarded and cells were resuspended in fresh 
medium to remove the trypsin-EDTA. 
 
6.2.3.1.2 Cultivation of suspension cells 
Suspension CHO cells were routinely cultured in appropriate serum-free suspension media 
at 37°C in a humid CO2 incubator in an atmosphere containing 5 to 9 % CO2 as static cultures 
or in an orbital shake incubator at 125 rpm (50 mm orbit). Every 2 to 3 days, cell number and 
viability were determined. To keep the cells in the logarithmic growth phase, cells were not 
allowed to grow to densities over 1x106 cells/mL. Routinely, cells were diluted to 2x105 
cells/mL. During adaptation to serum-free suspension media or adaptation to the orbital 
shake incubator, cells were seeded at higher cell densities of 3 to 5x105 cells/mL.  
 
6.2.3.2 Cryo-conservation 
For long-term storage, the cell lines were harvested as described above. 1x106 to 1x107 cells 
per cryo-vial were centrifuged (10 min, 100 xg, RT) and the supernatant was discarded. Cells 
were then resuspended in a cryo-medium consisting of 20 % FBS, 10% DMSO and 70% 
culture medium without antibiotics and transferred into 1.5 mL cryo-vial. Cryo-vials were 
immediately transferred into Cryo 1°C Freezing Containers (Nalgene®) to allow a slow and 
gradual freezing down to -80°C for 1-2 days. Then, the tubes were transferred to liquid 
nitrogen. For recultivation, cells were thawn in a 37°C water bath, transferred into culture 
medium and centrifuged (10 min, 100 xg, RT) to remove the DMSO. After resuspension in 
appropriate culture media, cells were cultivated as described.  
 
6.2.3.3 Determination of cell number and viability 
Cell numbers and viability were determined by manual counting in a Neubauer 
hemacytometer or automated counting using the MACSQuant® Analyzer. For counting in a 
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Neubauer hemacytometer cells were stained with Erythrosine B solution to differentiate 
between dead and living cells. Erythrosine B can only penetrate cells with damaged 
cytoplasm membranes and therefore, only dead cells are stained. Due to the defined volume 
in each square of the Neubauer hemacytometer, the cell concentration can be calculated as 
following: !"#!$#%&'%("#! !"!! = !!"#$%&!!"!!"#$%&!!"##$ ∗ !"#$%"&'!!"#$%&!"#$%&!!"!!"#$%&! ∗ 10! 
 
The vitality can be calculated by the numbers of viable and total cells:  !"#$"%"&'! % = !!"#$%&!!"!!"#$%&!!"##$!"#$%&!!"!!""!!"##$ ∗ 100 
 
Counting cells using the MACSQuant® analysis is only suitable for single cell suspension. To 
stain dead cells, 0.5 µL propidium iodide solution was added directly before measurement.  
Similar to Erythrosine B, propidium iodide can only penetrate cells with damaged cell 
membranes and the fluorescent dye then intercalates into the DNA. For cell counting, no 
forward/sideward scatter gate was set to include doublets into the counting and at least 
2x104 cells were counted at a flow rate lower than 1000 cells per second to increase accuracy.  
 
6.2.3.4 Transfection 
Several different chemical transfection reagents were tested and optimized for the used cell 
lines. Due to the best efficiencies and viabilities, adherent CHO cells were routinely 
transfected using the FugeneHD® transfection reagent. Optimal transfection efficiencies were 
reached by seeding the adherent CHO one day before transfection at cell densities of 1x105 
per 12-well plate (3.8 cm2) in 1 mL culture medium. For transfection, 1 µg DNA in 100 µL 
culture medium without serum was mixed with 4 µL FugeneHD® and incubated for 15 
minutes at room temperature. Per 12-well, 50 µL of this transfection mixture was added 
drop-wise onto the cells. For larger cell culture dishes and higher cell numbers the 
transfection mixture was upscaled. For transient transfections, cells were harvested 24 to 48 
hours after transfection for analysis of expressed fluorescent protein or the supernatant was 
harvested 3 to 5 days after transfection for analysis of secreted recombinant proteins.  
 
6.2.3.5 Selection of stable cell lines 
For the generation of stable cell lines, CHO cells were transfected as described above. In first 
transfections, stable cell lines were generated with a mild split rates of 1:3 to 1:6 24 hours 
after transfection and addition of selection pressure 48 hours after transfection. A harsher 
protocol with split rates of 1:8 to 1:20 into a larger culture flask directly into selection 
medium 24 hours after transfection was used as a standard protocol. These thin cell densities 
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ensure most stringent selection conditions. For P5CS selection, the used selection medium 
did not contain proline. Appropriate concentrations of antibiotics for antibiotic selections, 
MSX for GS selections and MTX for DHFR mediated MTX amplification were added (Table 
20). 
 
Table 20: Used selection reagents 
Selection reagent Concentration in selection medium 
 CHO-S CHO-K1 
Neomycin (G418) 800 µg/mL 400 µg/mL 
ZeocinTM 100 µg/mL  50 µg/mL 
Hygromycin B 800 µg/mL 600 µg/mL 
MTX 50/100/200 nM - 
MSX 25 µM  
 
To find appropriate concentrations, selection antibiotics and reagents were tested on 
untransfected cells. A suitable concentration leads to killing of cells in 7 to 10 days. 
Additionally, a determined range of concentration was tested during the stable cell line 
generation to optimize the concentrations. During selection, medium was changed once per 
week. Once cell started to grow up after selection, they were passaged and maintained as 
described in the appropriate selection medium.  
 
6.2.3.6 Clone isolation using limiting dilution 
To isolate clones, which are originated from one single cell to obtain a more homologous cell 
population, a single cell suspension of adherent CHO cells was filtered through a 40 nm cell 
strainer to remove any clumping cells. The cell suspension was counted in a Neubauer 
hemacytometer and diluted down to a concentration of 3 to 5 cells/mL. Dispensing 100 µL of 
this suspension per 96-well resulted in 0.3 to 0.5 cell/well. After about 10 days, 96-well plates 
were screened for formation of visible colonies by microscope. The supernatant of wells 
containing a colony was screended by ELISA for recombinant protein expression. 
 
6.2.3.6.1 Clone isolation by clone picking from semi-solid media 
To visualize secreted antibody the Genetix CloneDetect anti-human detection agent FITC-
labeled was used. Filtered single cells were seeded at 0.3 to 0.5 cell/well in a 96-well plate in 
the usual selection medium. After 24 hours, the medium was exchanged to semi-solid 
ClonePix medium. Formed colonies were screened for fluorescence by microscope 19 days 
after seeding. High-fluorescent cells were expanded.  
 
6.2.3.7 Flow cytometry analysis 
Flow cytometry is used to identify, characterize and separate different types of cells based on 
detecting and measuring the fluorescence emitted after excitation with a laser. Cells were 
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analyzed in PEB or CliniMACS® buffer (Miltenyi Biotec) using the MACSQuant® Analyzer 
and Software. Cell populations were identified by their physical properties in the forward 
scatter (FSC) and sideward scatter (SSC). Gating on the analyzed population in the FCS and 
SSC blot together with and propidium iodide staining ensured fluorescence analysis of 
single, living cells. Stained or fluorescent cells were always compared to non-fluorescing 
negative sample. Single fluorescing samples were used to compensate overlapping 
fluorescence emission spectra.  
 
6.2.3.8 Clone isolation by FACS sorting 
Fluorescence activated cell sorting (FACS®) allows to isolate defined cell poplations 
identified by flow cytometry. To isolate high-producing clones, stably expressing cell lines 
were FACS sorted (BD Bioscience InfluxTM Cell Sorter or BD Bioscience FACSVantageTM SE 
DIVA, at Fraunhofer IME, Aachen) according to the intensity of the coexpressed fluorescent 
protein. The 0.1 to 1 % brightest single or double positive cells were sorted as single cells into 
96-well plates containing selection media. To improve cloning recovery, antibiotic 
concentration were reduced factor 2 and serum concentrations were increased from 5% to 
10% during the first 5 days. After about 10 days, 96-well plates were screened for formation 
of visible colonies by microscope and recombinant protein expression by ELISA. 
 
6.2.3.9 Cell enrichment by MACS 
Magnetic-activated cell sorting (MACS®) enables the enrichment of specific cells using 
surface markers. First, the surface marker is directly or indirectly labeled with a conjugate of 
antibody and supermagnetic particle (microbead). The cell mixture is then separated on a 
column in a magnetic field. Labeled cells are retained and can be eluted from the column 
once the magnetic field is removed.  
 
6.2.3.9.1 Immunolabeling for MACS separation 
The surface marker used as target for magnetic enrichment was the membrane-bound GFP. 
Up to 1x107 cells in a single cell suspension, detached by TrypLE to reduce trypsin 
dependent degradation of the surface marker, were labeled indirect with a polyclonal rabbit-
anti-GFP antibody and anti-rabbit IgG MicroBeads or labeled directly with a monoclonal 
anti-GFP coupled to microbeads (Table 21) according to Miltenyi Biotec´s staining protocol.  
 
Table 21: Antibodies used for MACS enrichment 
 Direct staining Indirect staining 
First antibody µMACSTM Anti-GFP Microbeads 
(monoclonal) 
Living Colors® Full-Length A.v. Polyclonal 
Antibody (polyclonal rabbit anti-GFP) 
Second antibody - Anti-Rabbit IgG MicroBeads 
Labeling check Labeling Check Reagent-APC Labeling Check Reagent-APC 
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To avoid false-positive staining due to Fc receptor interactions, the mouse FcR Blocking 
Reagent was applied prior to antibody labeling. To reduce back round staining all steps were 
performed on ice and cells were washed twice after each labeling step. To control the 
specificity of the antibody staining, microbeads can be stained with the Labeling Check 
Reagent-APC according to the manufacturer’s instructions. 
 
6.2.3.9.2 MACS enrichment 
Magnetic-labeled cells were loaded on a 4°C pre-cooled MS column placed in the magnetic 
field of an OctoMACS™ Separator (Miltenyi Biotec). The column was washed to remove 
GFP-negative and low expressing cells. Magnetically labeled high-positive GFP cells were 
retained within the column and eluted as the positively selected cell fraction after removing 
the column from the magnet. To increase stringency, the eluted cells can be loaded on a 
second column. There, washing and elution is identical to the first column. Separation 
efficiency is monitored by GFP expression in the original, wash and elution fraction using 
MACSQuant® Analyzer (Miltenyi Biotec).  Eluted cells are cultured in the described selection 
medium. 
 
6.2.3.10 Test productions in orbital shake incubator 
6.2.3.10.1 Batch process 
Clones producing recombinant proteins adapted to growth in serum-free medium and the 
orbital shake incubator from the logarithmic growth phase were seeded at cell densities of 
2x105 cells/mL in 30 mL medium and incubated at 37°C in a humid CO2 shake incubator in 
an atmosphere containing 5 to 9 % CO2 at 125 rpm (50 mm orbital). Each day a 0.5 mL aliquot 
was taken to determine the cell number using the MACSQuant® Analyzer and the 
recombinant protein concentration in the supernatant by ELISA.  
 
6.2.3.10.2 Fed-batch process 
The fed-batch process is identical to the described batch process with the difference of a daily 
feed with CHO MACS Feed Supplement. Depending on the counted cell numbers, the 
feeding amount was increased: The feed was started with 3.1 % of culture medium once cell 
numbers of over 1x106 cells/mL were reached.  At over 5x106 cells/mL, it was increased to 
7.5% for two days and to 8% for the remaining culture time (Table 22).  
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Table 22: Feed during fed-batch culture 
Day 
Feed % of culture volume 
Slower growing 
clones 
Faster growing 
clones 
0 0 0 
1 0 0 
2 0 0 
3 3,1 3,1 
4 3,1 3,1 
5 3,1 7,5 
6 7,5 7,5 
7 7,5 7,5 
8 7,5 8 
> 9 8 8 
 
 
6.2.3.10.3 Specific productivity 
To quantitatively compare different clones, the cell specific productivity is calculated by the 
ration of integral viable cell density (IVCD) and produced recombinant protein 
concentration. The integral of viable cell density (IVCD) is the most frequently used method 
to compare the average viable cell density and is represented by the area under the curve 
when the concentration of viable cells is plotted against the culture time. To calculate the 
IVCD, the trapezoidal rule is used as an approximation technique (Adams et al, 2007).  
The specific productivity can be determined by graphically plotting the recombinant protein 
expression against the IVCD of the logarithmic growth phase (Figure 56). The resulting slop 
equates to the specific productivity. 
 
Figure 56: Determination of specific productivity 
The specific productivity can be determined by graphically plotting the recombinant protein expression against 
the IVCD of the logarithmic growth phase. The resulting slop equates to the specific productivity. 
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8 Appendix 
Appendix 1: Alignment of ALDH18A1 (P5CS) cDNA sequence from different species 
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Appendix 2: Alignment of OAT cDNA sequence from different species 
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Appendix 3: Alignment of P5CS cDNA sequence from proline-auxotroph and –protroph CHO-K1 
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Appendix 4: Amino acid concentration in dialyzed FBS 
Amino acid 
component 
Short form Concentraion in 
serum (nmol/mL) 
others 
Taurine Tau 4.97  
Urea Urea 608.56  
Aspartic acid Asp 322.44  
Hydroxyproline Hypro 4.65 Detected at λ= 440 nm 
Threonine Thr 322.34  
Serine Ser 599.50  
Asparagine Asn 189.00  
Glutamic acid Glu 410.06  
Glutamine Gln 194.64  
Proline Pro 389.13 Detected at λ= 440 nm 
Glycine Gly 615.85  
Alanine Ala 703.76  
Valine Val 443.51  
Methionine Met 153.88  
Isoleucine Ileu 373.78  
Leucine Leu 774.24  
Tyrosine Try 240.71  
Phenylalanine Phe 315.44  
β- aminobutric acid  β-Aba 
β-Aba 
4.17 
10.49 
Two peaks in time 
frame of 0.3 min 
γ- aminobutric acid γ-Aba 6.57  
Histidine His 144.08  
Tryptophane Trp 129.10  
Hydroxylysine  665.42  
Ornithine Orn 389.51  
Lysine Lys 718.98  
Ammonia NH3 311.92  
Arginine Arg 346.30  
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